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Abstract 
Abstract: Prostate cancer (PC) is the most common cancer and the second cause of cancer 
related death in men. Central to this, is the role of the androgen receptor (AR) which acts as a 
transcription factor, regulating the expression of genes required for normal prostate growth and 
cancer development. Consequently, the AR remains the primary target for therapeutic 
intervention. However, these treatments become ineffective, resulting in castrate resistant 
prostate cancer (CRPC) which generally retains AR expression. The AR interacts with several 
co-regulatory proteins which can perturb AR-targeted therapies in CRPC. Targeting these co-
regulatory proteins to indirectly target the AR signalling cascade may prove beneficial. 
Recently, our group identified KMT5A as a potential regulator of AR through selective siRNA 
library screening. 
KMT5A is a lysine methyltransferase that mono-methylates histone 4 lysine 20 and non-histone 
proteins, including p53. Using a relevant in vitro CRPC model it was shown that KMT5A 
acquires AR co-activator activity which is in contrast to androgen sensitive models where 
KMT5A co-represses AR activity. This highlights the importance of studying KMT5A 
regulation. KMT5A protein levels are tightly regulated by multiple E3 ligases for cell cycle-
dependent poly-ubiquitination-mediated degradation. KMT5A poly-ubiquitination by E3 
ligases SCFβ-TRCF, CRL4Cdt2 and APCCdh1 promotes degradation in G1, S and late mitosis cell 
cycle phases, respectively. Moreover, the Skp2 E3 ligase has been suggested to play a role in 
KMT5A ubiquitination and degradation but direct supporting evidence is currently absent. 
Additionally, Skp2 is suggested to directly regulate the AR signaling pathway. It is also 
unknown whether KMT5A could be modified directly by ubiquitination without promoting its 
degradation. As such, we aimed to investigate KMT5A mono-ubiquitination and the role of 
Skp2 in regulating KMT5A as well as independently regulating the AR signaling cascade.  
Mono-ubiquitinated KMT5A was demonstrated in a panel of PC cell lines. Its existence was 
further confirmed by performing ubiquitination assays in COS7 cells. Furthermore, the KMT5A 
C-terminal SET domain was identified as the target for mono-ubiquitination. Moreover, mono-
ubiquitinated KMT5A was highly enriched in S phase cells, coincident with extremely low 
levels of unmodified KMT5A. Mono-ubiquitinated KMT5A was exclusively cytoplasmic and 
its abundance was greatly enhanced by Skp2, but not associated with protein turnover. 
Together, this data suggests that cell cycle-dependent KMT5A mono-ubiquitination is an 
important mechanism to diminish nuclear, unmodified KMT5A levels to facilitate cell cycle 
progression. Thus, insight for the physiological significance of mono-ubiquitinated KMT5A 
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may provide a novel therapeutic target to indirectly target the AR. Finally, Skp2 was not found 
to have a direct effect on AR signaling. 
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1 Introduction 
1.1 The structure and function of the prostate  
The prostate is an accessory sex gland of the male reproductive system. In healthy adult males, 
the prostate is slightly larger than a walnut, weighing approximately 25 g. The main function 
of the prostate is the production of prostatic secretions, responsible for liquefaction of semen 
which is integral for sperm motility to facilitate fertilisation, therefore it plays an important role 
in reproduction (Lilja et al., 1989). Androgens are responsible for the growth, development, 
differentiation and function of the prostate under normal physiological conditions (Huggins and 
Neal, 1942; Frick and Aulitzky, 1991; Kumar and Majumder, 1995). The biological function 
of androgens is mediated by their binding to the androgen receptor (AR), a nuclear transcription 
factor in prostate cells. This leads to activation of the AR and transcription of genes that 
stimulate growth and survival of prostate cells.  
Anatomically, it lies immediately inferior to the bladder, posterior to the pubic symphysis and 
anterior to the rectum, surrounding the urethra in the pelvic cavity. The prostate consists of four 
zones: the peripheral zone (PZ), the central zone (CZ), the transitional zone (TZ) and the 
anterior fibromuscular stroma (AFS) as seen in Figure 1-1. The PZ constitutes approximately 
70% of the normal prostate, located at the posterior of the gland and surrounds the distal urethra. 
It is the main site of prostate cancer (PC) initiation and is felt against the rectum during a 
physical examination as it is the closest section of prostate to the rectum. The CZ forms 25% 
of the prostate, with its majority being surrounded by the PZ. The CZ itself surrounds the 
ejaculatory ducts and is the furthest region from the rectum. Initiation of cancer in this zone is 
rare, accounting for only 1-5% of cases. The TZ resides in the centre of the prostate and 
surrounds the urethra proximal to the verumontanum, which is the site where the urethra and 
the ejaculatory ducts from the testes merge together at a 35o angle. Overall, the TZ accounts for 
approximately 20% of PC initiation. The prostate is encapsulated by a layer of smooth muscle 
and fibrous tissue; the AFS, which does not contain any secretory ducts (McNeal, 1981; 
McLaughlin et al., 2005).  
The prostate has a ductal-acinar structure, composed of two major cellular compartments; the 
glandular epithelial compartment and the fibromuscular stroma, separated from each other by 
a basement membrane. Three types of epithelial cells reside in the glandular epithelial 
compartment. Secretory luminal cells are the most abundant, cuboidal in shape and line the 
inner surface of the ducts. These are differentiated cells which express AR, require androgens 
for survival and are responsible for the production of prostatic secretions (McNeal, 1988; Shah 
and Zhou, 2012). The basal cells which generally appear undifferentiated, are androgen-
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independent and reside between the basement membrane and luminal cells are presumed to 
have a protective role (Xin, 2013). Finally, the rare neuroendocrine cells which are sparsely 
scattered between the luminal and basal cell layers are believed to play a role in regulating the 
growth, development and secretory function of the prostate through paracrine effects of their 
neurosecretory products (Noordzij et al., 1995; Huang et al., 2007b). The epithelial 
compartment is in a dynamic cross-talk with its surrounding stroma. The stroma which is made 
up of fibroblasts, smooth muscle, nerves, blood vessels and immune cells forms an important 
part of the machinery that regulates proliferation and differentiation of epithelial cells (Tuxhorn 
et al., 2001).  
 
 
Figure 1-1: Diagram representing the anatomy of the human prostate.  
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1.2 Prostate abnormalities 
1.2.1 Benign prostatic hyperplasia (BPH) 
The most common benign proliferative disease of the prostate is BPH, in which there is an 
increase in the prostate volume due to hyper-proliferation of mainly the stromal compartment 
and to a lesser extent epithelial cells of the TZ (McNeal, 1990). BPH occurs in ageing men 
where its incidence increases by 42% and 90% in men between 40-50 years and those over 80 
years, respectively (McVary, 2006).  
Due to the TZ encapsulating the urethra, BPH causes lower urinary tract complications, partly 
as a result of mechanical compression on the urethra, including reduced urinary flow and 
increased frequency of urination, reducing the quality of life. There are different treatment 
options, depending on the severity of BPH symptoms. In some cases, lifestyle changes such as 
reduced fluid intake is sufficient to control urinary symptoms (Pinheiro and Martins Pisco, 
2012). Alternatively, blocking α1A type of α1-adrenoceptors which are commonly expressed in 
the prostate smooth muscle, cause it to relax, leading to reduced constriction of the urethra and 
increased urine flow. However, this treatment does not reduce the size of the prostate. Examples 
of α-adrenergic antagonists include doxazosin and alfuzosin (Bechis et al., 2014). The 
androgen, dihydrotestosterone (DHT), which is derived from a less active androgen, 
testosterone, mediates the growth of the prostate. Testosterone is converted to DHT in prostate 
cells by the membrane-bound enzyme 5α-reductase (Frick and Aulitzky, 1991). Therefore, 5α-
reductase inhibitors such as finasteride are utilised to block DHT production which reduces 
prostate proliferation and decreases prostate volume. The combination of these two inhibitors 
has been shown to be more beneficial. Patients with more advanced symptoms undergo 
transurethral resection of the prostate (TURP) or laser treatment (Pinheiro and Martins Pisco, 
2012).  
1.2.2 Prostatic intraepithelial neoplasia (PIN) 
PIN is an abnormal proliferation within the lining of prostatic ducts and is sub-divided into low 
and high-grade (Bostwick, 2000). It is an age-related disease, with high-grade PIN being more 
frequent in aging men. Patients with high-grade PIN develop PC over a period of 5-10 years. 
Moreover, as with PC, PIN primarily occurs in the PZ of the prostate and also shares similar 
genetic alterations, with more than 400 genes with aberrant expression being identified in both 
PIN and PC (Calvo et al., 2002). Some of these genetic alterations include the loss of tumour 
suppressors TP53 and RB1, and over-expression of the MYC oncogene (Bettendorf et al., 2008). 
Therefore, PIN is the most established precursor of PC.  
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In contrast to PC, PIN does not elevate the serum PSA concentration as the surrounding 
basement membrane and the vasculature remains intact, therefore PSA cannot be secreted into 
the blood (Ramos et al., 1999). As a result, biopsy is the only detection method. Treatment for 
PIN include androgen-deprivation therapy such as those utilised in the treatment of PC, 
however, 5α-reductase inhibitors have very little effect (Balaji et al., 1999).   
1.2.3 Prostate cancer  
1.2.3.1 Incidence and risk factors 
PC is the most common cancer and the second cause of cancer-related death among men in 
Western countries. In 2013, there were 47,300 new cases diagnosed in the UK alone, which 
equates to 130 men every day (Cancer Research UK, last reviewed 17 February 2016). It is 
estimated that 1 in 8 men develops PC in their lifetime (Prostate Cancer UK).  
The incidence of PC increases with age with the highest number of diagnosed patients being 
men aged 70-74 years (Cancer Research UK). Ethnicity is another considerable risk factor with 
black men being 3 times more likely to develop the disease in comparison to white men. Family 
history is also a recognised risk factor where men are twice as likely to be diagnosed with this 
disease if they have a first-degree relative (father, brother, son) with PC (Brawley et al., 1998a; 
Brawley et al., 1998b). The susceptibility of developing PC further increases with a history of 
both breast cancer and PC than PC alone (Thomas et al., 2012). Social and environmental 
factors including diet, lack of physical activity, heavy smoking, and alcohol consumption have 
also been associated with increased risk of PC (Hsing and Chokkalingam, 2006).  
1.2.3.2 PC initiation and genetic aberrations  
The molecular mechanisms leading to the initiation and progression of PC are still an area of 
ongoing research which has remained incompletely defined due to its complexity. As already 
alluded to, the incidence of PC is strongly linked to aging and therefore age-related damage is 
a contributor to the initiation of the disease. This includes accumulation of DNA damage due 
to increased somatic DNA mutations which increases the probability of a mutation occurring 
within an oncogene (Hanahan and Weinberg, 2000); as well as, DNA damage caused by DNA 
telomere shortening as a result of chronic inflammation and oxidative stress (Shen and Abate-
Shen, 2010).  
Several of the mutations observed in PC are initiated in PIN. For example, the frequent 8q21 
allelic loss-of-heterozygosity resulting in reduced expression of the tumour suppressor NKX3.1 
is present in 20% of high-grade PIN, 34% of hormone-refractory PC and 78% of metastases 
(Grasso et al., 2012). Similarly, phosphatase and tensin homolog (PTEN) is found mutated, 
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while PTEN deletion occurs in over 60% of metastatic prostate tumours. Both these genomic 
alterations lead to increased PI3K/Akt signalling, which translates into cell survival and 
proliferation through activating AR signalling independent of ligand-mediated activation of the 
AR (Feilotter et al., 1998; Feldman and Feldman, 2001). Furthermore, fusion of androgen-
regulated transmembrane protease serine 2 (TMPRSS2) and the E twenty-six (ETS) family of 
transcription factors including ERG, ETV1 and ETV4, is another common genomic aberration. 
The TMPRSS2-ERG fusion causes the oncogenic ETS transcription factors to be placed under 
the control of the androgen inducible TMPRSS2 promoter and is associated with tumour 
progression (Tomlins et al., 2005).  
A frequent mutation in primary PC is in the gene encoding Speckle-type POZ protein (SPOP), 
an E3 ligase, which is mutated in over 10% of primary PC tumours (Barbieri et al., 2012). 
Moreover, dysregulation of the tumour suppressor p53 is present in 5-10% of primary tumours, 
but increases to around 50% in metastatic disease (Bettendorf et al., 2008).  
1.2.3.3 Symptoms and diagnosis 
PC in its early stages is asymptomatic; however symptoms gradually develop and become 
pronounced as the disease progresses. These symptoms include, but are not limited to, bladder 
obstruction, dysuria, nocturia, haematuria and impotence. Disease progresses by invading 
surrounding tissues and metastasises to the lymph nodes, bladder and bone causing bone pain 
especially in the lower back, hips and upper thighs (Miller et al., 2003).  
There is no single and definitive test for PC to date. Initially, serum prostate specific antigen 
(PSA) is measured and a digital rectal examination (DRE) performed. PSA is an AR-targeted 
serine protease with increased levels in PC; however, it is not specific to PC cells as 
inappropriate rise can also be detected in multiple prostatic diseases and following an injury to 
the prostate (Balk et al., 2003; McCracken et al., 2010).  
Following the detection of elevated serum PSA level and prostate abnormalities during DRE, a 
transrectal ultrasonography (TRUS) guided biopsy is performed to determine the presence of 
cancer. The sample tissues from the biopsy are analysed and scored using the Gleason system 
where the sample is given a histological score based on its cellular differentiation. Moreover, 
the sample is staged which is important in the selection of the appropriate form of therapy 
(McCracken et al., 2010). Should the outcome of these tests be negative but PC is still suspected 
based on the initial PSA and DRE results, as well as persistent symptoms, magnetic resonance 
imaging (MRI) can be used as in addition to the prostate, it visualises tumours. Therefore, 
further TRUS can be performed to specifically take biopsies from tumours (Heidenreich et al., 
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2014). However, biopsies are not flawless where a major challenge in PC is distinguishing 
tumours that are clinically important and likely to metastasise compared to clinically 
insignificant tumours that will not cause significant symptoms. Therefore, there is a need for 
identification of novel biomarkers for PC detection that also enables patient stratification into 
appropriate treatment groups.   
1.2.3.4 Treatments  
The organ-confined disease, with a low-risk PC are initially not treated but are under watchful 
waiting or active surveillance whilst the patient remains asymptomatic. The patient is regularly 
monitored and treatment commences upon the onset of cancer progression. This prevents the 
unnecessary over-treatment of the disease and its associated side-effects (Klotz, 2013). The 
confined disease with an intermediate or high risk of progression can be treated surgically by 
removing the prostate, called radical prostatectomy (RP). Although effective in treating men 
below the age of 70, this procedure is associated with high risk of complications and unwanted 
side-effects which influences the quality of life. However, newer surgical techniques such as 
robot-assisted laparoscopic RP, which is becoming popular, may reduce complication rates. 
Furthermore, radiotherapy and brachytherapy can be utilised which have a similar progression-
free and overall survival rate to that of surgery, but are associated with high risk of toxicity 
(McCracken et al., 2010; Heidenreich et al., 2014).  
The treatment of advanced disease is aimed at prolonging life expectancy and preventing or 
controlling symptoms. As prostate development depends on the action of androgens and AR-
signalling, androgen deprivation therapy (ADT) is used to reduce prostate cell proliferation and 
survival. ADT can be achieved through a number of mechanisms and works by decreasing AR 
activity either directly or indirectly through decreasing circulating androgens.  
ADT by chemical castration involves the use of luteninising hormone-releasing hormone 
(LHRH) agonists, such as leuprorelin, which bind to LHRH receptors on gonadotropic cells in 
the anterior pituitary. This induces the hypothalamic signalling axis, leading to the release of 
luteinizing hormone (LH) and follicle stimulating hormone (FSH) and subsequent androgen 
biosynthesis in the testes (Rick et al., 2013). This initially results in elevated serum testosterone 
levels, often causing bone pain which may be diminished in most cases by co-treatment with 
anti-androgens (Bubley, 2001). However, overstimulation of the hypothalamic signalling 
pathways ultimately leads to down-regulation of LHRH receptors, therefore inhibiting 
testosterone release, resulting in a castrate level of serum testosterone (Rick et al., 2013).  
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To overcome the testosterone flare, another method of chemical castration using LHRH 
antagonists such as degarelix, is utilised (Bokser et al., 1990; Rick et al., 2013). These 
compounds bind LHRH receptors and inhibit them, causing the same outcome as LHRH 
agonists. Although, a faster response is achieved with LHRH antagonists without the initial 
flare, currently these drugs are not as long lasting as LHRH agonists (Rick et al., 2013). 
ADT is also achieved through direct inhibition of the AR using anti-androgens. The first anti-
androgen developed was cyproterone acetate (CPA), which is a steroidal anti-androgen 
(Goldenberg and Bruchovsky, 1991). Due to patient side-effects caused by the steroidal nature 
of the compound, non-steroidal AR antagonists including nilutamide, flutamide and the more 
frequently used, bicalutamide (casodex) were generated. As these compounds do not inhibit 
testosterone production, they are not associated with erectile dysfunction or loss of bone mineral 
density. However, they cause other significant side-effects including hot flushes, depressive 
mood disturbance, cognitive impairment, diminution of muscular strength, increase in body fat, 
cardiovascular disease and gynecomastia. Anti-androgens prevent the action of adrenal 
androgens and are used in combination with LHRH agonists to achieve complete androgen 
blockade (Mottet et al., 2015).  
Unfortunately, the ADT eventually fails and the cancer becomes hormone-refractory, called 
castrate-resistant PC (CRPC). Despite targeting the AR, it becomes aberrantly activated in 
CRPC through a number of mechanisms which are discussed in Chapter 1.3.3. At this stage, 
cytotoxic chemotherapeutic agents such as the taxane, docetaxel, which targets the microtubule 
network, in combination with prednisone are used to delay the progression of symptoms 
(Yagoda and Petrylak, 1993; Heidenreich et al., 2014).  
Second generation AR antagonists, MDV3100 (enzalutamide) and ARN-509, exhibiting a 
greater affinity for the AR ligand-binding domain (LBD) than casodex were generated for use 
in metastatic CRPC. They prevent AR nuclear localisation and binding to DNA (Tran et al., 
2009). Androgens are further produced through the action of the adrenal gland cytochrome 
P450 enzyme CYP17 and act to maintain high intratumoural androgen levels despite ongoing 
castration. Using abiraterone acetate, a CYP17 inhibitor prevents intracellular and adrenal 
androgen synthesis, thereby leading to a further decrease in circulating testosterone (Barrie et 
al., 1994). 
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1.3 The androgen receptor  
The AR is a transcription factor, belonging to the nuclear steroid receptor family. The gene 
encoding the AR is located on Xq11-12 and consists of 8 exons (Lubahn et al., 1988). The exon 
1 of AR, which is the largest of AR exons, encodes the entire N-terminal domain (NTD), and 
exons 2 and 3 encode the cysteine rich DNA-binding domain (DBD). Whilst the 5’ region of 
exon 4 encodes the hinge region of AR, its remaining region along with exons 5-8 encode the 
ligand-binding domain (LBD) (Kuiper et al., 1989; Brinkmann et al., 1996).  
1.3.1 Androgen receptor structure  
The AR protein consists of ~ 919 amino acids, generating a protein with a molecular weight of 
approximately 110 kDa. It has a multi-domain structure, composed of four functional domains: 
the NTD, the DBD, the hinge region and a carboxyl-terminal LBD (Claessens et al., 2008), 
demonstrated in Figure 1.2.  
The NTD is critical for the transcriptional activity of the AR. It harbours AR transcriptional 
activation function (AF-1) which contains two transcription activation units 1 and 5 (Tau-1 and 
Tau-5) required for full ligand-inducible and ligand-independent transcriptional activity, 
respectively (Jenster et al., 1991; Jenster et al., 1995). Furthermore, the majority of AR 
phosphorylation sites reside within the NTD (Gioeli et al., 2002). This domain is responsible 
for interactions with AR co-regulators, such as the steroid receptor co-activator 1 (SRC-1) 
(Christiaens et al., 2002). In addition, interleukin-6 stimulated STAT3 and MAPK recruitment 
at the NTD enables activation of the AR in the absence of ligand binding (Ueda et al., 2002).  
Moreover, the AR NTD consists of polymorphic glutamine and glycine repeats which have 
been linked to several disease states as the length of these repeats is inversely correlated with 
AR transcriptional activity (Chamberlain et al., 1994). For example, impaired spermatogenesis 
and infertility have been shown to result from decreased AR activity as a result of longer 
polyglutamine repeats (Tut et al., 1997). Additionally, longer repeats have been associated with 
a generally lower risk of PC (Buchanan et al., 2004).  
The DBD consists of two zinc fingers which function cooperatively to bind AR to the DNA. 
The first zinc finger composed of a P-box motif, binds to the major groove of DNA at androgen 
response elements (AREs), ensuring receptor selectivity. The second zinc finger entails a D-
box, which stabilises the DNA-AR interactions by binding to the phosphate backbone of DNA 
and is responsible for DNA-dependent dimerization of AR (Freedman, 1992).  
The hinge region links the DBD and LBD of the AR, and encompasses a bipartite AR nuclear 
localisation signal (NLS). This domain has multiple functions as it is involved in DNA binding, 
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transcriptional activity and nuclear localisation of the AR (Haelens et al., 2003; Tanner et al., 
2004; Haelens et al., 2007). The hinge region is involved in AR nuclear transport through 
interacting with microtubules as well as exposure of its NLS upon a conformational change 
induced by ligand binding. The hinge region is subject to post-translational modifications 
(PTMs) such as acetylation, methylation and phosphorylation. For example, AR methylation at 
K630 and K632 by the methyltransferase, SET9, has been shown to be required for androgen-
mediated AR transcriptional activity (Gaughan et al., 2011; Ko et al., 2011).  
The AR binds to its ligand, androgen, through its LBD. In addition, it is involved in interactions 
with AR co-regulators through its AF-2. Upon ligand binding, this domain undergoes a 
conformational change, leading to the formation of a surface referred to as Tau-2 that resides 
in AF-2. This in turn mediates the intramolecular interaction of AR with Tau-1 within the NTD, 
causing an overall conformational change in the AR (Moras and Gronemeyer, 1998). Moreover, 
anti-androgens target the LBD to disrupt N/C terminal interactions, recruitment of co-factors 
and ultimately, AR transcriptional activity (Gao et al., 2005; Korpal et al., 2013).  
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Figure 1-2: Schematic diagram of the AR protein. The diagram demonstrates different domains of the AR 
protein: N-terminal domain (NTD); DNA-binding domain (DBD), the hinge region and the ligand binding domain 
(LBD).  The key transcription activation units (TAU1, 5 and 2) are also highlighted. The image is taken from 
Lonergan and Tindall et al. (Lonergan and Tindall, 2011).
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1.3.2 AR function and mechanism of action 
In the absence of ligand, AR is inactive and is present diffusely throughout the cytoplasm in 
complex with several heat shock protein (HSPs) such as HSP90 and HSP70. Upon ligand 
binding, AR is activated and undergoes a conformational change leading to its dissociation from 
the HSPs in an ATP-dependent manner (Smith and Toft, 2008).  
The AR then translocates to the nucleus. The ligand-induced conformational changes expose 
interaction motifs which enables intra N/C terminal interactions of AR, as well as, inter-
molecular interactions leading to AR dimerisation. The AR typically homo-dimerises, however, 
hetero-dimerisation with ERα and testicular receptor 4 (TR4) has also been reported (Bennett 
et al., 2010).  
Once in the nucleus, the AR binds to the DNA at AREs in the enhancer or promoter of its target 
genes, leading to their transcriptional activation or suppression. Binding of the AR to DNA is 
facilitated by initially unwinding the chromatin around the ARE in order to make these regions 
more accessible for the AR to bind. This is generally mediated by FOXA1 pioneer transcription 
factor which has been shown to bind DNA prior to the AR (Wang et al., 2009).  
Following binding to its AREs, the AR recruits a multitude of proteins involved in chromatin 
remodelling and modification such as the SWI/SNF complex and histone acetyltransferases 
CBP/p300 and pCAF, respectively. The remodelled chromatin enables AR to recruit the 
preinitiation complex and mediate the transcription of AR target genes. In addition, the AR 
recruits a number of co-regulatory proteins which can either enhance or repress its 
transcriptional activity through various mechanisms (van de Wijngaart et al., 2012). Figure 1-3 
summarises the AR activation pathway. 
The AR regulates many critical cellular processes required for both the normal prostate growth 
and development of PC, including proliferation, metabolism, differentiation and apoptosis.  
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Figure 1-3: Summary of the AR signalling pathway. Diagram is drawn based on information from van de 
Wijngaart et al. and Bennett et al. (Bennett et al., 2010; van de Wijngaart et al., 2012). Abbreviations: ARE, 
androgen responsive element; DHT, dihydrotestosterone; HSP, heat shock protein; RNA pol II, RNA polymerase 
II. Free testosterone diffuses across the cell membrane into the prostate cell, and is converted to DHT by 5α-
reductase. DHT binds to the AR, induces dissociation of HSPs and activates the AR. The AR enters the nucleus, 
dimersies and binds to the ARE to transactivate the expression of its target genes leading to increased expression 
and survival. 
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1.3.3 Deregulation of AR activity and the mechanism of CRPC development 
The AR is a key molecule required for the initiation and development of PC and therefore, AR-
targeted therapies have been the mainstay of therapy. However, PC relapses and progresses to 
its lethal state; the CRPC where AR signalling has been shown to be aberrantly reactivated. 
Several mechanisms result in aberrant AR signalling which include: AR amplification and 
sensitisation to low levels of circulating androgens, activating mutations of the AR, generation 
of ligand-independent AR splice variants, persistent intratumoural androgens, AR activation by 
other signalling pathways and aberrant interaction with co-regulator proteins.  
The amplification of the AR gene is one of the most common genetic alterations in CRPC. This 
leads to over-expression of the AR protein and ultimately driving increased sensitisation of the 
AR pathway as it enables sustained cell growth in residual levels of androgen following 
androgen ablation therapy (Visakorpi et al., 1995; Koivisto et al., 1996).  
Mutations of the AR significantly increases in CRPC, where mutations of the NTD are mainly 
associated with increased AR activity and co-activator interactions in the absence of androgen, 
whilst mutations of the LBD lead to broadened ligand specificity of the AR. For example a 
common point mutation, T877A in AR LBD results in increased promiscuity of the receptor 
(Sack et al., 2001), enabling other non-androgenic steroids (oestrogen and progesterone) and 
anti-androgens (flutamide, an antagonist of wild-type AR) to bind and activate the AR (Suzuki 
et al., 1996). Similarly, another point mutation in the LBD, H874Y, has the same effect on AR 
ligand specificity by causing a conformational change of the AR, leading to enhanced binding 
with the p160 family of co-activators (Steketee et al., 2002; Duff and McEwan, 2005). 
Alternative splicing of the AR, leads to the formation of aberrant AR isoforms lacking the AR 
LBD. These AR isoforms are able to bind DNA independently of ligand binding and are 
therefore constitutively active even in the absence of androgen. There are over a dozen AR 
isoforms that have been identified, with AR-V7 being the most characterised and observed to 
be up-regulated in patients with relapsed disease following antiandrogen therapy (Dehm et al., 
2008; Guo et al., 2009).  
In addition to changes in AR structure and levels, alterations in steroid metabolism leading to 
increased production of AR ligand, DHT, causes sensitisation of the AR signalling pathway 
post-ADT. Testes are the major source of testosterone production in males. Testosterone is 
synthesised from cholesterol and then converted into its more potent form, DHT in the prostate. 
In normal males, testosterone is the primary precursor of DHT. However, in CRPC patients, 
intratumoural synthesis of DHT can occur through a number of mechanisms such as up-
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regulation of enzymes involved in the ‘classical’ DHT production pathway and utilisation of a 
‘backdoor pathway’ which enables DHT production from a different precursor, progesterone 
(Locke et al., 2008). Moreover, an ‘alternative’ pathway contributes to DHT production where 
androgens produced by the adrenal gland are converted to DHT in the prostate (Chang et al., 
2011).  
Evasion of the AR blockade by tumours may also be achieved by the up-regulation of the 
glucocorticoid receptor (GR). The GR belongs to the same class of nuclear steroid receptors 
(class 1) as AR, where these two receptors have been shown to have overlapping 
transcriptomes. Therefore, the GR is able to drive gene transcription of AR target genes even 
in the absence of AR. GR up-regulation promotes tumour resistance to novel AR inhibitors, 
enzalutamide and ARN-509, with its knockdown leading to sensitisation of cells to these 
therapies (Arora et al., 2013; Sahu et al., 2013).  
The activation of many oncogenic signalling pathways following androgen deprivation and AR 
inhibition has been implicated in post-transcriptional regulation of the AR and can promote 
aberrant AR activation independently of ligand binding. For example, the activation of the 
PI3K/AKT and MAPK pathways by receptor tyrosine kinases (RTKs) such as the insulin-like 
growth factor receptor (IGFR), epidermal growth factor receptor (EGFR) and fibroblast growth 
factor receptor (FGFR) which have been shown to be over-expressed in CRPC (Culig et al., 
1994; Craft et al., 1999). Furthermore, up-regulation of proteins involved in the DNA damage 
response (DDR) are also reported in CRPC. The AR has been shown to be activated in response 
to DNA damage to promote DNA repair and cell survival through the regulation of DDR gene 
expression programmes. The transcription factor, c-MYB, also involved in the DDR, shares a 
subset of DDR target genes with the AR. In the absence of the AR, c-MYB dominantly regulates 
the expression of their common DDR genes, maintaining their high levels to support cell 
survival (Goodwin et al., 2013; Li et al., 2014b).   
Furthermore, the AR is regulated by many co-regulatory proteins, several of which are 
dysregulated in CRPC. Whilst interactions with its co-activators are enhanced, AR interaction 
with its co-repressors is decreased leading to sustained AR signalling. The co-regulators of AR 
modulate AR activity through different mechanisms such as mediating AR PTMs. A large 
number of these co-regulator proteins are epigenetic enzymes which mediate chromatin 
remodelling through PTMs of histones. The N-terminal tails of histones undergo PTMs such as 
acetylation, methylation, ubiquitination and phosphorylation, leading to altered chromatin 
15 
 
structure which in turn affects gene expression without a change in the DNA sequence, termed 
epigenetics. This indirectly facilitates AR activity by affecting AR-mediated gene transcription.  
Examples of epigenetic enzymes include co-activators such as two p160 histone acetyl-
transferases (HATs), SRC and transcriptional intermediary factor-2 (TIF2), which are 
frequently shown to be up-regulated in CRPC patients (Gregory et al., 2001). These HAT 
enzymes recruit a number of general co-activators, CREB binding protein (CBP), p300 and 
p300/CBP-associating factor (PCAF), all of which possess HAT activity and together acetylate 
specific lysines on histones H3 and H4. This leads to chromatin relaxation and removal of a 
physical barrier, thereby promoting the recruitment of the basal transcriptional machinery 
(Powell et al., 2004). Furthermore, ADT has also been found to increase the expression of p300 
and CBP in PC cells (Heemers et al., 2010). Similarly, other HAT enzymes, including the 
MYST protein family member, Tip60, are elevated in patients with late stage disease and are 
found to acetylate the AR, leading to increased AR transcriptional activity (Brady et al., 1999; 
Gaughan et al., 2001; Gaughan et al., 2002).  
Methyltransferases are a family of epigenetic enzymes with an evolutionary conserved SET 
(Suppressor of variegation, Enhancer of Zeste, Trithorax) domain responsible for their catalytic 
activity. There are 48 SET domain-containing proteins and one SET domain-lacking histone 
lysine methyltransferase, DOT1L encoded within the human genome. They catalyse the 
methylation of histones H3 and H4 either on arginine or lysine residues. Moreover, they 
methylate non-histone proteins ranging from chromatin machinery enzymes to transcription 
factors, including the AR.  
Mis-regulation of methyltransferases and demethylases has been associated with cancer 
aggressiveness, including in PC. For example, the lysine-specific demethylase 1 (LSD1; also 
known as BHC110) interacts with the AR and forms a chromatin complex upon androgen 
stimulation. LSD1 removes the repressive H3K9Me marks and facilitates AR-mediated gene 
transcription (Metzger et al., 2005). High expression of LSD1 has been associated with PC 
aggressiveness (Kahl et al., 2006; Metzger et al., 2006).  
Another example is SET7/SET9/KMT7, a histone methyltransferase that specifically mono-
methylates lysine 4 on histone H3 and up-regulates gene transcription (Wang et al., 2001). 
SET9 was also found to directly methylate the AR which facilitated AR N/C terminal 
interaction, leading to enhanced AR transcriptional activity. Moreover, SET9 was aberrantly 
expressed in CRPC (Gaughan et al., 2011; Ko et al., 2011). Additionally, KMT5A (SET8), a 
specific mono-methyltransferase for lysine 20 on histone H4 has recently been found to be 
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elevated in PC compared to benign samples (Coffey et al, unpublished data). KMT5A is the 
focus of this project and will be discussed in detail throughout this chapter.  
These co-regulators themselves undergo PTMs which can in turn influence their activity and 
ultimately AR activity and function. The AR regulates a distinct transcriptional programme in 
hormone sensitive versus castrate-resistant models of PC, where there is a substantial increase 
in the number of AR regulated genes involved in cell cycle progression in CRPC (Wang et al., 
2009). Therefore understanding the interplay between co-regulators and the AR, but also the 
mechanisms that modulate the co-regulatory proteins themselves may help in providing novel 
therapeutics to inhibit AR signalling in CRPC.  
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1.4 Ubiquitination  
Ubiquitination is the process of post-translationally modifying proteins via the covalent 
conjugation of the highly evolutionary conserved 76 amino acid protein, ubiquitin. Ubiquitin is 
an abundant protein in mammalian cells which can either be found free or covalently attached 
to other proteins. Ubiquitination is an important mechanism in many critical regulatory 
processes including: DNA repair, cell cycle control and the stress response, each requiring a 
specific type of ubiquitination. The outcome of ubiquitination is diverse ranging from protein 
degradation by the proteasome to activation of transcription factors. The wide range of signals 
as a result of ubiquitination depends on the number of ubiquitin molecules that are attached, for 
example proteins can be mono-ubiquitinated or poly-ubiquitinated, and its configuration which 
is the way these ubiquitin moieties are conjugated together to form chains (Weissman, 2001). 
Ubiquitination is a reversible process where ubiquitin can be removed in a hydrolysis reaction 
by deubiquitinating enzymes (DUBs) (Komander et al., 2009). 
1.4.1 Process of ubiquitination  
Ubiquitination results in the formation of an iso-peptide linkage between ubiquitin and the 
acceptor protein. Ubiquitin is ligated through its C-terminal glycine residue to the Ɛ-amino 
group of a lysine in the substrate protein. Moreover, ubiquitin itself consists of 7 lysine residues, 
each of which can be ligated to other ubiquitin molecules to form different chains of ubiquitin 
polymers (Vijay-kumar et al., 1987).  
The ubiquitination process is an enzymatic cascade which takes place in three stages, 
summarised in Figure 1-4. Firstly, ubiquitin is activated by an E1 ubiquitin-activating enzyme 
in an ATP-dependent manner. The activated ubiquitin is then transferred to an ubiquitin-
conjugating enzyme (E2) and is finally conjugated to the substrate protein by an ubiquitin-ligase 
(E3). These enzymes ensure the tight regulation of ubiquitination and the specificity of this 
process (Ciechanover et al., 1981). So far, two E1 enzymes capable of ubiquitin activation, 
approximately 40 E2 enzymes and around 600 E3 ligases have been identified to be encoded 
by the human genome (Villamil et al., 2013). 
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Figure 1-4: Process of ubiquitination. Ubiquitin is activated by an ubiquitin-activating (E1) enzyme using energy 
from ATP hydrolysis and passed to an ubiquitin-conjugating (E2) enzyme. Ubiquitin is then transferred to a 
substrate protein, specified by the distinct E3 ligase that binds both the substrate and the E2. E3 ligases may contain 
really interesting new gene (RING) domains that act as a scaffold to pass ubiquitin from the E2 directly to the 
substrate protein. Alternatively, homologous to E6-AP carboxy-terminus (HECT) E3 ligases form a covalent bond 
with ubiquitin itself first and then transfer the ubiquitin onto the substrate. The diagram was drawn independently 
based on figures from Weissman et al. and Kerscher et al (Weissman, 2001; Kerscher et al., 2006). Abbreviations: 
Ub, ubiquitin; K, lysine; G, glycine.  
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1.4.1.1 E1 ubiquitin-activating enzymes  
In the first stage, ubiquitin becomes activated and ligated to an E1 activating enzyme in an 
ATP-dependent manner. Ubiquitin activation occurs on the carboxyl group of its C-terminal 
glycine residue which is ligated to the catalytic cysteine of the E1 active site through thioester 
linkage to form a thioester-linked E1~Ub conjugate. As a result of ATP and ubiquitin binding, 
E1 undergoes a conformation change which exposes its ubiquitin-fold domain (UFD) required 
for binding to E2 (Ciechanover et al., 1981).  
There has been eight E1 enzymes identified to date, where only two of them, UBE1 and UBA6 
(UBE1L2 or E1-L2), cause ubiquitin activation. In addition to ubiquitin, UBA6 also activates 
the human leukocyte antigen F-associated transcript 10 (FAT10) (Chiu et al., 2007; Jin et al., 
2007; Pelzer et al., 2007). Most of the other E1 enzymes are involved in the activation of 
ubiquitin-like modifiers (ULM) such as small ubiquitin related modifier (SUMO) and neuronal 
precursor cell-expressed developmentally down-regulated protein (NEDD) (Groettrup et al., 
2008).  
1.4.1.2 E2 conjugating enzymes  
Following the formation of the thioester-linked E1~Ub conjugate, an E2 docks non-covalently 
to this complex and the activated ubiquitin is then transferred onto the E2 active site cysteine 
via a transthioesterification reaction. Loaded E2 enzymes can then either associate with E3 
ligases or in a few instances, directly engage with the substrate. Whilst all E2 enzymes interact 
with an E1 enzyme, they can interact with multiple E3 ligases. Of the approximately 40 E2 
enzymes, at least 26 are involved in the transfer of ubiquitin and the remaining transfer 
ubiquitin-like protein such as SUMO and NEDD8 (Huang et al., 2007a; Lee and Schindelin, 
2008).  
An example of an E2 enzyme capable of ubiquitin chain initiation is UBE2D2, which lacks 
specificity for a lysine residue in the substrate protein. On the other hand, UBE2T is an example 
of a selective E2 enzyme which specifically mono-ubiquitinates its substrate FANCD2. Whilst 
these E2s can add the first ubiquitin, the E2 enzyme, UBE2S lacks this capability and is instead 
able to extend lysine 11-specific polyubiquitin chains (Ye and Rape, 2009; Hibbert et al., 2011).   
20 
 
1.4.1.3 E3 ligases 
In the final stage of ubiquitination, the E3 enzyme facilitates the ligation of ubiquitin from the 
active E2 to the substrate protein. The E3 ligase can be a protein or a protein complex and acts 
as an adaptor as it binds to both the E2 and the substrate. There are three classes of E3 ligases 
consisting of: really interesting new gene (RING) domain family, the homology to E6AP C 
terminus (HECT) and the RING-between-RING (RBR) family (Berndsen and Wolberger, 
2014; Scheffner and Kumar, 2014).  
RING E3 ligases are the largest and diverse family of E3 enzymes. They do not have enzymatic 
activity and instead mediate the transfer of ubiquitin from the E2 directly to the substrate by 
simultaneously binding to both components. They commonly function as homomeric or 
heteromeric complexes by interacting with each other or a related RING protein, respectively 
(Brzovic et al., 2001; Campbell et al., 2012). Moreover, a subset of E3 ligases, also known as 
cullin-RING ligases (CRL), are a component of a multi-subunit complex, where E2 and 
substrate binding occurs on different subunits of the complex, linked together by a cullin-type 
protein scaffold. In these complexes, substrate recognition and binding is carried out by a 
variable adaptor protein, forming a bridge between the substrate and the E3 ligase complex. An 
example is the RING protein RBX1 which is part of the SKP1-CUL1-F-box (SCF) complex 
(Jackson et al., 2000).  
In contrast, HECT containing E3 ligases are a relatively small group of E3 enzymes with 28 
members identified in humans thus far. They possess catalytic activity and transfer ubiquitin 
from E2 on to the substrate by catalysing two distinct reactions. Firstly, a transthioesterification 
reaction in which ubiquitin is transferred from the E2 active site cysteine onto a cysteine in the 
HECT domain active site. Secondly, the transfer of ubiquitin from HECT on to a lysine in the 
substrate (Huibregtse et al., 1995).   
The RBR E3 ligases constitute properties of both the RING and HECT E3 families. These 
enzymes consist of a putative RING domain, followed by an in-between ring (IBR) and a less 
conserved RING-like domain. Similar to the RING E3s, RBR interacts with the E2~Ub by non-
covalent interactions through its first RING domain. Then, as in the HECT E3 ligases, the 
activated ubiquitin is transferred onto a conserved cysteine in the RING-like domain, prior to 
being conjugated to the substrate (Wenzel and Klevit, 2012).  
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1.4.2 Ubiquitin function 
Covalent ligation of ubiquitin to the substrate protein causes a diverse range of cellular 
consequences such as destruction of the substrate by the proteasome, altered substrate activity, 
localization and affinity to binding partners or other non-proteolytic events. This is due to the 
vast array of possible ubiquitin chain compositions. Proteins can be modified by a single 
ubiquitin molecule (mono-ubiquitination) or ubiquitin polymers (poly-ubiquitination). 
Ubiquitin chains are formed when ubiquitin itself is ubiquitinated through its lysine residues 
(K6, K11, K27, K29, K33, K48 and K63) or the N-terminal methionine residue (M1). These 
chains can be homotypic, comprising only a single linkage type i.e. chains are formed using the 
same lysine residue in each ubiquitin; or heterotypic, containing mixed linkages within the same 
polymer. Furthermore, heterotypic chains can also be branched i.e. one ubiquitin molecule is 
ubiquitinated at two or more lysine sites. These chains are poorly characterised (Komander and 
Rape, 2012). A summary of the different ubiquitin linkages is provided in Figure 1-5.  
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Figure 1-5: Examples of ubiquitin chain linkages. Ubiquitin is represented as the black open circle. G, glycine; 
K, lysine; M, methionine. The diagram is drawn based on figures from Komander et al (Komander and Rape, 
2012). 
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1.4.2.1 Mono-ubiquitination  
Mono-ubiquitination is the addition of a single ubiquitin molecule to one lysine in the protein 
substrate. It regulates proteins through several mechanisms such as: changing stability, 
subcellular localisation, conformation, activity and interacting partners. Mono-ubiquitination is 
involved in distinct cellular functions including histone regulation, DNA damage response, 
endocytosis, and the budding of retroviruses from the plasma membrane. Although mono-
ubiquitination is associated with non-proteolytic functions by the proteasome, it has been shown 
to cause proteasomal-mediated degradation. Moreover, mono-ubiquitination is the first step in 
the formation of poly-ubiquitin chains. In addition, proteins can be modified by multi mono-
ubiquitination, which is the conjugating of a single ubiquitin at several lysine sites in the 
substrate protein. It can be a signal for internalisation of cell-surface receptors and their 
subsequent degradation in lysosomes, or recycling to the cell surface. Moreover, it has also 
been shown to be involved in proteasomal-mediated degradation (Boutet et al., 2007). 
1.4.2.2 Poly-ubiquitination  
Homotypic chains at all the seven lysine residues of ubiquitin have been shown to be formed 
in vivo (Peng et al., 2003; Xu and Peng, 2006). Each of these linkages have been associated 
with specific functions, with K-48 linked ubiquitin chains being the best characterised as 
responsible for elimination of the target protein by the proteasomal degradation system. K-48 
and K-11 linked ubiquitin chains are the most abundant linkages (Xu et al., 2009). A summary 
of the roles for each ubiquitin linkage is described in Table 1.1. 
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Linkage Physiological function 
K6 K6 linkages increase in response to UV radiation – indirectly associated with 
DNA damage response although not fully elucidated. Example of E3 ligase 
assembling K6-linked ubiquitin chain includes the BRCA1–BARD1 heterodimer 
(Wu-Baer et al., 2003). 
 
Role in promoting protein stabilisation by preventing proteasomal degradation 
(Shang et al., 2005). 
 
Role in Parkin-mediated mitophagy by modulating cellular localisation. The E3 
ligase Parkin is responsible for ubiquitination-mediated destruction of depolarized 
dysfunctional mitochondria by autophagy (mitophagy). K6-linked chains prevents 
Parkin localisation to depolarised mitochondria, preventing mitophagy (Durcan et 
al., 2015).  
 
K11 Involved in cell cycle control. The APC/C complex assembles the K11-linked 
ubiquitin chains on proteins involved in mitosis and targets them for proteasomal 
degradation to mediate mitotic exit and cell cycle progression (Matsumoto et al., 
2010). 
 
Implicated in cellular adaptation to hypoxia. The transcription factor HIF-1α is 
modified by K-11, causing its destabilisation. K11-linkage-specific DUB Cezanne 
(OTUD7B) promotes the stability and expression level of HIF-1α (Bremm et al., 
2014).  
 
Linked to the endoplasmic reticulum-associated degradation (ERAD) pathway 
(Xu et al., 2009).  
 
Role in cell signalling. TNF-α stimulation and activation of NF-κB requires the  
addition of K11-linked chains on receptor-interacting protein 1 (RIP1) (Dynek et 
al., 2010).  
 
K27 Role in DNA damage response by protein recruitment. RNF168-mediated K27-
linked poly-ubiquitination of histone H2A proteins is a major ubiquitin linkage on 
chromatin following DNA damage, required for the recruitment of several crucial 
DNA damage response mediators such as 53BP1 and Rap80 at sites of DNA 
damage (Gatti et al., 2015). 
 
Role in signal transduction and are required for the innate immune response 
triggered by microbial DNA. For example, AMFR and INSIG1, an E3 ubiquitin 
ligase complex mediates K27-linked poly-ubiquitination of an essential host 
immune response protein, STING. This activates a series of downstream 
signalling, ultimately leading to activation of the interferon regulatory factor-3 
(IRF3) and/or NF-κB signalling pathways (Wang et al., 2014).  
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Linkage Physiological function 
K29 Role in protein stabilisation. K29 linked ubiquitin of β-catenin enhances its 
stability leading to up-regulation of the Wnt signalling pathway (Hay-Koren et 
al., 2011). 
 
Role in cell signalling. Axin, a component of the Wnt signalling pathway is 
involved in destruction of β-catenin. The E3 ligase, Smurf, mediates K29-linked 
poly-ubiquitination of Axin and prevents its interaction with Wnt co-receptors 
LRP5/6, thereby represses Wnt/β-catenin signalling (Fei et al., 2013).  
 
Signals for lysosomal destruction. The E3 ligase, AIP4 is a negative regulator of 
the Notch pathway. It mediates K29-linked poly-ubiquitination of the positive 
regulator of the Notch pathway, Deltex, and targets for lysosomal degradation 
(Chastagner et al., 2006).  
 
K33  Role in inhibition of T-cell antigen receptor (TCR) signalling. K33-linked poly-
ubiquitination of T-cell receptor-ζ prevents it from undergoing phosphorylation 
resulting in inhibition of downstream signal transduction (Huang et al., 2010).  
 
Role in inhibition of AMP-activated protein kinase (AMPK)-related protein 
kinase signalling. K33-linked ubiquitination of AMPK-related kinases, NUAK1 
and MARK4, may inhibit their phosphorylation by the LKB1-tumour suppressor 
kinase and prevent their activation (Al-Hakim et al., 2008).  
 
Role in post-Golgi protein trafficking. Attachment of non-degradable K33-linked 
ubiquitin chains onto coronin7 (Crn7) by the E3 ligase Cul3–KLHL20, promotes 
Crn7 recruitment to the trans-Golgi network (Yuan et al., 2014).  
 
K48 Targets proteins for destruction by the proteasome (Chau et al., 1989). 
K63 Role in activating the NF-κB signalling by enabling protein-protein interactions 
to facilitate signal transductions (Conze et al., 2008). Involved in activation of the 
T-cell receptor pathway. NF-κB activation by T- and B-cell receptors in response 
to antigen-receptor stimulation is mediated through K63-linked poly-
ubiquitination of an essential NF-κB modulator, NEMO (Zhou et al., 2004).  
 
 
Role in protein trafficking, including endocytosis of cell-surface receptors by 
endosomal and vacuolar sorting complexes (Lauwers et al., 2009; MacDonald et 
al., 2012).  
 
Role in the control of protein synthesis through activation of ribosomes at specific 
points in the cell cycle (Spence et al., 2000). Moreover, K63 ubiquitination in 
increased in response to oxidative stress which serves to stabilize the ribosome 
complex and polysomes, thereby promoting protein synthesis and cellular 
viability (Silva et al., 2015).  
 
Important in DNA damage response. K63 poly-ubiquitination of histone H2A by 
the E3 ligase RNF8 following DNA damage is required for the recruitment of 
53BP1 and BRCA1 (Huen et al., 2007). Moreover, K63-linked chains on FANCG 
following DNA interstrand crosslinks enables the recruitment of the BRCA1 
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complex and the formation of Rad51 foci at the damage site. This initiates the 
homologous recombination repair pathway (Zhu et al., 2015). 
Table 1.1: Reported roles for homogeneous lysine linked ubiquitin chains. 
 
In addition to the canonical lysine linked ubiquitin chains, ubiquitin can be ligated to protein 
substrates via its N-terminal methionine (M1) and forms a linear ubiquitin chain. This is 
assembled by the RBR E3 ligase complex, linear ubiquitin chain assembly complex (LUBAC) 
(Kirisako et al., 2006). Ubiquitin M1 linkages are pivotal in inflammatory and immune 
responses by regulating the activation of the transcription factor NF-κB. As such they have an 
important role in the immune and inflammatory responses (Iwai and Tokunaga, 2009; Ikeda et 
al., 2011).  
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1.5 KMT5A 
The KMT5A protein, also known as SET8 and PR-SET7, is a member of the SET domain 
family of lysine methyltransferases. It is located on chromosome 12q24.31, encoding a 393 
amino acid protein with a molecular weight of approximately 42 kDa. KMT5A specifically 
mono-methylates histone 4 on lysine 20 (H4K20Me1), and is the sole mono-methyltransferase 
responsible for this histone modification in higher eukaryotes (Couture et al., 2005; Xiao et al., 
2005). It recognises the sequence RHRK20VLRDN within H4 N-terminus (Yin et al., 2005). 
Moreover, it mono-methylates a number of non-histone proteins including p53. As such, 
KMT5A plays a key role in maintaining genome integrity, gene transcription and cell cycle 
progression through regulating higher-order chromatin structure either directly or indirectly, 
modulating the expression of genes that are important for DNA synthesis and in the G1-S phase 
transition. 
1.5.1 Structure of KMT5A 
The structure of KMT5A is divided into two functional domains: the SET or enzymatic domain 
located at the C-terminus and the N-terminal histone binding domain (Yin et al., 2005; Yin et 
al., 2008). As already alluded to, KMT5A’s enzymatic activity is restricted to the addition of 
one methyl group from the co-factor, S-adenosylmethionine (SAM), to the side-chain nitrogen 
of lysine 20 on H4. Moreover, KMT5A exhibits greater enzymatic activity towards 
nucleosomal H4 over either histone octamer or H4 polypeptide (Fang et al., 2002; Nishioka et 
al., 2002).  
This has been shown following the determination of the structure of KMT5A SET domain by 
crystallographic studies. For example, the active site of KMT5A, where it accommodates the 
amino group of its substrate is a small pocket, is only capable of housing a mono-methylated 
lysine compared to other H4K20 methyltransferases, Suv4-20h1 and Suv4-20h2, which have a 
more open active site and catalyse di- and tri-methylation (Xiao et al., 2005). Furthermore, an 
evolutionary conserved tyrosine residing in the active site of KMT5A ensures methylation is 
terminated after the conjugation of one methyl group by forming hydrogen bonds with the 
mono-methylated lysine of the substrate. Moreover, part of the KMT5A specificity is governed 
by an array of contacts with the surrounding residues, in particular the histidine residue flanking 
K20 in H4. This residue is recognised by KMT5A and contributes to the complete formation of 
KMT5A’s lysine-access channel which connects the substrate and cofactor binding sites and as 
a result enables efficient enzymatic activity (Couture et al., 2005; Xiao et al., 2005).  
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The insert or Set-1 region (i-set) is a region approximately in the middle of the SET domain 
which is responsible for mediating the enzyme’s interactions with its substrate. Recently, it was 
reported that KMT5A binds the nucleosome through multivalent interactions mediated by c-
terminal (s-set) and n-terminal (n-set) flanking regions of i-set. Subsequently, this was proposed 
to enable KMT5A to recognise the nucleosome architecture in addition to individual elements 
in its substrate (Girish et al., 2016).  
In contrast to the C-terminal domain, the N-terminal region of KMT5A-related proteins, as well 
as, KMT5A isoforms share low sequence homology with the exception of a conserved region 
containing a Cdk phosphorylation consensus sequence and a D-box destruction motif 
recognised by the APC/C ubiquitin ligase complexes (Wu et al., 2010). Although, the structure 
of KMT5A N-domain has not been resolved to date, it has been speculated to have a floppy 
structure and play a role in stabilising the interaction of KMT5A with the nucleosome. 
Consistently, using deletion mutants, immunostaining and imaging techniques, Yin 
demonstrated that the KMT5A N-domain truncation mutant was always located in the nucleus 
and was responsible for binding to H4 N-terminal (Yin et al., 2008).  
1.5.2 Isoforms of KMT5A 
There are three isoforms of KMT5A which all share the same C-terminus, but differ in their N-
terminal sequence. Two of the isoforms were identified by Abbas in U2OS cells (a human 
osteosarcoma derived cell line) as Set8a and Set8b following their observation of KMT5A 
protein running as a doublet on SDS-PAGE (Abbas et al., 2010).   
Set8a is reported to consist of 352 amino acids and correspond to the heavier and slower-
migrating KMT5A band. Set8b is composed of 322 amino acids and is a splice variant of Set8a, 
which is generated as a result of missing amino acids 10-40 within exon 2 of KMT5A. 
Furthermore, Set8b was shown to be functional in vivo and more abundant than Set8a (Abbas 
et al., 2010). Although not stated by the group, Set8a and Set8b have a molecular weight of 
approximately 39 and 36 kDa. Moreover, the largest isoform of KMT5A is a 393 amino acid 
long protein with a molecular weight of approximately 42 kDa. This isoform differs to Set8a 
by a sequence of 41 amino acids extended in its N-terminus and an alternative sequence in 
amino acids 42-57 (Figure 1.6, information from UniProt and NCBI websites).  
Most of the studies have numbered KMT5A residues based on the 352 amino acid long protein. 
The 42 kDa isoform is the observed form of KMT5A by our group and is consistent with the 
molecular weight stated by the anti-KMT5A antibody datasheets. Therefore, KMT5A residues 
have been numbered based on the 393 amino acid long protein in this work.
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Figure 1-6: Structure of KMT5A isoforms. The diagram is drawn based on information from UniProt, Abbas et al (Abbas et al., 2010), Wang et al (Wang et al., 2015) and Wu 
and Rice (Wu and Rice, 2011).  
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1.5.3 Function  
KMT5A mediates its function primarily through mono-methylating H4K20. The methylation 
status of H4K20 contributes to chromosome behaviour and it can undergo further methylation 
to become di- and tri-methylated by distinct methyltransferases, Suv4-20h1 and Suv4-20h2, 
respectively (Schotta et al., 2004). The single methyl group can also be removed from 
H4K20Me1 by demethylase, PHF8, whilst no demethylase for H4K20Me2/3 has been 
identified (Liu et al., 2010; Qi et al., 2010). Each degree of methylation is uniquely distributed 
throughout the genome. Whilst H4K20Me2 is widely present on chromatin, H4K20Me1 and 
H4K20Me3 are less abundant (Pesavento et al., 2008; Yang et al., 2008). Furthermore, they 
each have distinct functions for example, H4K20Me1 is associated with chromatin 
condensation processes (Trojer et al., 2007) and has a role in both the activation and repression 
of gene transcription (Barski et al., 2007). H4K20Me2 is involved in the DNA repair pathway 
by guiding DNA repair proteins to DNA strand breaks (Sanders et al., 2004; Botuyan et al., 
2006). Finally, H4K20Me3 is enriched in pericentromeric heterochromatin and is correlated 
with transcriptional repression (Schotta et al., 2004) where global loss in its level are associated 
with tumourigenesis (Fraga et al., 2005). However, KMT5A-mediated mono-methylation of 
H4K20 is the first step and the primary substrate required for the formation of subsequent 
methylation states (Oda et al., 2009).  
The enzymatic activity of KMT5A is essential for viability. Its biological importance was 
demonstrated to be critical during embryonic development in Drosophila, where KMT5A null 
mutation leading to its complete loss-of-function caused lethality at the third instar larval stage 
(Karachentsev et al., 2005). This was further demonstrated using KMT5A knockout mouse 
model in which loss of KMT5A led to embryonic lethality at the four-cell stage of 
embryogenesis. However, restoring KMT5A function by microinjection of mRNA encoding 
the wild-type, but not its catalytically-dead form into the two-cell embryo rescued its 
development (Oda et al., 2009). Therefore, KMT5A has a critical role in regulating the genomic 
integrity, DNA-based processes and the development of eukaryotic cells.  
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1.5.3.1 Cell cycle progression 
KMT5A and H4K20Me1 levels are under precise regulation during the cell cycle. Their levels 
change dynamically, being most abundant during G2/M phase and absent in S phase of the cell 
cycle. This fluctuation reflects the essential role of KMT5A-mediated H4K20Me1 in regulating 
higher-order chromatin structure and subsequently the proper progression of the cell cycle. The 
impact of KMT5A loss on cell cycle progression has been extensively studied in mammalian 
cells using mainly knockdown approaches in transformed cells, as well as, a knockout and a 
conditional knockout mouse and Drosophila models with contrasting conclusions.   
In accordance with KMT5A and H4K20Me1 demonstrating high levels in mitosis, KMT5A null 
mutation in Drosophila neuroblasts led to the formation of abnormal chromosomes, defective 
in chromosome condensation and separation during mitosis. These neuroblasts also exhibited 
delayed progression through early stages of mitosis and decreased S phase population 
(Sakaguchi and Steward, 2007). Similarly, conditional inactivation of the KMT5A gene in 
mouse embryonic stem (ES) cells caused decondensation of chromosomes during mitosis and 
accumulation of cells in G2/M phase of the cell cycle, as well as delayed S phase progression. 
Detailed analysis using cell cycle arrest experiments revealed that cell cycle progression was 
disturbed in the following S phase and G2/M phase when cells had undergone a single round 
of mitosis without KMT5A protein, which was when H4K20Me1 levels started to decrease, 
suggesting cell cycle defects are due to reduced H4K20Me1 levels rather than KMT5A protein 
per se (Oda et al., 2009). Furthermore, similar observations were made with transient depletion 
of KMT5A in HEK293 cells, which caused cell cycle arrest at G2 with subsequent increased 
G2/M population and global decondensation of chromosomes (Houston et al., 2008). The 
failure of chromosome compaction could be linked to either of the H4K20Me1-binding 
proteins, L3MBTL1 or condensin 2, which are both involved in chromatin compaction (Trojer 
et al., 2007).  
In contrast, although cell cycle was impaired with KMT5A knockdown, it was shown to be due 
to delayed S phase progression by causing defective replication fork activity and origin firing 
rather than slowed mitotic progression in U2OS human osteosarcoma cells (Jørgensen et al., 
2007; Tardat et al., 2007). Moreover, KMT5A was hypothesised to have other substrates than 
H4K20 during S phase to promote S phase progression (Tardat et al., 2007). 
Collectively, KMT5A has a critical role maintaining genomic stability, either through having a 
role in accurate completion of DNA replication or mitosis, and potentially links these two 
processes together.  
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1.5.3.2 DNA replication  
As already alluded to, despite the very low levels of KMT5A and H4K20Me1 during S phase 
(Oda et al., 2009), KMT5A-mediated H4K20Me1 generation has been shown to be critical for 
DNA replication. Firstly, studies of several well-characterised human replication origins, which 
are discrete chromosomal sites where genome duplication initiates, including Top1, MCM4, 
LaminB2 and β-globin genes (Goren et al., 2008; Miotto and Struhl, 2008; Miotto and Struhl, 
2010) showed a transient increase in H4K20Me1 by KMT5A. This event proceeded the onset 
of DNA-replication licensing at the end of mitosis (Tardat et al., 2010), a critical process 
responsible for activation of replication origins that starts towards the end of mitosis, continues 
through to G1 and terminates in S phase (Remus and Diffley, 2009).  
Secondly, although KMT5A is highly unstable during S phase, inhibiting KMT5A proteasomal-
mediated degradation leads to its stabilisation and is found to localise at sites of active 
replication (Tardat et al., 2007), where it interacts with PCNA (Proliferating cell nuclear 
antigen) through its PCNA-interacting motif (PIP domain) (Jørgensen et al., 2007; Huen et al., 
2008). Furthermore, physiological expression of KMT5A resistant to CRL4Cdt2-mediated 
ubiquitination and degradation during S phase leads to maintained H4K20Me1 and DNA re-
replication exemplified by cells with a larger nuclear volume and >4n DNA content, which 
occurred dependent on the catalytic activity of KMT5A (Abbas et al., 2010; Tardat et al., 2010). 
Moreover, inhibiting PCNA and CRL4Cdt2-mediated KMT5A degradation leads to 
disappearance of H4K20Me1 at replication origins and prevents origin licensing (Tardat et al., 
2010).  
Finally, as discussed previously, progression through S phase is delayed upon loss of KMT5A 
catalytic activity accompanied by reduced numbers of active origins in S phase (Jørgensen et 
al., 2007; Tardat et al., 2007). Consistent with having a positive role in replication licensing, 
KMT5A silencing impairs the chromatin loading of CDC6, MCMs and ORC2 which are 
components of the pre-replicative complex (pre-RC), a multi-protein complex that is recruited 
at origins to make them competent for replication. Furthermore, artificial targeting of a 
catalytically active KMT5A to an origin-free locus in the genome promotes H4K20Me1 and 
recruitment of the pre-RC components (Tardat et al., 2010).  
In addition to KMT5A mediated H4K20Me1 creating an environment for origin firing as one 
of the mechanisms for facilitating DNA replication, H4K20Me1 may affect the status of H4 
acetylation which also modulates replication licensing. In this case, another H4 modifying 
enzyme, HBO1 which acetylates H4 at origins in G1 phase and induces replication licensing is 
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found at origins enriched with H4K20Me1 during mitosis (Iizuka et al., 2006; Miotto and 
Struhl, 2008; Miotto and Struhl, 2010). In contrast to KMT5A, HBO1 level is stable throughout 
the cell cycle and does not cause DNA re-replication if overexpressed (Iizuka et al., 2006; 
Miotto and Struhl, 2008). Therefore, a DNA replication model modulated by a cascade of H4 
modifications has been proposed in which a burst of KMT5A-mediated H4K20Me1 in mitosis 
is followed by increased acetylation of H4 at K5, K8 and K12 during G1 phase. The degradation 
of KMT5A through PCNA and CRL4Cdt2 dependent mechanisms and its removal from the 
origins at the onset of S phase then ensures DNA replication occurs once in each cell cycle 
(Brustel et al., 2011).  
Moreover, KMT5A regulation of DNA replication can be through transcriptional regulation of 
E2F-1 target genes that are important for DNA synthesis and in the G1-S phase transition 
(Abbas et al., 2010; Liu et al., 2010). Consistently, KMT5A has been shown to repress E2F-
target genes by directly docking to L3MBTL1 (lethal 3-malignant brain tumour like protein 1) 
at E2F target gene promoters (Trojer et al., 2007; Kalakonda et al., 2008).  
1.5.3.3 DNA damage and repair 
A large number of studies have shown that mammalian cells lacking KMT5A undergo 
extensive DNA damage. For example, a massive spontaneous DNA damage was induced in 
mouse ES cells with complete loss of KMT5A function (Oda et al., 2009), as detected by an 
increase in γ-H2AX, a well-established marker for DNA double strand breaks (DSBs) (Pilch et 
al., 2003). Interestingly, unlike mouse ES cells, there was no major change in the level of γ-
H2AX, as well as the 53BP1 DNA repair protein in KMT5A-/- embryos which did not survive 
past the eight-cell stage, suggesting DNA damage is not necessarily responsible for lethality in 
these embryos (Oda et al., 2009). Similar to mouse ES cells, substantial DNA damage was 
observed in HEK293 and U2OS cells lacking KMT5A. This led to activation of the DNA 
damage response via ATM and ATR kinase-mediated pathways, two critical DNA damage 
checkpoints, followed by p53-dependent DNA damage response (DDR) (Jørgensen et al., 2007; 
Tardat et al., 2007; Houston et al., 2008). The spontaneous DNA damage upon KMT5A 
inhibition also led to sensitisation of breast cancer cells to DNA damage (Yu et al., 2013). 
Consistently, in an unbiased siRNA screen to identify proteins important in maintaining 
genome stability through modulating the DDR, KMT5A depletion led to increased γ-H2AX in 
HeLa cells (Paulsen et al., 2009).  
The DNA damage caused by KMT5A depletion was dependent on cells undergoing DNA 
replication. Furthermore, this damage was suppressed with depletion of Rad51, a key regulator 
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of the homologous recombination pathway, which is a pathway that plays an important role in 
the DDR during DNA replication (Jørgensen et al., 2007). Recruitment of 53BP1, a critical 
component of mammalian DDR that is involved in the initial sensing and signalling of DNA 
strand breaks and is pivotal in determining non-homologous end joining (NHEJ)-directed repair 
(Ward et al., 2006; Panier and Boulton, 2014), was speculated to be disrupted upon KMT5A 
depletion, as an underlying mechanism for the DNA damage induction. However, this was 
refuted by Jørgensen (Jørgensen et al., 2007) as KMT5A depletion did not influence the 
recruitment of 53BP1 at DNA DSBs, and was bound to H4K20Me2 (Jørgensen et al., 2007). 
On the other hand, although H4K20Me2 was an important determinant in 53BP1 binding at 
DSBs, KMT5A-mediated H4K20Me1 was shown to be the upstream event required for de novo 
H4K20Me2 by Suv4-20 and efficient NHEJ-directed repair. Moreover, recruitment of KMT5A 
at DSBs was mediated by NHEJ Ku70 protein (Tuzon et al., 2014). In line with this, NHEJ-
directed repair was severly impaired in KMT5A-depeleted cells, concurrent with accumalated 
unrepaired DSBs (Houston et al., 2008; Oda et al., 2009). Interestingly, KMT5A levels were 
shown to be a determinant of the DDR pathway as KMT5A depletion severly impared the 
NHEJ-directed repair, whilst the HDR was significantly enhanced.  
Although loss of KMT5A robustly induces DNA damage which has been attributed to genomic 
instability as a result of defective DNA replication and mitosis, degradation of KMT5A is 
required to enable DNA repair. KMT5A was shown to be recruited to sites of laser-induced 
DNA damage and bound chromatin through docking to PCNA. The CRL4Cdt2 complex then 
ubiquitinated and degraded KMT5A. This mechanism restricts the presence of KMT5A on 
chromatin after DNA damage in order to relax the chromatin to enable access of DNA repair 
pathway proteins. In line with KMT5A destruction following DNA damage, a proteomics study 
conducted global ubiquitin profiling in whole-cell lysates to identify DNA damage-regulated 
ubiquitination sites and revealed KMT5A is ubiquitinated at 11 lysine residues, all of which 
were residing in the KMT5A C-terminal domain. KMT5A ubiquitination was induced in 
response to UV and ionizing radiation which marked KMT5A for proteasomal degradation as 
the lysine sites could only be detected in the presence of the proteasomal inhibitor, MG132 
(Elia et al., 2015). 
1.5.3.4 Gene regulation/ Transcription 
The role of KMT5A and its mark, H4K20Me1 in regulating gene transcription is controversial. 
Earlier studies found KMT5A is enriched within transcriptionally repressed chromatin (Fang et 
al., 2002; Nishioka et al., 2002). Consistently, H4K20Me1 was shown to have a putative role 
in X chromosome inactivation, where in combination with histone H3 lysine 27 tri-methylation 
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(H3K27Me3) marked the beginning of X inactivation in mouse ES cells (Kohlmaier et al., 
2004). Furthermore, detailed analysis using ChIP-chip experiments on a large subset of the 
genome in HeLa cells revealed KMT5A is preferentially enriched within gene bodies of specific 
genes. The expression of these H4K20Me1-enriched genes was upregulated upon loss of 
KMT5A and H4K20Me1 (Congdon et al., 2010). Moreover, H4K20Me1 is shown to localise 
at repressed E2F-target genes. Stable expression of KMT5A inhibited the transcription of 
various E2F1-regulated genes including cyclin E2, cyclin A2, CDC25A, geminin, MCM7 and 
Cdt1, as well as histone genes H2A, H2B, H3 and H4 where full repression was dependent on 
KMT5A catalytic activity (Abbas et al., 2010). KMT5A also repressed a subset of p53 target 
genes, described in Chapter 1.5.3.5.  
Deposition of H4K20Me1 by KMT5A is suggested to repress transcription by directly 
promoting chromatin compaction (Lu et al., 2008; Oda et al., 2009), or indirectly through the 
recruitment of the repressor protein L3MBTL1 (Trojer et al., 2007). Indeed, L3MBTL1 
preferentially binds mono- and di-methylated forms of H4K20 (Li et al., 2007; Min et al., 
2007). Moreover, the transcription of endogenous H4K20Me1-associated genes including 
RUNX1 and c-myc were up-regulated with the loss of H4K20Me1 and subsequent depletion of 
L3MBTL1 (Trojer et al., 2007; Sims and Rice, 2008). Additionally, loss of PHF8 and the 
subsequent elevation in H4K20Me1 level leads to increased L3MBTL1 binding which causes 
increased repression of E2F-controlled genes (Liu et al., 2010).  
In contrast, H4K20Me1 enrichment has also been detected in active promoters, where it 
overlaps with RNA polymerase II (RNA pol II) (Talasz et al., 2005) and transcribed regions 
which suggested it as a marker of transcription elongation (Vakoc et al., 2006), implicating a 
role in activating transcription. Consistently, a genome-wide ChIP analysis in human T 
lymphocytes found H4K20Me1 is associated with gene activation as it was found downstream 
of transcription start sites (TSS) of active genes (Barski et al., 2007). This was further supported 
as H4K20Me1 was one of the histone modifications highly correlated with active transcription 
(Wang et al., 2008b).  
In line with a role in activating transcription, gene-specific studies have also provided evidence 
for H4K20Me1 positively regulating gene transcription. For example, KMT5A-mediated 
H4K20Me1 at the PARPγ gene causes an up-regulation of PARPγ to promote adipocyte 
differentiation (Wakabayashi et al., 2009). Furthermore, KMT5A was shown to be required for 
ERα-mediated gene expression through deposition of H4K20Me1. In MCF7 cells, H4K20Me1 
level was elevated at the ER-α target gene promoter, TFF1, upon receptor activation. On the 
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other hand, this enrichment was almost abolished in KMT5A depleted MCF7 cells. 
Interestingly, KMT5A interacting partners differed at various regions of the TFF1 gene. Whilst 
KMT5A and ERα were co-occupied only at TFF1 promoter, KMT5A was then found to co-
occupy with pol II only at TFF1 coding regions, consistent with a role in both transcriptional 
initiation and elongation (Li et al., 2011a). Similarly, H4K20Me1 and KMT5A were enriched 
at Wnt target genes upon Wnt stimulation. The activation of Wnt signalling led to the 
recruitment of KMT5A into the β-catenin/TCF4 transcription complex, required to activate 
Wnt-mediated gene transcription in both mammalian cells and zebrafish; therefore, suggested 
to act as a co-activator (Li et al., 2011b). Interestingly, KMT5A was discovered to act as a dual 
transcriptional regulator at TWIST-target genes, E-cadherin and N-cadherin. TWIST which is 
a pivotal transcription factor in promoting epithelial-mesenchymal transition (EMT) leading to 
metastasis, interacts with KMT5A. Whilst this interaction causes suppression of the epithelial 
marker, E-cadherin, it activates the transcription of the mesenchymal marker, N-cadherin (Yang 
et al., 2012).  
Importantly, KMT5A is also found to interact with the AR and through deposition of 
H4K20Me1, activate the transcription of an AR-target gene, PSA, in the androgen dependent 
PC cell line model, LNCaP. Further, stimulation of AR signalling by DHT led to enriched 
KMT5A and H4K20Me1 at the PSA promoter (Yao et al., 2014). The role of KMT5A in 
regulating the AR has also been extensively studied in the Solid Tumour Target Discovery 
(STTD) group by Dr Kelly Coffey, who has demonstrated KMT5A exhibits differing functions 
towards the AR between models of androgen dependent and independent PC. KMT5A 
knockdown experiments in the LNCaP PC cell line representative of androgen sensitive PC led 
to an increase in the AR regulated genes, PSA and TMPRSS2 at the mRNA and protein levels. 
In contrast, this led to a reduction in AR regulated genes in the CRPC model, LNCaP-AI cells, 
as well as other drug-resistant PC cell lines. Furthermore, KMT5A and H4K20Me1 were 
enriched at inactive androgen-responsive genes which were lost upon AR activation in LNCaP 
cells whereas, they were enriched at AR-responsive genes upon AR activation in LNCaP-AI 
cells. This suggests that KMT5A acts as a co-repressor in LNCaP cells but an activator in 
LNCaP-AI cells (Figure 1.7, Coffey et al, unpublished data). 
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Figure 1-7: Summary of previous KMT5A findings in regulating the AR in LNCaP and LNCaP-AI cells (Coffey 
et al, unpublished data). 
1.5.3.5 Non-histone proteins  
In addition to histone methylation, KMT5A has been shown to methylate non-histone proteins, 
with the most archetypal substrate being p53. KMT5A methylates p53 at lysine 382 (K382) and 
causes repression of the highly responsive p53-target genes, PUMA and p21. KMT5A prevents 
p53-mediated transcriptional activation of these genes by inhibiting p53 binding at gene 
promoters. However, KMT5A did not influence weaker p53-responsive genes such as Bax and 
NOXA. Negative regulation of p53 function by KMT5A was further demonstrated as KMT5A 
and p53K382Me1 were decreased with DNA damage whereas KMT5A knockdown led to 
enhanced p53 activity and increased apoptosis. However, KMT5A-mediated mono-methylation 
of p53 at K382 is suggested to be more complex than just acting as a switch for p53 activity, as 
it positively regulates the expression of the DNA repair gene, GADD45. It was therefore 
speculated that whilst p53 activity is dampened under normal conditions, KMT5A-mediated 
mono-methylation causes it to be predisposed to specific cellular stress signals, perhaps milder 
cellular insults. This would enable activation of p53-dependent DNA repair without causing 
cell death (Shi et al., 2007).  
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As well as directly regulating p53 function, KMT5A negatively modulates the pro-apoptotic 
activity of the p53-Numb interaction. Numb is involved in promoting apoptosis and its pro-
apoptotic function mainly depends on p53, which is mediated through their interaction with 
each other in the nucleus, causing p53 stabilisation. However, KMT5A methylates the p53-
interacting domain of Numb at two lysine residues, K158 and K163. This prevents the binding 
of p53 and Numb, leading to increased p53 ubiquitination and degradation. This interaction 
however, was not influenced by KMT5A-mediated p53 mono-methylation at K382 (Dhami et 
al., 2013). 
Moreover, PCNA undergoes methylation at K248 by KMT5A which is mediated through 
interaction with the PIP motif of KMT5A. This leads to stabilisation of the PCNA protein by 
protecting PCNA from ubiquitination and degradation. Furthermore, methylation enhances the 
binding of PCNA with FEN1, a structure-specific nuclease with both 5’ flap endonuclease and 
5’-3’ exonuclease activities (Lieber, 1997). FEN1 is recruited to DNA replication loci during S 
phase in a methylated-PCNA, interaction-dependent manner and is responsible for RNA primer 
removal during Okazaki fragment processing, as well as participating in DNA base excision 
repair (Chen et al., 1996; Zheng et al., 2007). Inhibiting PCNA methylation abrogates its co-
localisation with FEN1, retards Okazaki fragment maturation, DNA replication and induces 
DNA damage. As FEN1 deregulation has been associated with cancer and the fact that 
methylated PCNA promotes increased cell growth, together with observed overexpression of 
KMT5A and PCNA in various cancers, means abnormal interaction between PCNA and FEN1 
may cause carcinogenesis (Takawa et al., 2012).  
Recently, a screening experiment conducted by Dr Fabio Pittella Silva (Memorial Sloan 
Kettering Cancer Centre, USA), with the aim of identifying novel KMT5A substrates revealed 
that almost half of the substrates identified are cytoplasmic proteins. This highlights the 
important role of KMT5A and suggests many other, as yet un-identified signalling pathways 
that KMT5A regulates (personal communication).  
1.6 Regulation of KMT5A  
KMT5A protein expression is under tight regulation in a cell cycle-dependent manner, being at 
its highest level in G2/M, declines in G1 and is absent during S phase (Rice et al., 2002; Yin et 
al., 2008; Oda et al., 2010). This is also reflected in the level of H4K20Me1 which follows a 
similar oscillation pattern throughout the indicated cell cycle phases (Oda et al., 2009). KMT5A 
level is primarily regulated by post-translational modifications (PTM). However, there is 
evidence of KMT5A regulation at the transcriptional level, where its deregulation has been 
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associated with the onset and outcome of various cancers. In addition to its protein level, 
KMT5A localisation and activity are also directly regulated by PTMs. It is speculated that, 
KMT5A is subject to additional, as yet unidentified modifications which may in turn influence 
its function.  
1.6.1 Transcriptional regulation of KMT5A 
KMT5A fluctuations have also been observed at the mRNA level, however it does not correlate 
well with the dynamic changes in KMT5A protein throughout the cell cycle (Rice et al., 2002). 
Additionally, ectopically expressed KMT5A from a constitutively active promoter exhibits 
similar protein levels as endogenous KMT5A during the cell cycle (Oda et al., 2010).  
Interestingly however, KMT5A gene transcription has been indicated to play a role in lineage 
development and maintenance. In adipogenesis, the peroxisome proliferator activated receptor 
γ (PPARγ) protein, a pro-adipogenic transcription factor regulates KMT5A gene expression. 
PPARγ-mediated up-regulation of KMT5A is required for differentiation of pre-adipocytes into 
differentiated adipocytes. Subsequently, KMT5A-mediated H4K20Me1 at PPARγ gene 
enhances PPARγ transcription, where they work in a positive feedback loop to facilitate 
terminal adipocyte differentiation (Wakabayashi et al., 2009). However, it is not shown whether 
KMT5A mRNA levels correlated with its protein levels. In addition, using skin-specific 
KMT5A knockout mouse models, it was shown that KMT5A is a transcriptional target of c-
Myc and is essential in mediating Myc-induced proliferation and differentiation of skin 
(Driskell et al., 2012).  
In addition, KMT5A is subject to post-transcriptional regulation by microRNAs (miRNAs). 
These are a class of noncoding small RNAs that bind to the 3’ untranslated region (3’UTR) of 
target mRNA by complementary base pairing, leading to degradation of the mRNA and 
translational repression (Bartel, 2004). KMT5A was found to be negatively regulated by 
miRNA-7, which degraded KMT5A mRNA and subsequently inhibited H4K20Me1 in breast 
cancer cell lines. Repression of KMT5A by miRNA-7 led to suppression of EMT and invasion 
of breast cancer cells (Yu et al., 2013). 
1.6.2 Post-translational modifications (PTM) of KMT5A 
KMT5A is regulated through multiple PTMs including acetylation, phosphorylation, 
sumoylation and ubiquitination. These modifications have a diverse range of effects on KMT5A 
including modulating KMT5A stability, structure, cellular localisation and interacting partners. 
Whilst ubiquitination has been shown to be responsible for maintaining KMT5A protein level 
under control, acetylation and sumoylation are involved in modulating KMT5A activity rather 
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than its protein levels (Spektor et al., 2011). Phosphorylation however, is reported to regulate 
both the expression level and enzymatic activity, as well as, localisation of KMT5A (Yin et al., 
2008). The dynamic regulation of KMT5A throughout the cell cycle depends on the 
orchestrated regulation of these PTMs and their cross-talk to ensure timely cell cycle 
progression. A summary of PTMs regulating KMT5A protein level is provided in Figure 1.8. 
The aim of this project is to further elucidate how KMT5A is regulated by a type of ubiquitin 
conjugation: mono-ubiquitination.  
1.6.2.1 Phosphorylation  
Phosphorylation of KMT5A modulates its protein stability by regulating KMT5A 
ubiquitination as many ubiquitin ligases either require phosphorylation or dephosphorylation 
of their substrate prior to their recognition. Additionally, phosphorylation can directly influence 
the enzymatic activity of KMT5A.  
A KMT5A orthologue has been shown to be phosphorylated in X. laevis specifically during 
mitosis (Stukenberg et al., 1997). KMT5A protein sequence contains a consensus sequence S-
P-X-K/R which is highly conserved and is recognised by the Cdk1-cyclin B complex for 
phosphorylation. KMT5A was subsequently shown to be phosphorylated by this kinase 
complex at serine 100 (S100) during prophase to early anaphase. This phosphorylation event 
inhibits KMT5A ubiquitination and proteasomal-mediated proteolysis by the anaphase-
promoting complex, APCCdh1, leading to stabilisation of KMT5A during mitosis. Moreover, it 
leads to removal of KMT5A from mitotic chromosomes without altering KMT5A enzymatic 
activity. The extrachromosomal KMT5A is then rapidly dephosphorylated by the Cdc14 
phosphatase which enables KMT5A ubiquitination and subsequent proteasomal degradation by 
the APCCdh1 complex during late mitosis (Wu et al., 2010). 
Recently, KMT5A has been reported to be phosphorylated by casein kinase 1 (CK1) on serine 
253 (S253). CK1-mediated phosphorylation promotes KMT5A ubiquitination and its 
destruction by the SCFβ-TRCP complex, leading to KMT5A reduction (Wang et al., 2015). 
1.6.2.2 Ubiquitination  
KMT5A ubiquitination has been extensively studied and several ubiquitin ligases are shown to 
down-regulate the abundance KMT5A protein. Some of these ligases are suggested to work 
synergistically to tightly regulate KMT5A stability through ubiquitination-mediated 
proteasomal degradation at different stages of the cell cycle, which is essential for both the 
compaction of mitotic chromosomes and for the control of replication origins.  
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The CRL4Cdt2 ubiquitin ligase complex has been shown to be a master regulator of cell cycle 
progression, through ubiquitin-mediated degradation of its substrates, the replication initiation 
protein Cdt1 (Arias and Walter, 2005; Abbas et al., 2008) and the Cdk inhibitor p21 (Abbas et 
al., 2008; Kim et al., 2008; Nishitani et al., 2008), whose expression are incompatible with 
DNA replication. The CRL4Cdt2also governs KMT5A levels during S phase and in response to 
DNA damage (Abbas et al., 2010; Centore et al., 2010; Oda et al., 2010; Jørgensen et al., 2011). 
The ubiquitination and degradation of KMT5A by the CRL4Cdt2 complex requires the binding 
of KMT5A to PCNA via the PIP degron (Havens and Walter, 2009). KMT5A consists of two 
PIP boxes, PIP box 1 (amino acids 51-58) and PIP box 2 (amino acids 178-185), where PIP box 
2 has been shown to be responsible for KMT5A binding to PCNA and in turn Cdt2 as mutations 
of critical residues within this region disrupts these interactions and causes KMT5A 
stabilisation. On the other hand, KMT5A with mutations in PIP box 1 is still able to interact 
with PCNA and is dispensable for KMT5A degradation (Abbas et al., 2010). Therefore, 
KMT5A suppression during S phase is dependent on proteasome activity, KMT5A PIP2 degron 
and its interaction with both PCNA and Cdt2. Interestingly, although KMT5A PIP mutant 
degradation was delayed in replicating cells (S phase), it was not abolished even in the presence 
of Cdt2 knockdown. It was therefore suggested that during S phase, there are additional 
mechanism(s) which contribute to KMT5A destruction independently of PIP degron and Cdt2 
mechanisms (Centore et al., 2010).  
Moreover, KMT5A undergoes ubiquitination and degradation by the APCCdh1 ligase complex 
during late mitosis. This complex binds to KMT5A through a D-box destruction motif to 
perform its ubiquitination function. Although, there was a modest change in KMT5A 
transcription during the cell cycle which could partially account for the fluctuations in KMT5A 
protein level in this study, it was suggested that due to the short half-life of the KMT5A protein, 
KMT5A is predominantly regulated at the protein level (Wu et al., 2010). 
In addition, KMT5A is reported to undergo ubiquitination and degradation by the SCFSkp2 E3 
ligase complex during G1 to S transition phase. This multi-component E3 complex recognises 
and interacts with its substrates via its modular F-box component, Skp2. Additionally, the 
activity of the SCF complex is regulated by the abundance of Skp2 protein. A number of tumour 
suppressor proteins, including the cell cycle inhibitors, p27 and p21 are destructed by the 
SCFSkp2. As a consequence, cells are induced to undergo G1-S transition and mitosis. Therefore, 
Skp2 plays a crucial role in cell cycle progression. Consistently, elevated Skp2 expression is 
frequently observed in various cancer types such as breast and prostate carcinomas. The ability 
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of Skp2 to degrade KMT5A is based on the findings that KMT5A protein expression is 
suppressed as cells exit G1 to enter S phase and that Skp2 silencing leads to elevated KMT5A 
protein level during the same phase (Yin et al., 2008). Similarly, Skp2 has been suggested to 
destabilise KMT5A, though outside of the chromatin context. This is because whilst UV 
treatment led to KMT5A suppression in wild-type MEFs, it was unable to down-regulate 
KMT5A in Skp2-/- MEFs in the whole-cell extracts. However, in the chromatin-bound fraction, 
KMT5A stabilisation was only subtle upon Skp2 knockout after UV treatment (Oda et al., 
2010). Therefore, it was suggested that KMT5A stability is regulated through two independent 
pathways, one being Cdt2 and the other Skp2. However, the major limitation of Oda and Yin’s 
work is the lack of demonstrating Skp2 direct ubiquitination of KMT5A and whether Skp2-
mediated ubiquitination does indeed cause KMT5A destruction by the proteasome. Conversely, 
Abbas et al demonstrated that the SCFSkp2 complex does not play a role in KMT5A regulation 
as knockdown of the SCF complex subunit, Cullin 1 (CUL1) did not influence KMT5A 
degradation in U2OS cells (Abbas et al., 2010).  
Recently, β-TRCP, an F-box protein was found to interact with KMT5A using mass 
spectrometry. It was subsequently shown that the SCFβ-TRCP E3 ligase complex targets KMT5A 
for poly-ubiquitination in a CK1δ-dependent phosphorylation on S253 during G1 phase of the 
cell cycle. This complex is activated by DNA-damaging agents and also contributes to 
ultraviolet-induced KMT5A poly-ubiquitination and degradation in the same manner. The 
regulation of KMT5A by the SCFβ-TRCP complex is independent of the PIP degron and CRL4Cdt2 
mechanisms as KMT5A PIP mutant which is protected from Cdt2-mediated ubiquitination and 
destruction, is efficiently ubiquitinated and degraded by co-expression of CK1δ and SCFβ-TRCP. 
Moreover, generation of KMT5AΔPIP/S253A mutant which is resistant to destruction by both Cdt2 
and β-TRCP ligases led to a more stable form of KMT5A. The F-box protein, Skp2, however 
was reported to have no effect on KMTA levels (Wang et al., 2015), in contrast to work by Yin 
and Oda (Yin et al., 2008; Oda et al., 2010).
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Figure 1-8: Summary of PTMs regulating KMT5A protein levels throughout the cell cycle. (A) Relative abundance of KMT5A protein level during each phase of the cell 
cycle. (B) Model of KMT5A protein level regulation by various enzymes. During G1, KMT5A resides at specific loci resulting in H4K20Me1 (closed red circles). In this phase, 
KMT5A is phosphorylated at S253 by Ck1δ which targets it for ubiquitination and degradation by β-TRCP. KMT5A is degraded at the G1-S border by the CRL4Cdt2 complex in a 
PIP-domain and PCNA dependent manner. Skp2 is suggested to degrade extra-chromosomal KMT5A. The Cdk1/Cyclin B complex phosphorylates the chromatin-bound KMT5A 
on serine 29 (S29) leading to its stabilisation during mitosis, enabling KMT5A to carry out its function on mitotic chromosomes. KMT5A is then dephosphorylated by Cdc14A/B 
which facilitates its degradation by the APCCdh1 complex. Image adapted from Wu and Rice (Wu and Rice, 2011). 
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1.7 KMT5A and the AR  
As already discussed, KMT5A is the sole mono-methyltransferase for H4K20, as well as 
regulating an array of non-histone proteins. It therefore plays a vital role in regulating 
chromatin-based processes and other cellular pathways. Deregulation of KMT5A activity has 
been associated with a number of cancers, including PC. The initiation and progression of PC 
is regulated by a key transcription factor, the AR. The activity of the AR itself is modulated by 
a plethora of regulatory proteins.  
KMT5A was identified as a potential regulator of the AR from selective siRNA library 
screening in the PC cell line LNCaP, which was undertaken by members of the STTD group. 
Following its identification, KMT5A was taken forward for extensive validation across a 
number of PC cell lines including LNCaP, LNCaP-AI, LNCaP-casodex resistant (LNCaP-
CdxR) and LNCaP-MDV3100 resistant (LNCaP-MDV3100R). Subsequently, KMT5A was 
found to act as a functional repressor of AR in LNCaP cells which represent the androgen-
dependent stage of PC. However, KMT5A exhibited differing functions towards the AR in 
LNCaP-AI cells representative of a more aggressive castration-resistant PC and in a number of 
other drug-resistant PC cell lines, in which KMT5A switched to act as an AR co-activator. 
Although the underlying mechanism(s) responsible for the opposing role of KMT5A in AR 
modulation has remained largely unclear, it was demonstrated that KMT5A participates in the 
ability of the AR to bind to chromatin by regulating AR phosphorylation. This suggests that 
deregulated KMT5A activity may in turn enhance the activity of the AR. Indeed, KMT5A is 
over-expressed in different types of cancer and cancer cell lines including bladder cancer, non–
small cell lung carcinoma (NSCLC), small cell lung carcinoma (SCLC), chronic myelogenous 
leukaemia, hepatocellular carcinoma, pancreatic cancer (Takawa et al., 2012) and PC (Coffey 
et al, unpublished data). Whilst, high expression of KMT5A is positively correlated with poor 
overall and disease free survival in breast cancer patients (Yang et al., 2012; Liu et al., 2016), 
low expression is associated with decreased susceptibility to epithelial ovarian cancer and 
longer survival time (Song et al., 2009; Wang et al., 2012). Moreover, as a positive regulator 
of EMT in association with TWIST, KMT5A expression has been shown to promote breast 
cancer metastasis. Consistently, inhibiting KMT5A expression suppressed EMT and invasion 
of breast cancer cells. Additionally, KMT5A suppresses p53-dependent transcriptional 
activation in cancer cells by monomethylating p53 at lysine 382.  Furthermore, recently, 
KMT5A has been identified as a druggable target in Neuroblastoma. KMT5A ablation using 
either genetic or pharmacological approaches, inhibited tumour xenograft growth and extended 
murine survival. The significant survival advantage observed in these pre-clinical xenograft 
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Neuroblastoma models was shown to be due to the activation of the p53 canonical pathway. As 
such KMT5A is emerging as a promising clinical target.  
The activity of KMT5A is primarily regulated through PTMs to maintain precise levels of 
KMT5A throughout the cell cycle, where ubiquitination plays a vital role. Moreover, KMT5A 
is reported to undergo dynamic cellular localisation in a cell cycle dependent manner. KMT5A 
ubiquitination and degradation by a number of ubiquitin ligases has been extensively studied 
and it is becoming evident that multiple ubiquitin ligases target KMT5A through different 
mechanisms. However, as ubiquitination is known to cause a number of outcomes, it is not 
known whether KMT5A undergoes any other type of ubiquitination which could modulate 
KMT5A other than causing its destruction.  
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1.8 Hypothesis  
The overall hypothesis of this thesis is that PTMs of KMT5A could in turn either directly or 
indirectly modulate AR activity. The identification of novel PTMs regulating KMT5A could 
be exploited to indirectly target the AR in CRPC.  
1.8.1 Aims  
 Investigate whether KMT5A is modified by other forms of ubiquitination, specifically 
mono-ubiquitination 
 Identify the site of KMT5A mono-ubiquitination 
 Determine whether KMT5A mono-ubiquitination is subject to cell cycle control  
 Investigate the effect of mono-ubiquitinated KMT5A on cell cycle  
 Determine the role of Skp2 in KMT5A ubiquitination  
 Investigate the role of Skp2 in AR signalling  
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2 Materials and methods 
2.1 Reagents and antibodies 
Routinely used chemicals were molecular or analytical grade and were purchased from either 
Sigma-Aldrich or Fisher Scientific unless otherwise stated. A list of antibodies used is listed in 
Table 2.1.  
Antibody 
IgG clone 
type 
Host Manufacturer 
Catalogue 
number 
AR-N20 Polyclonal Rabbit Santa Cruz biotechnology sc-816 
ATAD2 Polyclonal Rabbit Sigma-Aldrich 
Kind gift from 
Dr Steven 
Darby 
(Newcastle 
University) 
Flag Monoclonal Mouse Sigma-Aldrich F3165 
KMT5A Monoclonal Rabbit Cell Signalling 2996 
KMT5A Monoclonal Mouse Abcam ab3798 
KMT5A Polyclonal Rabbit Santa Cruz biotechnology sc-135009 
Mouse Immunoglobulin 
Fraction (Normal) 
Negative Control 
- Mouse Millipore 12-371 
p27 (c-19) Polyclonal Rabbit Santa Cruz biotechnology sc-528 
PARP1/2 (H-250) Polyclonal Rabbit Santa Cruz biotechnology sc-7150 
PSA (H117) Monoclonal Mouse BioGenex  MU014-UCE 
pSer10 H3 Polyclonal Rabbit Millipore 06-570 
Rabbit anti-mouse 
immunoglobulins 
HRP conjugate 
Polyclonal Rabbit Dako P0260 
Rabbit 
Immunoglobulin 
Fraction (Normal) 
Negative Control 
- Rabbit Dako X0903 
Skp2 (8D9) Monoclonal Mouse Invitrogen  32-3300 
Swine anti-rabbit 
immunoglobulins HRP 
conjugate 
Polyclonal Swine Dako P0217 
α-tubulin  Monoclonal Mouse Sigma-Aldrich T9026 
Table 2.1: List of primary and secondary antibodies used. 
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2.2 Mammalian cell culture  
2.2.1 Reagents  
All cell culture plastic-ware was purchased from Corning. RPMI-1640 growth media with 
HEPES modification and foetal calf serum (FCS) was from Sigma. Dextran-coated charcoal 
(DCC) treated FCS was from Thermo Scientific. L-glutamine and trypsin were obtained from 
Sigma Aldrich.  
2.2.2 Cell lines 
All cell lines were purchased from the American Type Culture Collection (ATCC). All cell 
lines except LNCaP-AI were maintained in RPMI-1640 supplemented with 1% L-glutamine 
(20 mM) and 10% FCS, termed as full media (FM). LNCaP-AI was maintained in RPMI-1640 
supplemented with 1% L-glutamine (20 mM) and 10% DCC, termed as steroid depleted FCS 
media (SDM). All cells were grown in a humidified 5% CO2 incubator (Sanyo) at 37 
oC. 
COS7: These kidney-derived cells were from the African green monkey, Cercopithecus 
aethiops. 
HEK293T: These cells were derived from the human embryonic kidney. COS7 and HEK293T 
cell lines are suitable for transfections and were utilised for overexpression studies due to the 
ease with which they can be transfected and high levels of exogenous protein expression.  
LNCaP: Lymph node carcinoma of the prostate (LNCaP) cell line was derived from a metastatic 
site of the left supraclavicular lymph node of a 50 year old Caucasian male in 1980 
(Horoszewicz et al., 1980). LNCaP cells are AR positive and are sensitive to androgens. They 
are a model of hormone sensitive PC.  
LNCaP-AI: LNCaP-Androgen-Independent (LNCaP-AI) were derived from the serial passage 
of LNCaP cells under androgen depleted conditions, in SDM media. LNCaP-AI cells are AR 
positive and sensitive to androgens; however, these cells are independent of androgens for 
growth. They are a model of androgen-independent PC.  
2.2.3 Cell passaging  
Cells were grown in flasks and were sub-cultured when reaching approximately 70% 
confluency. Culture media was removed and cells were washed with phosphate buffered saline 
(PBS). Cells were then trypsinised in the presence of 1x trypsin and left to incubate at 37 oC, 
5% CO2 until the cells detached. Once detached, cells were resuspended in sufficient fresh 
growth medium to neutralise the trypsin and placed into an appropriate tissue culture flask, or 
seeded as required.  
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2.2.4 Cell storage and recovery 
Sub-confluent cells were trypsinised as in Chapter 2.2.3 and resuspended in sufficient fresh 
growth medium. The suspension was centrifuged at 300 g for 5 minutes and the supernatant 
was removed. The cells were then resuspended in freezing media (10% DMSO, 10% FCS 
diluted in FM) and 1 mL was aliquoted into cryovials at a density of 2-5 x 106 cells/mL. The 
cells were initially frozen at -80 °C overnight before being transferred to liquid nitrogen for 
long-term storage.  
For recovery, frozen cells were immediately thawed in a 37 oC water bath. Once thawed, cells 
were gently transferred into 10 mL pre-warmed FM and centrifuged at 300 g for 5 minutes. 
Pelleted cells were then resuspended in fresh growth medium and left to reattach in a T25 flask. 
They were subsequently passaged as in 2.2.3.  
2.2.5 Mycoplasma test 
All cell lines were routinely subjected to mycoplasma testing using Mycoalert mycoplasma 
detection kit (Cambrex, East Rutherford, USA) at the Northern Institute for Cancer Research. 
One mL of culture media in which cells were grown for at least 48 hours was removed and sent 
for testing by Dr Liz Matheson.  
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2.3 Transient DNA transfection  
Cells were plated at appropriate numbers depending on the size of the dish being used so that 
they were 50-60% confluent after 24 hours. The following day, transfection cocktail was 
prepared by mixing RPMI-1640 + 1% glutamine (20 mM), termed basal media (BM), with 
optimized amount of plasmid DNA. Lipofectamine (TransIT-LT1 Transfection Reagent, 
Geneflow) was added at a ratio of 2:1 lipofectamine to DNA. The cocktail was incubated at 
room temperature for 30 minutes to allow lipid-DNA complexes to form. Plasmid DNA 
concentrations were balanced with the corresponding empty vector. The mixture was then 
added to cells in a drop-wise manner and incubated for 48 hours at 37 °C and 5% CO2. All 
plasmid DNAs used for transient DNA transfection are listed in Table 2.2. 
Subsequent KMT5A point mutants and C-terminus truncation mutations were generated in 
house by site directed mutagenesis (Aglient Technologies) using pSG5-Flag-KMT5A WT and 
pSG5-Flag-KMT5A C-terminus as a template, respectively. See Chapter 3.3.1 for more details.  
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Construct  Source  
pFLAG-AR Professor Ralf Janknecht (Oklahoma University) 
pARE3-luc 
Generated by members of the STTD group as described in 
(Brady et al., 1999) 
pCMV-β-gal 
Generated by members of the STTD group as described in 
(Brady et al., 1999) 
pcDNA3-Flag-Cul1 Professor Meloche Sylvain (Université de Montréal) 
pcDNA3-HA-Rbx1 Professor Meloche Sylvain (Université de Montréal) 
pcDNA3-HA-Skp1 Professor Meloche Sylvain (Université de Montréal) 
pcDNA3-Flag-Skp2 Professor Neil Perkins (Newcastle University) 
p-LRR-Skp2 Professor Hui-Kuan Lin (The University of Texas) 
pSG5-Flag-KMT5A WT Professor Judd Rice (University of Southern California) 
pSG5-Flag-KMT5A C-terminus Professor Judd Rice (University of Southern California) 
pSG5-Flag-KMT5A N-terminus Professor Judd Rice (University of Southern California) 
pSG5-Flag-KMT5A K205R Generated in house  
pSG5-Flag-KMT5A K234R Generated in house 
pSG5-Flag-KMT5A K236R Generated in house 
pSG5-Flag-KMT5A K245R Generated in house 
pSG5-Flag-KMT5A K267R Generated in house 
pSG5-Flag-KMT5A K297R Generated in house 
pSG5-Flag-KMT5A K321R Generated in house 
pSG5-Flag-KMT5A K342R Generated in house 
pSG5-Flag-KMT5A K349R Generated in house 
pSG5-Flag-KMT5A C1 Generated in house 
pSG5-Flag-KMT5A C2 Generated in house 
pSG5-Flag-KMT5A C3 Generated in house 
pSG5-Flag-KMT5A C4 Generated in house 
pSG5-Flag-KMT5A C5 Generated in house 
pSG5-Flag-KMT5A C6 Generated in house 
pSG5-Flag-KMT5A C3 K321R Generated in house 
pSG5-Flag-KMT5A N-C1 Generated in house 
pSG5-Flag-KMT5A N-C2 Generated in house 
pSG5-Flag-KMT5A N-C3 Generated in house 
Table 2.2: List of plasmids used.
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2.4 Transient siRNA reverse transfection 
Reverse transfection was used to introduce small interfering RNA (siRNA) to the cells in order 
to silence the gene of interest. A list of the siRNA oligonucleotide sequences, including the 
negative non-silencing control, are provided in Table 2.3. Transfection cocktail was prepared 
by mixing LipofectamineTM RNAiMAX (Invitrogen) with basal media and the siRNA (50 μM 
stock) to give a final concentration of 25 nM siRNA per well. The mixture was added to the 
wells and incubated at room temperature for 30 minutes to allow sufficient time for lipid-RNA 
complexes to form. Meanwhile, cells were diluted in the appropriate volume, type of media and 
concentration depending on their proliferation rate. They were then added to the wells 
containing the siRNA transfection cocktail, mixed gently and incubated at 37 °C, 5% CO2 for 
72 hours.  
In case of DHT treatment to stimulate the cells following siRNA knockdown, cells were 
simultaneously starved and siRNA treated in SDM. After 72 hours, existing SDM was replaced 
with freshly prepared SDM containing 10 nM DHT, unless otherwise stated, and incubated for 
various time periods. 
Target siRNA Sequence 5’-3’ 
KMT5A-1 CCAUGAAGUCCGAGGAACA 
KMT5A-2 CAGGAAGAGAACUCAGUUA 
Non-silencing  UUCUCCGAACGUGUCACGU 
Skp2-1 AAGGGAGUGACAAAGACUUUG 
Skp2-2 GAGGAGCCCGACAGTGAGA 
Skp2-3 GUGAUAGUGUCAUGCUAAA 
Table 2.3: List of siRNA oligonucleotide used. All siRNA oligonucleotides were purchased from Sigma-Aldrich. 
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2.5 Bacterial transformation 
This procedure was performed under sterile conditions using aseptic techniques, autoclaved 
plastic-ware and Luria-Bertani (LB) medium.  
Plasmids were propagated by transforming NEB 5-alpha competent Escherichia coli (E.coli) 
(New England BioLabs). Briefly, 1 µL of plasmid was mixed with 25 µL of bacteria and 
incubated on ice for 20 minutes. Bacteria were then heat shocked by placing in a 42 oC water 
bath for 90 seconds and then back on ice for 5 minutes. One mL of LB medium (10 g/L tryptone, 
5 g/L yeast extract, 10 g/L NaCl) was added and bacteria were incubated at 37°C while shaking 
at 200 rpm for 1 hour. The transformation mixture was spread on LB agar plates containing 
ampicillin (50 ng/mL) and incubated at 37 °C overnight. Successful bacterial transformation 
with the plasmid DNA will result in resistance to plasmid-derived antibiotic gene (ampicillin 
resistance), and formation of colonies on LB agar containing ampicillin. Bacteria without the 
plasmid DNA will lyse.  
A single bacterial colony was picked and inoculated into 10 mL ampicillin-containing LB 
medium and shaken at 200 rpm at 37 °C for approximately 6 hours. The starter culture was then 
added to 200 mL LB medium, supplemented with ampicillin and incubated overnight while 
shaking at 200 rpm at 37 °C. The plasmid DNA was purified using the Endo-free plasmid maxi 
kit (Invitrogen) performed according to the manufacturer’s instructions. DNA quality and yield 
was determined using a NanoDrop® ND-1000 UV-Vis Spectrophotometer. 
2.6 Protein expression analysis 
2.6.1 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS- PAGE) 
Cell lysates were prepared by adding SDS sample buffer (0.125 M Tris, pH 6.8, 2% (w/v) SDS, 
10% (v/v) glycerol, 10% (v/v) β-mercaptoethanol and 0.01% (w/v) bromophenol blue) directly 
to cultured cells washed in PBS or any other sample which was analysed by SDS-PAGE and 
immunoblotting. The samples were boiled at 100 oC for 10 minutes to ensure proteins were 
denatured and loaded into wells of polyacrylamide gels. Gels were prepared using Bio-Rad gel 
casting apparatus according to Table 2.4. Separation buffer (2X) consisted of: 375 mM Tris-
HCL, pH 8.8 and 0.1% SDS. Stacking buffer (2X) was comprised of: 125 mM Tris-HCL, pH 
6.8 and 0.1% SDS.  
First a resolving gel was poured and allowed to set, followed by the addition of a lower 
percentage stacking gel on the top, in which a well comb was inserted. Electrophoresis was 
carried out at 180-200 V for approximately 45 minutes in 1x running buffer (25 mM Tris-HCl, 
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190 mM glycine, 0.1% SDS). A protein marker, Spectra™ Multicolor Broad Range Protein 
Ladder (Thermo Fisher Scientific) was run alongside the samples to mark molecular weight. 
Ingredient 10% resolving gel 5% stacking gel 
30% Acrylamide 3.33 mL 0.83 mL 
2X separation buffer 5 mL - 
2X stacking buffer - 2.5 mL 
Tetramethylethylenediamine (TEMED) 10 µL 5 µL 
10% ammonium persulfate (APS) 100 µL 50 µL 
dH2O 1.67 mL 1.67 mL 
Total volume 10.1 mL 5.1 mL 
Table 2.4: Recipes of resolving and stacking gels. 
2.6.2 Western blotting 
Proteins separated by electrophoresis were transferred to Hybond-C nitrocellulose membrane 
(GE Healthcare) in transfer buffer (25 mM Tris-HCl pH 8.3, 190 mM glycine, 10% methanol) 
using a Bio-Rad Transfer system at 100 V for 60 minutes on ice, or at 30 V overnight at room 
temperature. Membrane with transferred proteins was blocked in 5% non-fat milk (Marvel) in 
TBS (0.5 M NaCl, 0.02 M Tris-HCl, pH 7.5) for 60 minutes at room temperature. After washing 
the membrane twice in TTBS (0.5 M NaCl, 0.02 M Tris-HCl, 0.001% Tween-20, pH 7.5) for 5 
minutes, it was incubated overnight at 4 oC with appropriate primary antibody diluted in 1% 
milk (Marvel) in TTBS to reduce non-specific antibody binding. The membrane was then 
washed twice with TTBS for 5 minutes to remove unbound primary antibody before being 
incubated with appropriate horseradish peroxidase (HRP)-conjugated secondary antibody 
(Dako) diluted in 1% milk-TTBS for 1 hour at room temperature. The membrane was then 
washed twice in TTBS for 10 minutes and once in TBS. Visualisation of HRP-conjugated 
immune complexes was achieved using ECL reagent (GE Healthcare) which was washed over 
the membrane for 1 minute and exposed to X-ray film (Fuji Film) and developed using an 
automated developer. A list of primary and secondary antibodies used are provided in Table 
2.1. 
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2.7 Gene expression analysis  
All RNA work was performed using pipette barrier tips (Scientific Laboratory Supplies Ltd). 
2.7.1 RNA extraction  
The adherent cells grown as a monolayer in 6 well plates was washed with ice cold PBS before 
being lysed directly in the culture dish by adding 500 µL of Trizol and incubated for 5 minutes 
at room temperature to permit complete dissociation of the nucleo-protein complex. The 
homogenised sample was transferred to an Eppendorf tube and 250 µL of chloroform was 
added. Samples were mixed vigorously for 15 seconds and incubated at room temperature for 
10 minutes, followed by centrifugation at 12,000 x g for 15 minutes at 4 oC. The mixture 
separates into a lower red phenol-chloroform phase, an interphase, and a colourless upper 
aqueous phase which contains RNA exclusively. The aqueous phase was carefully transferred 
into a fresh tube and RNA was precipitated by adding 250 µL propan-2-ol. Samples were 
incubated at room temperature for 30 minutes, followed by centrifugation at 12,000 x g for 10 
minutes at 4 oC. The supernatant was completely removed and the RNA pellet was washed with 
75% ethanol and centrifuged at 7500 x g for 5 minutes at 4 oC. The RNA pellet was air-dried 
and resuspended in an appropriate volume of Diethylpyrocarbonate (DEPC) treated water and 
heated to 55 oC for 10 minutes.  
RNA concentration and purity was determined using a NanoDrop® ND-1000 UV-Vis 
Spectrophotometer. The integrity of the sample was assessed by the 260/280 ratio (the ratio of 
absorbance at 260nm and 280 nm). The optimal 260/280 ratio for RNA is 2.0. 
2.7.2 RNA reverse transcription  
Reverse transcription of mRNA to cDNA was carried out using the MMLV reverse 
transcription kit (Promega) according to the manufacturer’s protocol. Briefly, 1 µg of isolated 
RNA was mixed with DEPC water to a final volume of 12.7 µL, and incubated at 65 oC for 5 
minutes to denature the RNA secondary structures. The RNA samples were then incubated at 
37 oC for 1 hour with 7.3 µL of Moloney Murine Leukaemia Virus (MMLV) master-mix 
containing: 4 µL 5x MMLV reaction buffer, 2 μL 4 mM dNTP mix (dGTP, dATP, dCTP and 
dTTP), 1µL 50µg/mL Oligo-dT15 and 0.3 µL MMLV reverse transcriptase enzyme. The 
samples were further incubated for 5 minutes at 95 °C to inactivate the MMLV-RT enzyme and 
the resulting cDNA was stored at -20 °C until required. 
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2.7.3 Quantitative real time PCR 
Quantitative real time PCR (qPCR) was carried out using the Platinum® SYBR® Green qPCR 
SuperMix-UDG w⁄ROX (Invitrogen), and was performed in the 384-well plate ABI 7900HT 
thermocycler (Applied Biosystems). The absolute quantification method was used to determine 
gene expression levels in the unknown samples which required the generation of a standard 
curve for each gene under investigation. A standard curve was generated using a sample which 
is known to express the gene of interest and was serially diluted to include 5 concentrations. To 
control for PCR contamination, a sample with no template cDNA was included.  
A total reaction volume of 10 μL, containing 8 μL reaction cocktail (according to Table 2.5) 
and 2 μL cDNA was dispensed respectively in each well of a MicroAmp® 384-well plate (Life 
Technologies). A list of PCR primers used is provided in Table 2.7. The plate was then sealed 
with Applied Biosystems® MicroAmp® Optical Adhesive Film (Life Technologies). The 
reactions were achieved under the following PCR conditions: 95 oC for 10 minutes, 95 oC for 
15 seconds and 60 oC for 1 minute over 40 cycles. The data was analysed using Sequence 
Detection System software (SDS) version 2.3 (Applied Biosystems). The detector used was 
SYBR and ROX was applied as a passive reference. The expression levels of each gene was 
then normalised to the housekeeping gene Hypoxanthine phosphoribosyltransferase 1 
(HPRT1). 
Reagent Volume added per well 
SYBR Green  5 μL 
dH2O 2.2 μL 
Forward primer 0.4 μL 
Reverse primer 0.4 μL 
cDNA 2 μL 
Total volume 10 μL 
Table 2.5: Constituents of the reagent mix for each RT-PCR reaction. 
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2.7.4 Quantitative PCR primers  
The primer sequences were either obtained from the published literature or designed using the 
Primer-BLAST program and were verified for target specificity using NCBI BLAST:Basic 
Local Alignment Search Tool. All primers were purchased from Sigma-Aldrich. The primers 
were resuspended in nuclease-free water and used at a concentration of 2.5 µM in the reaction 
cocktail to give a final concentration of 0.1 µM. 
Gene  Forward primer sequence  Reverse primer sequence  
AR CATGTGGAAGCTGCAAGGTCT  TCTGTTTCCCTTCAGCGGC  
PSA (KLK3) GGTGCATTACCGGAAGTGGAT  TGGTCATTTCCAAGGTTCCAA  
KLK2 AGCATCGAACCAGAGGAGTTCT  TGGAGGCTCACACACCTGAAGA  
TMPRSS2 CTGCTGGATTTCCGGGTG  TTCTGAGGTCTTCCCTTTCTCCT  
ATAD2 GGAATCCCAAACCACTGGACA GGTAGCGTCGTCGTAAAGCACA 
HPRT1 TTGCTTTCCTTGGTCAGGCA  AGCTTGCGACCTTGACCATCT  
Table 2.6: List of qRT-PCR primers used. 
 
2.8 Luciferase reporter assay  
2.8.1 Luciferase activity measurement 
HEK293T cells were seeded into 24-well plates in 1 mL SDM and incubated for at least 24 
hours to ensure seeding down and sufficient starvation of cells. Once the cells were 
approximately 70% confluent, they were transfected with the plasmid constructs as in Section 
2.3 and incubated for a further 24 hours. The cells were then stimulated with 10 nM DHT for 
24 hours. Upon completion of the assay in the 24-well plates, cells were washed with PBS 
before being lysed in 50 μL of 1 x lysis buffer (Promega) at 37 C for 10 minutes followed by 
a freeze-thaw cycle. The plates were then scraped, the lysate mixed and 10 μL of each sample 
was transferred into a well of an opaque flat-bottomed 96-well plate to be analysed using a 
FLUOstar Omega microplate reader (BMG LABTECH). The injector adds 50 μL of Luciferase 
Assay Reagent (Promega) per well and the well was read immediately to determine the 
luciferase counts per second (LCPS). The plate is advanced to the next well and the process is 
repeated until all wells are read. Each reading was normalised to its corresponding β-
galactosidase absorbance (Chapter 2.8.2).  
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2.8.2 β-galactosidase normalisation assay 
In order to account for variations in transfection efficiency and cell numbers, β-galactosidase 
activity was measured, where a constant amount of pCMV-β-galactosidase (β-gal) was added 
to each transfection reaction. An equal amount of cell lysate (10 μL) as in Chapter 2.8.1 was 
incubated with 10 μL of β-gal assay substrate (2 mM MgCl2, 100 mM β-mercaptoethanol, 1.33 
mg/mL o-nitrophenyl-β-D-galactopyranoside (ONPG) and 100 mM sodium phosphate buffer, 
pH 7.3) at room temperature in a clear 96 well flat-bottomed plate (Corning) until the mixture 
turned yellow. The reaction was terminated by adding 50 μL of 1 M Na2CO3 and absorbance at 
415 nm was measured using a 96-well model 680 plate reader (Bio-Rad).  
2.9 Immunoprecipitation (IP) 
2.9.1 Native immunoprecipitation 
Cells were plated in 90 mm dishes at appropriate numbers depending on their proliferation rate 
and grown to 90% confluency in FM. Cells were washed and collected by scraping into ice-
cold PBS. They were then centrifuged at 12,000 rpm for 10 minutes at 4 oC before being 
resuspended in 1 mL lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 0.2 mM Na3VO4, 1% 
NP-40 alternative, 1 mM PMSF, 1mM Dithiothreito (DTT), protease inhibitor cocktail tablet 
(Roche)) for 1 hour with agitation at 4 oC. Cellular debris were removed by centrifuging the 
lysed cells at 14,000 rpm for 3 minutes and collecting the supernatant. At this point, 100 µL of 
supernatant was taken as an input sample and 30 µL Protein G Sepharose (PGS; GE Healthcare) 
was added to the remaining 900 µL supernatant which was pre-cleared for 4 hours at 4 oC.  
PGS was removed after centrifugation at 14,000 rpm for 3 minutes and the supernatant was 
split into two equal volumes and each incubated with the appropriate antibodies overnight at 4 
oC. Endogenous or ectopically expressed protein of interest was immunoprecipitated using the 
appropriate antibody and an equivalent amount (2 µg) of normal IgG was used as a negative 
control. PGS was added the following day for 1 hour at 4 oC to immunoprecipitate the antibody-
protein complexes. The beads were then collected by centrifugation at 14,000 rpm for 5 minutes 
and washed once with 1 mL IP wash A (PBS, 350 mM NaCl, 0.2% Triton) and twice with 1 
mL IP wash B (PBS, 0.2% Triton). PGS was resuspended in SDS loading buffer containing 
10% β-mecarptoethanol for Western analysis.  
2.9.2 Denaturing nickel pull down 
Cells were seeded in 90 mm dishes and were grown to 80% confluency at the time of collection. 
Cells were collected by scraping into 1 mL ice-cold PBS and 100 µL was removed, centrifuged 
and the pellet was used as an input sample. The remaining 900 µL was centrifuged at 2,000 rpm 
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at 4 oC for 10 minutes. PBS was removed and cells were lysed by resuspending them in a 
denaturing lysis buffer (6 M guanidine-HCl, 0.1 M Na2HPO4/NaH2PO4, 0.01 M Tris-HCl, pH 
8, 5 mM imidazole, 10 mM β-mercaptoethanol) and mixed gently on a shaker for 1 hour at 4 
oC. Fifty µL of Ni-NTA agarose beads (Qiagen) were added to samples followed by overnight 
incubation at 4 oC. Histidine (His) tagged proteins bind to the nickel ions through their His tag 
with high affinity and form a complex. To pull down the complexes, samples were centrifuged 
the following day and the supernatant discarded. Ni-NTA agarose beads were washed with 
several denaturing IP wash buffers in the following order: buffer 1 (6 M guanidinium-HCl, 0.1 
M Na2HPO4/NaH2PO4, 0.01 M Tris-HCl, pH 8, 10 mM β-mercaptoethanol), buffer 2A (8 M 
Urea, 0.1 M Na2HPO4/NaH2PO4, 10 mM β -mercaptoethanol, 0.01 M Tris, pH 8), buffer 2B (8 
M Urea, 0.1 M Na2HPO4/NaH2PO4, 10 mM β -mercaptoethanol, 0.01 M Tris, pH 6.3, 0.2% 
(v/v) Triton X-100), and buffer 2C (8 M Urea, 0.1 M Na2HPO4/NaH2PO4, 10 mM β -
mercaptoethanol, 0.01 M Tris, pH 6.3, 0.1% (v/v) Triton X-100), where beads were 
resuspended in each of the wash buffers and rotated for 5 minutes at room temperature. They 
were then centrifuged at 12,000 rpm for 5 minutes and the supernatant was removed before 
resuspending in the next wash buffer. To elute the complexes, Ni-NTA agarose beads were 
resuspended in elution buffer (200 mM imidizole, 0.1 M Na2HPO4/NaH2PO4, 0.15 M Tris-HCl, 
pH 6.7, 10 mM β-mercaptoethanol, 30% (v/v) glycerol, 5% (w/v) SDS) and mixed by rotating 
on a wheel for 20 minutes. The supernatant was collected after centrifugation to which SDS 
loading buffer containing 10% β-mercaptoethanol was added. Samples were then analysed by 
Western blotting.  
2.10 Cytoplasmic/nuclear extraction  
Nuclear and cytoplasmic extracts were generated using the NE-PER™ extraction kit (Thermo 
Scientific) according to the manufacturer’s protocol. Briefly, cells were harvested by 
trypsinisation, pelleted by centrifugation at 300 g for 5 minutes, and washed with PBS. Cell 
pellets were then resuspended in 200 µl CER I solution, vortexed vigorously and incubated on 
ice for 5 minutes. Eleven µl CER II solution was added, vortexed and incubated on ice for 1 
minute to allow cell membrane disruption. The lysed cells were vortexed briefly again and 
centrifuged at 16,000 g for 10 minutes. The supernatant which is the cytoplasmic extract was 
then immediately transferred to a new pre-chilled tube. The remnant nuclear pellet was washed 
with PBS prior to being lysed in 100 µl NER solution, vortexed and incubated on ice for 10 
minutes. This was repeated for a total of 40 minutes, followed by a final 10 minutes 
centrifugation at 16,000 g. All centrifugations were carried out at 4 oC. The nuclear extract was 
transferred to a new pre-chilled tube.  
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2.11 Flow cytometry cell cycle analysis  
2.11.1 Hoechst cell staining and sorting 
Hoechst is an exclusive DNA-binding dye which is taken up passively by live cells and 
preferentially binds to A-T base regions of the DNA. The amount of DNA present in a cell 
based on its phase of the cell cycle at a particular time determines the amount of Hoechst 
binding and in turn its fluorescence. This enables live cells to be specifically separated into 
different phases of the cell cycle (G0/G1, S and G2/M) based on DNA content analysis. 
Propidium Iodide (PI) was added to exclude dead cells.  
Exponentially growing cells were harvested by trypsinisation, trypsin was then deactivated, and 
cells were counted with a haemocytometer, after which 20 x 106 cells were centrifuged at 300 
g for 5 minutes.  The supernatant was removed and the cells were resuspended in 10 mL culture 
medium containing 20 μg/mL (stock 1 mg/mL) Hoechst 33342 (Sigma-Aldrich). The samples 
were then incubated in the dark at 37 oC for 45 minutes, while gently shaken every 10 minutes. 
After incubation, cells were resuspended in their existing Hoechst-containing medium at a 
concentration of 10 x 106 cells/mL and transferred into FACs tubes (BD Biosciences) for 
sorting. Immediately prior to sorting, PI was directly added to the samples which were 
subsequently analysed using BD FACS Aria Fusion. The sorted cells were collected into FACs 
tubes containing 250 μL FBS, before being pelleted at 300 g for 5 minutes and resuspended in 
SDS-sample buffer. Cells were sorted based on the amount of DNA by defining three regions 
(G0/G1, S and G2/M) for sorting. Hoechst 33342 excitation took place with the UV laser at 350 
nm and emission collected at 450/50 nm. PI was excited at 560 nm and emission collected at 
610/20 nm. Live cells were collected by gating out PI positive cells. They were ensured to be 
single cells by gating out doublets and clumps using a dot plot showing Hoechst parameters 
area vs height and area vs width. All data analysis was carried out using FlowJo software. 
2.11.2 Propidium Iodide (PI) cell staining 
PI is another fluorescent dye that also binds DNA and is taken up in cells with permeablised 
cell membrane. Cells were seeded in a 6-well plate and upon completion of the experiment, 
both culture media and trypsinised cells were collected in FACs tubes (BD Biosciences). The 
cells were pelleted at 300 g for 5 minutes, and washed once with PBS. They were then 
resuspended in 100 µL citrate buffer (0.25 M sucrose, 40 mM sodium citrate, pH 7.6), 400 µL 
DNA staining/ lysis buffer (20 µg/mL PI, 0.5% NP-40, 0.5 mM EDTA) and 10 µL RNase A 
(stock 10 mg/mL). Following gentle mixing, the cells were incubated at 4 oC for 45 minutes in 
the dark. Samples were analysed using a BD FACsCalibur to quantify PI binding, capturing 
10,000 events per sample. Data acquisition was performed using CellQuest software. Single 
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cells were only gated in a FL2-W vs FL2-A plot, excluding cell aggregates/ debris. All data 
analysis was carried out using Cyflogic software. 
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3 Evidence that KMT5A is a mono-ubiquitinated protein and 
identification of the sites of mono-ubiquitination 
3.1 Introduction  
As the AR remains active in advanced and relapsed disease, targeting the AR remains a valid 
therapeutic target. Deregulation of AR regulators is one of the underlying mechanisms of AR 
activity in advanced disease (Abeshouse et al., 2015). Therefore, targeting AR regulators to 
indirectly target AR activity is important. KMT5A has been identified as a novel regulator of 
the AR by our group (Coffey et al., unpublished data). Interestingly, KMT5A was found to 
regulate AR activity in an opposing manner in models of androgen sensitive disease compared 
to castrate resistant disease. Therefore, KMT5A regulation itself is important which can in turn 
influence AR activity.  
KMT5A is primarily regulated through post-translational modifications in a cell cycle 
dependent manner. Ubiquitination-mediated proteasomal degradation plays a key role in the 
regulation of KMT5A protein stability and activity. Under physiological conditions, as well as 
in response to DNA damage, KMT5A is tightly controlled and maintained at low levels by the 
CRL4Cdt2 complex during G1-S transition phase of the cell cycle. CRL4cdt2 binds to KMT5A-
bound chromatin in a PCNA-dependent manner, mediating KMT5A poly-ubiquitination and its 
subsequent proteasomal degradation (Abbas et al., 2010; Centore et al., 2010; Oda et al., 2010). 
Furthermore, the SCFβ-TRCP complex poly-ubiquitinates KMT5A and marks it for degradation 
by the proteasome during G1 phase (Wang et al., 2015). Moreover, KMT5A is targeted for 
poly-ubiquitination and proteasomal-mediated proteolysis by the APCCdh1 complex during late 
mitosis, to maintain low levels of KMT5A in late mitosis and G1 phases of the cell cycle (Wu 
et al., 2010). Although, poly-ubiquitination of KMT5A and its degradation by the proteasome 
has been extensively studied, it is not known whether KMT5A could be modified directly by 
ubiquitination allowing it to carry out a specific function before being subjected to further 
ubiquitination and degradation. For example, SETDB1, a histone methyltransferase that tri-
methylates H3K9 and contributes to euchromatic gene silencing is required to undergo mono-
ubiquitination as this modification is essential for its catalytic activity (Sun and Fang, 2016).  
In a number of studies there has been a higher molecular weight KMT5A band observed in 
Western blots with KMT5A-directed antibodies, which has either been reported to be a non-
specific band without much investigation, or completely ignored and in most cases not even 
acknowledged, despite being present in some published figures. The higher molecular weight 
KMT5A band can be observed in some of the work by Tardat, Houston, Sims, Abbas, Centore, 
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Congdon, Jorgensen and Dulev et al (Tardat et al., 2007; Houston et al., 2008; Sims and Rice, 
2008; Abbas et al., 2010; Centore et al., 2010; Congdon et al., 2010; Jørgensen et al., 2011; 
Dulev et al., 2014). Our group, which has been studying the role of KMT5A in regulating the 
AR signalling in disease progression to CRPC, also observed the same slow migrating KMT5A 
band in Western blots. This band has a molecular weight of approximately 50 kDa, which is a 
molecular weight equivalent  to the predicted molecular weight of KMT5A (42 kDa) conjugated 
to a single ubiquitin (8 kDa), suggesting the possibility of a mono-ubiquitinated form of 
KMT5A.  
3.2 Hypothesis 
KMT5A is predominantly mono-ubiquitinated and this alteration generates a physiologically 
relevant form of modified KMT5A.  
3.2.1 Aims   
 To determine and confirm the presence of mono-ubiquitinated KMT5A in cell line 
models 
  Identify the site(s) of mono-ubiquitination  
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3.3 Specific materials and methods  
3.3.1 Site-directed mutagenesis 
Site-directed mutagenesis was performed using the QuikChange II XL Site-Directed 
Mutagenesis Kit (Agilent Technologies) according to the manufacturer’s instructions. It was 
used to create ubiquitination-deficient mutants of KMT5A at individual lysine sites, where the 
lysine of interest has been substituted with arginine in the full-length KMT5A construct. 
Furthermore, deletion mutants of the C-terminus KMT5A were created by replacing the amino 
acid of interest with a stop codon. 
Briefly, oligonucleotide primers (Table 3.2) containing the desired mutation were designed to 
have a melting temperature (Tm) of ≥ 78oC based on the formula below:  
Tm = 81.5 + 0.41 (%GC) – (675/N) – % mismatch  
Where N is the primer length in bases and values for GC% and % mismatch are whole numbers.  
The pSG5-Flag KMT5A WT or pSG5-Fag KMT5A C-terminus plasmids were used as a 
template for single lysine mutants and deletion mutants, respectively. The reactions then 
underwent 18 cycles of PCR as in Table 3.1.  
 
Table 3.1: Parameters of the PCR cycles. 
  
Cycles Temperature (oC) Time (secosnds)
1 95 60
95 50
60 50
68 480
68 420
18
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Mutation  Primer 
direction  
Sequence 5’-3’ 
K205R 
 
Forward GGGGGCCTGTCTGCCCTTGATGGGCTT 
Reverse  AAGCCCATCAAGGGCAGACAGGCCCCC 
K234R 
 
Forward GAAGGAGCTCCAGGAGGAGCAAAGCCGAGCTG 
Reverse CAGCTCGGCTTTGCTCCTCCTGGAGCTCCTTC 
K236R 
 
Forward GCTCCAGGAAGAGCAGAGCCGAGCTGCAGTC 
Reverse GACTGCAGCTCGGCTCTGCTCTTCCTGGAGC 
K245R 
 
Forward GCTGCAGTCTGAAGAAAGGAGAAGAATAGATGAATTGATTG 
Reverse CAATCAATTCATCTATTCTTCTCCTTTCTTCAGACTGCAGC 
K267R 
 
Forward GACCTCATCGATGGCAGAGGCAGGGGTGTGATTG 
Reverse CAATCACACCCCTGCCTCTGCCATCGATGAGGTC 
K297R 
 
Forward GAGCCTCCCGTTTCCTGGCGTCGGTGATC 
Reverse GATCACCGACGCCAGGAAACGGGAGGCTC 
K321R 
 
Forward GCATCCACGCAGTAGGTTCTGCTCAGATACTGAAAAT 
Reverse ATTTTCAGTATCTGAGCAGAACCTACTGCGTGGATGC 
K342R 
 
Forward GACTGATCAATCACAGCAGATGTGGGAACTGCCAAAC 
Reverse GTTTGGCAGTTCCCACATCTGCTGTGATTGATCAGTC 
K349R 
 
Forward GGAACTGCCAAACCAGACTGCACGACATCG 
Reverse CGATGTCGTGCAGTCTGGTTTGGCAGTTCC 
C1 
truncation 
Forward GCAAAGCCGAGCTGCAGTCTTAAGAAAGGAAAAGAATAGATG 
Reverse CATCTATTCTTTTCCTTTCTTAAGACTGCAGCTCGGCTTTGC 
C2 
truncation 
Forward CTGAAAATAGTACATGTATCAGCCCGTGGAAGGGTC 
Reverse GACCCTTCCACGGGCTGATACATGTACTATTTTCAG 
C3 
truncation 
Forward GCGTGGATGCAACTAGATAGACAAATCGCCTAGG 
Reverse CCTAGGCGATTTGTCTATCTAGTTGCATCCACGC 
C4 
truncation 
Forward CAGCAAATGTGGGAACTGACAAACCAAACTGCACGAC 
Reverse GTCGTGCAGTTTGGTTTGTCAGTTCCCACATTTGCTG 
C5 
truncation 
Forward CATCGCGGCTGGGTAGGAGCTCCTGTA 
Reverse TACAGGAGCTCCTACCCAGCCGCGATG 
C6 
truncation 
Forward GCAAGGCTTCCATTTAAGCCCACCCGTGGC 
Reverse GCCACGGGTGGGCTTAAATGGAAGCCTTGC 
Table 3.2: List of the primers used for the mutagenesis work.  
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Following PCR, samples were treated with Dpn 1 restriction enzyme and incubated at 37 oC for 
1 hour to digest the methylated and hemi-methylated parental, non-mutated DNA template. The 
end product was transformed into NEB 5-alpha competent E.coli under ampicillin selection (50 
ng/mL) (Chapter 2). Subsequently, up to 3 colonies were picked for propagation and were 
miniprepped using GenElute™ Mammalian Genomic DNA Miniprep Kit (Sigma-Aldrich). The 
purified plasmids were subject to Sanger sequencing (Beckman Coulter Genomics) to confirm 
successful mutagenesis.  
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3.4 Results 
3.4.1 Identification of mono-ubiquitinated KMT5A in prostate cancer cell lines 
Consistently, a distinct high molecular weight band of KMT5A has been observed when 
Western blotting for KMT5A by our group. This is a persistent band of 50 kDa which has not 
been described previously to be a modified form of KMT5A. As native KMT5A is a 42 kDa 
protein in the absence of any post-translational modifications, and ubiquitin is an 8 kDa peptide, 
this higher molecular weight species may represent a mono-ubiquitinated form of KMT5A.  
To investigate the presence of this putative mono-ubiquitinated KMT5A form, a panel of PC 
cell lines were tested. The cells were grown in their native media and whole cell lysates were 
collected for Western blot analysis using an anti-KMT5A antibody from Cell Signalling. 
Unmodified, native KMT5A (42 kDa) was found to be present in all the cell lines, though to 
varying degrees. Interestingly, the higher molecular weight KMT5A band at 50 kDa was also 
present, except in the DU145 cell line. The putative mono-ubiquitinated KMT5A band appeared 
to be a prevalent form of the total KMT5A as the ratio of the two bands were approximately 
equal as shown in Figure 3.1A. In order to exclude the fact that the 50 kDa band was due to 
non-specific binding of this particular antibody, a smaller panel of PC cell lines were tested 
with a different anti-KMT5A antibody purchased from Santa Cruz. As seen in Figure 3.1B, the 
same higher molecular weight KMT5A species was present at 50 kDa and the unmodified 
KMT5A at 42 kDa, as expected.  
 
 
Figure 3-1: Identification of a putative mono-ubiquitinated KMT5A form using different anti-KMT5A 
antibodies. Western blot analysis of endogenous KMT5A expression and the loading control α-tubulin in a panel 
of PC cell lines grown in their native media. All sample were collected with SDS sample buffer and two different 
anti-KMT5A antibodies used were from (A) Cell Signalling and (B) Santa Cruz. This is a representative image of 
multiple repeats.  
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3.4.2 Exogenously generated KMT5A exists as both unmodified and mono-ubiquitinated 
species 
There are two isoforms of KMT5A, produced by alternative splicing. (Abbas et al., 2010). The 
larger isoform is 42 kDa, which we describe as the unmodified form of KMT5A. The second 
isoform is around 3 kDa smaller as it lacks the first 41 amino acids in the KMT5A N-terminus. 
Having demonstrated unmodified KMT5A and its larger, putatively representing mono-
ubiquitinated form at 50 kDa endogenously, we wished to determine whether the larger 
KMT5A was also evident from a plasmid construct encoding the 42 kDa KMT5A. A third anti-
KMT5A antibody (Abcam) was used alongside one of the antibodies (Cell Signalling) in the 
previous section 3.4.1, to examine KMT5A expression. Consistently, the higher molecular 
weight 50 kDa KMT5A form was observed when KMT5A was overexpressed in COS7 cells, 
though at a smaller ratio relative to the unmodified KMT5A (Figure 3.2A) when compared to 
the PC cell lines. Anti-KMT5A antibodies from Cell Signalling and Abcam, Figure 3.2A and 
B respectively, were both able to detect the higher molecular weight KMT5A form with a 
consistent band position for both antibodies. As three different anti-KMT5A antibodies 
recognising different regions of KMT5A were able to detect the 50 kDa KMT5A band, it was 
considered satisfactory to describe it as a genuine KMT5A product. The Cell Signalling anti-
KMT5A antibody worked more robustly and was therefore used for the rest of the work, unless 
mentioned otherwise. 
 
Figure 3-2: Validation of mono-ubiquitinated KMT5A expression using an overexpression system. Western 
blots of KMT5A and the loading control α-tubulin after COS7 cells were transfected with 500 ng control empty 
vector (EV) or pSG5-FLAG KMT5A WT plasmid vectors for 48 hours prior to cell lysis using SDS sample buffer. 
Anti-KMT5A antibodies from Cell Signalling (A) and Abcam (B) were used to test KMT5A expression. 
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3.4.3 In vivo ubiquitination assay in COS7 cells confirms KMT5A is mono-ubiquitinated 
In order to confirm the high molecular weight band at 50 kDa is a mono-ubiquitinated form of 
KMT5A, an ubiquitination assay using polyhistidine pull down technique was performed in 
COS7 cells which overexpressed His-tagged ubiquitin (His-Ub) and Flag-KMT5A. In this 
assay, the histidine tag binds to nickel cations immobilised onto agarose beads (Ni-NTA beads), 
and captured proteins had undergone covalent modification by exogenously expressed His-Ub 
under denaturing conditions. Following pull down of His-tagged ubiquitinated proteins from 
the cell lysate, they were eluted off the beads and the resultant sample was analysed by Western 
blotting with anti-KMT5A antibody to detect ubiquitinated KMT5A. Figure 3-3 3.3 
demonstrates that the polyhistidine pull down was very specific as only the ubiquitinated-
modified forms of KMT5A were pulled down. Results showed that, the addition of His-Ub 
leads to the formation of the higher molecular weight band at 50 kDa which confirms it is mono-
ubiquitinated KMT5A as this band was absent when KMT5A or His-Ub were overexpressed 
alone (Figure 3.3). Moreover, additional higher molecular weight products, likely representing 
poly-ubiquitinated KMT5A were also apparent as seen by the upward mobility shift of KMT5A, 
a typical pattern of protein poly-ubiquitination. KMT5A mono-ubiquitination and consequently 
its poly-ubiquitination were markedly enhanced when the proteasome inhibitor, MG132, was 
added which further validates these are genuinely ubiquitinated species of KMT5A as they are 
stabilised upon inhibiting the proteasome, in line with the current literature. Furthermore, there 
are other heavier products of multi-ubiquitinated KMT5A formed with the addition of Ub, such 
as the distinct bands around 60 and 70 kDa regions which could correspond to di- and tri-
ubiquitinated KMT5A. Alternatively, they could also be mono-ubiquitination at two and three 
different lysine residues, respectively. For this work, we concentrated on the single mono-
ubiquitination of KMT5A as this is the prominent band in PC cell lines. 
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Figure 3-3: KMT5A is mono-ubiquitinated in vivo. COS7 cells were transfected with the indicated plasmids for 
48 hours. Cells were then subjected to 20 µM MG132 treatment in the final 16 hours, where indicated. In vivo 
ubiquitination assay using Ni-NTA (nickel beads) was then performed to pull down ubiquitinated proteins. The 
resultant samples were subject to Western analysis following the addition of SDS sample buffer. Anti-KMT5A 
and anti-flag antibodies were used to detect pulled down ubiquitinated KMT5A products. This is a representative 
blot of at least 3 independent experiments. 
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3.4.4 Inhibiting KMT5A expression using siRNA does not affect mono-ubiquitinated 
KMT5A levels 
Mono-ubiquitination is known to have non-proteolytic functions such as regulating protein 
stability. Therefore, it was hypothesised that inhibiting the expression of unmodified KMT5A 
should not influence mono-ubiquitinated levels of KMT5A. As such, KMT5A was depleted 
using two independent siRNA oligonucleotides that target the KMT5A C-terminus, as this 
domain is shared across the two isoforms of KMT5A. This also further validates the 50 kDa 
band is not due to KMT5A isoforms. As KMT5A was found to function in an opposing manner 
between the two PC cell lines, LNCaP and LNCaP-AI, both cell lines were taken forward for 
investigation.  
Figure 3.4 demonstrates that KMT5A is efficiently depleted with both siRNA oligonucleotides 
compared to the non-silencing (N/S) control. However, mono-ubiquitinated KMT5A levels 
remained unchanged following KMT5A knockdown across the two PC cell lines tested, 
indicating mono-ubiquitination causes stabilisation of KMT5A. Interestingly, di-ubiquitinated 
KMT5A levels were markedly reduced following inhibition of KMT5A expression. This 
however may not be a direct consequence of KMT5A knockdown, which will be discussed 
later. Moreover, persistence of the 50 kDa band after targeting the C-terminus of KMT5A using 
siRNA, further confirms KMT5A isoforms do not play a role in this phenomenon.  
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Figure 3-4: KMT5A depletion does not affect mono-ubiquitinated KMT5A level. PC cell lines were reverse 
transfected with 25 nM non-silencing (N/S) or KMT5A siRNA for 96 hours, in their native growth medium. Post-
transfection, cells were lysed with SDS sample buffer to be analysed by Western blotting for KMT5A expression 
and the loading control α-tubulin.  
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3.4.5 Mapping of the KMT5A domain for mono-ubiquitination  
Having provided strong evidence that mono-ubiquitinated KMT5A exists, we then sought to 
determine which domain(s) of KMT5A is targeted for mono-ubiquitination. Figure 3.5 A shows 
a schematic representation of full-length KMT5A and its defined regions, including the 
catalytic SET domain. To this end, plasmid constructs encoding KMT5A N or C-terminus 
(Figure 3-5A) were overexpressed alone or in combination with His-Ub, in COS7 cells and 
KMT5A levels were assessed by Western blotting (Figure 3-5B).  
Overexpression of KMT5A C-terminus construct alone led to the expression of unmodified C-
terminus fragment and a heavier band, the equivalent weight of a mono-ubiquitinated C-
terminus form, as marked on Figure 3-5B, right panel. Addition of Ub enhanced the level of 
this heavier C-terminus product, in keeping with the full length KMT5A findings. Similarly, 
KMT5A N-terminus construct was overexpressed and an anti-KMT5A antibody from Abcam 
which recognises the N-terminus region of KMT5A was used for Western blotting. 
Unfortunately, this antibody which is currently the only anti-KMT5A antibody available 
against the N-terminus domain of KMT5A did not detect any protein bands, despite extensive 
testing. This antibody has also proved difficult and unreliable for Western blotting when tested 
by a former member of the lab working on KMT5A, and has not been used in any of the 
publications so far. Instead, the KMT5A N-terminus was detected using an anti-flag antibody 
which detected the correct molecular weight protein of ~ 15 kDa. However, in our hands the 
anti-flag antibody only detects unmodified KMT5A N-terminus efficiently and is not consistent 
in detecting its modified products. As KMT5A C-terminus entails the larger section of KMT5A, 
containing all the conserved lysine residues, we decided to continue our investigations with the 
assumption that the C-terminus KMT5A contains the lysine(s) responsible for mono-
ubiquitination.   
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Figure 3-5: C-terminal domain of KMT5A is targeted for mono-ubiquitination. (A) Schematic diagram of 
full-length KMT5A (aa 1-393), and its N (aa 1-169) and C (aa 170-393) domains. (B) COS7 cells were transfected 
with 0.5 µg of each plasmid as indicated for 48 hours. All reactions were balanced with appropriate empty vector. 
Cells were lysed using SDS sample buffer and subjected to Western blotting using anti-KMT5A antibody from 
Abcam or Cell Signalling for detecting the N-terminus and C-terminus KMT5A, respectively. 
 
  
75 
 
3.4.6 C-terminus of KMT5A is a lysine rich domain  
Before commencing our mutagenesis work to identify the site(s) of mono-ubiquitination in 
KMT5A C-terminus, it was required to closely study the information available on its lysine 
residues. KMT5A protein consists of 37 lysine residues, of which 25 of them are located in its 
C-terminus. There are a number of lysine residues in this domain which are highly conserved, 
including K236, K267, K342 and K382 which are conserved across human, mouse, rat, 
zebrafish and chicken species (Figure 3.6). Moreover, K245 and K255 are conserved in three 
and four of the indicated species, respectively. Additionally, K172 which is another highly 
conserved lysine, is responsible for KMT5A sumoylation (Spektor et al., 2011).  
A number of KMT5A lysine residues have been identified as positive hits for sites of 
ubiquitination by various mass spectrometry studies; though, no confirmatory validation work 
has been carried out. All of these predicted lysines are located in the C-terminus of KMT5A 
which include K236, K245, K255, K267, K342 and K382. Furthermore, in a quantitative 
proteomics study, carrying out global profiling of ubiquitination, acetylation and 
phosphorylation sites in proteins regulated by the DNA damage response, the same lysine 
residues except K382 were identified to be sites of ubiquitination for subsequent degradation 
of KMT5A. Moreover, additional lysine residues, K260, K275, K297, K298, K349 and K39 
were also identified as sites of ubiquitination (Elia et al., 2015).  
Considering the information available, it was decided to initially carry out mutagenesis to 
generate full-length KMT5A point mutants at each of the single lysine residues for the six 
following lysines: K236, K245, K255, K267, K342 and K382.  
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Figure 3-6: KMT5A C-terminus sequence. All the lysines in the C-terminus have been highlighted in different 
colours. Blue: sumoylation site; red: lysines conserved across human, mouse, zebrafish, chicken and rat; green: 
lysines conserved across 3 or more of the species including human. The orange boxed region is the defined SET 
domain.  
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3.4.7 KMT5A mono-ubiquitination is not specific to a single lysine residue  
We next assessed whether the lysine residues K236, K245, K255, K267, K342 or K382 located 
in the C-terminus could be the site of KMT5A mono-ubiquitination. We chose these positions 
because these lysines were highly conserved, predicted and some of them previously shown to 
be sites of ubiquitination. Wild-type full-length KMT5A template was used to generate the 
single point mutations using site-directed mutagenesis, replacing lysine with an arginine at the 
indicated positions. Once KMT5A mutants were generated and verified by DNA sequencing 
the plasmid constructs were overexpressed in COS7 cells, cell lysates were prepared and 
subjected to Western blot to assess mono-ubiquitinated KMT5A levels. However, mutating a 
single lysine at a time at any of these positions did not abolish KMT5A mono-ubiquitination 
(data not shown). As a result, we continued to individually mutate the remainder of the lysine 
residues in KMT5A C-terminus, including the identified sumoylation site at K172, and found 
no detectable change in KMT5A mono-ubiquitination (data not shown). Although, some of the 
KMT5A mutants including K205R, K234R, K236R, K245R, K267R, K297R, K321R, K342R 
and K349R showed a small change in the level of mono-ubiquitinated KMT5A; but, nothing 
that was significant. Thus, overexpression of these mutants was repeated and samples were 
subjected to Western blotting. The different KMT5A plasmid constructs expressed the 
unmodified KMT5A protein at different levels, which was not due to loading differences as the 
total protein content of the cells, assessed by α-tubulin levels (data not shown) was similar. 
Hence, it was difficult to determine changes in the mono-ubiquitination levels of the mutant 
constructs compared to wild-type KMT5A. Therefore, serial dilution of samples was carried 
out to achieve equivalent levels of unmodified KMT5A in mutants, as well as, wild-type 
KMT5A Regrettably, no appreciable reduction in KMT5A mono-ubiquitination was evident 
upon repeating the overexpression (Figure 3.7). 
While the site-directed mutagenesis work was being conducted using full-length KMT5A, mass 
spectrometry was carried out using partially purified KMT5A C-terminus. This was based on 
the assumption that KMT5A C-terminus contains the site(s) of mono-ubiquitination for reasons 
previously described (Chapter 3.4.5 and 3.4.6), in turn reducing noise by eliminating the lysine 
residues in KMT5A N-terminus. For this purpose, Flag-tagged C-terminus KMT5A was co-
expressed with His-Ub at 1 µg each in three 90 mm dishes, in COS7 cells. After 48 hours 
incubation, ubiquitinated forms of KMT5A C-terminus were separated from the cell lysate 
using Ni-NTA beads (Chapter 2.9.2) where we attempted to generate a concentrated sample. 
The sample was resolved by SDS-PAGE and sent to the Newcastle University protein and 
proteome analysis facility run by Dr Achim Treumann and his staff. They then excised the 
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region of our gel where mono-ubiquitinated KMT5A C-terminus was predicted to resolve and 
analysed this by MS. Unfortunately, no signal was detected which was thought to be due to the 
low concentration of material. In a follow up meeting with Dr Treumann, we were advised to 
generate a much higher concentrated sample which was not within the scope of the project at 
that time. Consequently, mass spectrometry work was terminated.  
 
  
79 
 
 
Figure 3-7: KMT5A mono-ubiquitination is not abolished by mutating a single lysine residue. A 
representative blot of some of the mutagenesis work. Site-directed mutagenesis was performed on full-length wild-
type KMT5A. KMT5A was mutagenised to generate a single point mutation, replacing lysine with an arginine, 
for each lysine individually in KMT5A C-terminus. The following lysine to arginine mutants are shown: K205R, 
K234R, K236R, K245R, K267R, K297R, K321R, K342R and K349R. Wild-type (WT) or mutant KMT5A 
constructs were overexpressed in COS 7 cells at 0.5 µg for 48 hours. Cells were lysed using SDS sample buffer, 
samples serially diluted and subjected to Western blotting. Different exposures are shown, exposure 1 being the 
shortest and exposure 3, the longest. 
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3.4.8 Generation and validation of truncated KMT5A C-terminus fragments 
As our attempts in identifying the site(s) of KMT5A mono-ubiquitination did not yield any 
lysine residue that markedly abrogates mono-ubiquitination through mutagenesis of each lysine 
individually in KMT5A C-terminus, we next sought to determine the region in KMT5A C-
terminus that is targeted for mono-ubiquitination.  
Therefore, we created a series of KMT5A truncated mutants derived from the C-terminus of 
KMT5A. These mutants were generated by introducing a stop codon at selected sites using site-
directed mutagenesis. We initially focused on creating KMT5A C-terminus truncations as our 
assumption was that mono-ubiquitination occurs in the C-terminal domain of KMT5A (Chapter 
3.4.5 and 3.4.6). Further, all our earlier mutagenesis work was conducted on the lysines located 
in KMT5A C-terminus (Chapter 3.4.7). Therefore, we aimed to eliminate any interference from 
the KMT5A N-terminus, though the lysines in the N-domain should not play a role in KMT5A 
mono-ubiquitination.  
Six truncated C-terminal domain fragments were generated, C1 being the smallest (not shown) 
and C6 the largest, as shown schematically in Figure 3.8A and Figure 3.9A. The smallest 
fragment (C1) was made long enough to ensure it contains the important arginine, R230, 
required for anti-KMT5A antibody binding. For each deletion construct, three clones were 
selected for propagation and the subsequent overexpression in COS7 cells as before. As 
demonstrated in Figure 3.8B, for all the truncations, the three clones were successfully 
expressed and were all of the predicted molecular weight. Although it is difficult to clearly 
distinguish the bands on this blot, it is clear that each fragment displays a different banding 
pattern.  
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Figure 3-8: Truncated deletion mutants of KMT5A C-terminus show a different profile of modified KMT5A 
levels. (A) Schematic diagram of KMT5A C-terminus truncated fragments created by introducing a stop codon in 
different regions of KMT5A C-terminus by site-directed mutagenesis. All the truncated forms were derived from 
full-length KMT5A C-terminus plasmid. (B) The constructs, C-terminus (200-393) and its derivatives, C3 to C6 
were overexpressed at 0.5 µg in COS7 cells. Following 48 hours incubation, cell lysates were generated by lysing 
cells in SDS sample buffer and analysed by Western blotting for KMT5A and the loading control α-tubulin. For 
each fragment, three independent constructs were generated, A-C. Red boxes display unmodified KMT5A. 
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3.4.9 KMT5A C-terminus truncated fragments C3-6 are targeted for mono-ubiquitination 
In order to further analyse the KMT5A C-terminus fragments, a representative construct was 
selected for each of the three independent constructs available for each fragment. The samples 
were again analysed by Western blotting and this time loaded to ensure equal level of 
unmodified KMT5A was achieved.  
Results showed that unmodified C-terminus (200-393) and its mono-ubiquitinated form were 
expressed consistently as before. All other fragments were also expressed at the correct 
predicted molecular weight in their unmodified forms (Figure 3.9). Interestingly, truncating the 
C-terminus to C2 abolished KMT5A mono-ubiquitination, as well as higher molecular weight 
forms of ubiquitinated KMT5A C-terminus. Whereas, mono-ubiquitination was retained in the 
larger C3 truncated KMT5A C-terminus. Further, mono-ubiquitination was retained for the 
other larger truncated deletion mutants, C4-C6. Surprisingly, although present, mono-
ubiquitinated levels markedly declined when larger C-terminal fragments of KMT5A were 
expressed (compare C3 to C4-C6). As seen in Figure 3.9, fragment C3 displayed the highest 
proportion of its mono-ubiquitinated form, and other ubiquitinated products such as its di-
ubiquitin form were also evident, which were even stronger than the KMT5A C-terminus (200-
393).   
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Figure 3-9: KMT5A C-terminus fragments C3-C6 undergo mono-ubiquitination. (A) Schematic diagram of 
truncated KMT5A C-terminus fragments, including C2. (B) Western blot analysis against KMT5A, assessing 
mono-ubiquitinated levels of representative constructs for each of the truncations compared to KMT5A C-terminus 
(200-393), with different exposures (exposure 1-3). N/T: non-transfected.  
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3.4.10 C-terminus of KMT5A requires amino acids 310-330 for mono-ubiquitination  
To determine if the truncated KMT5A C-terminus fragments are indeed altered by mono-
ubiquitin conjugation, in vivo ubiquitination assays using Ni-NTA beads was performed for 
fragments C2-C4 in COS7 cells. Only three of the fragments were selected for validation as we 
were specifically interested in the region responsible for mono-ubiquitination of KMT5A, 
which appears to be located between C2 and C3 (Chapter 3.4.9).  
For this purpose, KMT5A C-terminus fragments were overexpressed either in the absence or 
presence of His-Ub. Following pull down of ubiquitinated proteins modified by exogenous His-
Ub using the Ni-NTA beads, samples were subjected to Western blot analysis to assess mono-
ubiquitination of the fragments. Figure 3.10 clearly demonstrates that C3 undergoes mono-
ubiquitination when overexpressed in combination with His-Ub whereas it fails to become 
ubiquitinated when expressed alone. In addition, C3 was also heavily di-ubiquitinated and poly-
ubiquitinated, in keeping with the banding pattern as apparent in Figure 3.9.  
Similarly, fragment C4 was also mono-ubiquitinated, but the degree of ubiquitination appeared 
to be at a much smaller proportion relative to the level of unmodified C4 when compared to 
C3. However, C4 mono-ubiquitination was more abundantly expressed (Figure 3.9B) than what 
is demonstrated in this particular Western blot as the input shows considerably lower α–tubulin 
levels (Figure 3.10). In contrast, C2 was not modified by mono-ubiquitination and no other 
forms of ubiquitination were evident, which is consistent with the data in Chapter 3.4.9. As 
KMT5A mono-ubiquitination was abolished by truncating KMT5A C-terminus to the smaller 
fragment C2 and subsequently restored upon extending the C-terminus to fragment C3, it 
implies that the primary site of KMT5A mono-ubiquitination is located in the region between 
these two fragments.  
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Figure 3-10: Amino acids 310-330 in KMT5A C-terminus are required for KMT5A mono-ubiquitination. 
In vivo ubiquitination assays were performed in COS7 cells transfected with the indicated plasmids for 48 hours. 
Subsequently, samples were mixed with SDS sample buffer and subjected to Western blotting for KMT5A and 
the loading control α-tubulin.  
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3.4.11 The single additional lysine, K321, in fragment C3 is not responsible for KMT5A 
mono-ubiquitination 
Having determined the region of KMT5A undergoing mono-ubiquitination, we then sought to 
identify the lysine residue(s) that is being modified. As seen in Chapter 3.4.10, the region being 
responsible for KMT5A mono-ubiquitination is the section between C2 and C3 of KMT5A C-
terminus. Analysis of the amino acid sequence in this section revealed there is only one lysine, 
K321, different between these two fragments which is located in C3 (Figure 3.11A), suggesting 
K321 is the primary ubiquitin acceptor site in KMT5A.  
To test whether K321 is the lysine responsible for KMT5A mono-ubiquitination, the KMT5A 
C-terminus fragment C3 construct was mutagenised at K321 to generate a single point mutation, 
replacing lysine with an arginine (K321R) using site-directed mutagenesis, as before. Three 
independent constructs were generated as seen in Figure 3.11B which were overexpressed in 
COS7 cells and then mono-ubiquitinated KMT5A levels were assessed by Western blotting.  
Non-ubiquitinated, unmodified KMT5A fragment C3 mutagenised at K321 (C3 K321R) was 
expressed at the expected molecular weight, in line with wild-type fragment C3 (C3 WT). 
Unfortunately, mutagenesis at K321 was found not to cause any change in the levels of the 
mono-ubiquitinated form of KMT5A C3 (C3 K321R) when compared to wild-type C3 (C3 
WT). In contrast to the earlier indication (Chapter 3.4.10), this result indicates that the site of 
KMT5A mono-ubiquitination does not lie in the section between C2 and C3 of KMT5A C-
terminus. As a result, we have identified a region in KMT5A C-terminus which is required for 
KMT5A mono-ubiquitination.  
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Figure 3-11: K321 in KMT5A C-terminus fragment C3 is not the primary ubiquitin acceptor site. (A) 
Schematic diagram of KMT5A C-terminus fragments C2 and C3. The orange box represents the extended amino 
acid sequence, comprising the only additional lysine, K321, which is missing in C2. (B) KMT5A C-terminus 
fragment 3 was mutagenised at K321 by site-directed mutagenesis. The constructs were overexpressed in COS7 
cells. Following 48 hours post-transfection, cell lysates were collected using SDS sample buffer and analysed by 
Western blotting for KMT5A and the loading control α-tubulin. N/T: non-transfected. 
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3.4.12 The role of N-terminus KMT5A in KMT5A mono-ubiquitination  
Having demonstrated and validated the reasons for investigating the site(s) of mono-
ubiquitination in KMT5A C-terminus, we wanted to rule out the possibility that our results 
could have been influenced by the absence of the KMT5A N-terminus. Furthermore, although 
the site(s) of mono-ubiquitination was not identified, we had KMT5A C-terminus truncated 
constructs that were mono-ubiquitin competent and mono-ubiquitin deficient which could be 
utilised for investigating the functional analysis of the mono-ubiquitinated form of KMT5A. 
However for functional analysis, a better representative of full-length KMT5A is required, 
rather than working with C-terminus truncations only.  
Therefore new KMT5A truncated deletion constructs were generated to include the KMT5A 
N-terminal domain, extended to include the C-terminus deleted fragments (C1, C2 and C3) 
generated in Chapter 3.4.8. Site-directed mutagenesis was performed on full-length wild-type 
KMT5A construct with the same primers, which were used to generate C-terminus fragments, 
to introduce a stop codon at the same sites in KMT5A C-terminus as performed previously 
(Figure 3.12A). Following overexpression of the new constructs in COS7 cells, and their 
analysis by Western blotting, three constructs for each of the KMT5A fragments (fragments N-
C1, N-C2 and N-C3) were expressed at the expected molecular weight in their unmodified 
forms. Figure 3.12B clearly demonstrates a different profile of bands for each of the newly 
created fragments, where there were more of the higher molecular weight bands of KMT5A 
fragment N-C3, as well as, increased amounts of them. However, there were fewer bands for 
fragment N-C2 and even less for fragment N-C1, despite the higher protein expression level of 
their unmodified forms compared to fragment N-C3. The C-terminus fragment C1 (41 amino 
acids in length; aa 200-240, Chapter 3.4.8) which was previously derived from the KMT5A C-
terminus (200-393) construct, could not be resolved on Western blotting due to its very small 
size of 5 kDa; hence, not presented on earlier western blots. Although, KMT5A C-terminus 
fragment C1 was not expected to be mono-ubiquitinated as it is a shorter version of fragment 
C2 which was demonstrated to not be subject to mono-ubiquitination, it is included in this 
section as an additional mono-ubiquitin deficient form of KMT5A which can now be resolved 
due to its larger size by the addition of the KMT5A N-terminus. 
As we expected, the inclusion of the N-terminus did not alter the mono-ubiquitination pattern 
of KMT5A C-terminus fragments, as the new fragment N-C2 failed to undergo any mono-
ubiquitination. In contrast, the new fragment N-C3 was subject to mono-ubiquitination (Figure 
3.12B), in keeping with KMT5A C-terminus truncated deletion mutants (Figure 3.10). Even 
though there were bands present for fragments N-C1 and N-C2 which may appear to be mono-
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ubiquitinated forms, their molecular weight was not equivalent to any ubiquitin conjugated 
product. However, we cannot completely rule out the absence of fragments N-C1 and N-C2 
mono-ubiquitination, as it is difficult to judge from this Western blot, but if there is any mono-
ubiquitination of these fragments it is very low compared to fragment N3, and possibly due to 
background non-specific mono-ubiquitination of other lysine residues. 
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Figure 3-12: N-terminus of KMT5A does not alter mono-ubiquitination of C-terminus fragments. (A) 
Schematic diagram of truncated C-terminus fragments containing the KMT5A N-domain. (B) The wild-type full 
length KMT5A construct was used as a template to generate the same truncated C-terminus fragments with the 
additional N-terminal domain. Site-directed mutagenesis was carried out to introduce a stop codon using the same 
primers as in section 3.4.8, and three constructs (A-C) was generated for each fragment. The constructs were 
subsequently overexpressed in COS7 cells for 48 hours. SDS sample buffer was used to lyse the cells and samples 
were analysed by Western blotting for KMT5A and α-tubulin as the loading control. N/T: non-transfected. 
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3.4.13 Amino acids 310-330 are required for KMT5A mono-ubiquitination independently of 
the KMT5A N-terminal domain 
Given the consistent pattern of mono-ubiquitination for KMT5A fragments in the presence of 
the KMT5A N-terminus, ubiquitination assays were used to confirm the attenuated ability of 
the new fragments N-C1 and N-C2 to be modified by mono-ubiquitin conjugation relative to 
the new fragment N3 to undergo this modification. In line with our previous findings for 
KMT5A C-terminus truncated mutants, the new fragment N-C3 was demonstrated to be mono-
ubiquitinated, as well as di- and poly-ubiquitinated; whereas, fragments N-C1 and N-C2 
remained unmodified (Figure 3.13). This further validated our initial data that the lysine(s) 
modified by mono-ubiquitination does not reside in the KMT5A N-terminus and that the region 
between C2 and C3 is critical for ubiquitination. 
Interestingly, there was an additional band formed in fragment N-C3, as indicated on the 
Western blot (Figure 3.13). This band is possibly an ubiquitinated product of fragment N-C3 
with an additional post-translational modification as its molecular weight is greater than a 
mono-ubiquitinated form but lower than a di-ubiquitinated product of this fragment.   
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Figure 3-13: N-terminal domain extended fragments maintain the same mono-ubiquitination pattern as C-
terminus fragments. In vivo ubiquitination assay in COS7 cells following 48 hours of transfection with the 
indicated plasmids. Western blotting was performed for KMT5A and the loading control, α-tubulin. N/T: non-
transfected. The red asterisk indicates a poly-ubiquitinated KMT5A product with an additional post-translational 
modification.   
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3.5 Discussion 
Whilst considerable attention has been directed to KMT5A poly-ubiquitination and its degradation 
by the proteasome as a crucial mechanism in controlling KMT5A activity during the cell cycle, no 
studies have investigated the presence of mono-ubiquitinated KMT5A as a prominent post-
translational modification. This significance is backed up by the lack of studies in investigating an 
abundant form of KMT5A with a higher molecular weight, indicative of a mono-ubiquitinated 
KMT5A. In this chapter, various methods were utilised to provide evidence for the existence of 
mono-ubiquitinated KMT5A.  
The data presented in this chapter revealed the existence of mono-ubiquitinated KMT5A in a panel 
of PC cell lines which were expressed at different levels. Notably, the level of endogenous mono-
ubiquitinated KMT5A was similar to unmodified KMT5A levels for each cell line, except for 
DU145 cells which did not show detectable mono-ubiquitinated KMT5A (Figure 3.1). This could 
be due to these cells being devoid of an enzyme to mono-ubiquitinate KMT5A or it is possible that 
KMT5A is ubiquitinated and eliminated rapidly in DU145 cells, making it below the detection 
limit of our system. It would be interesting to investigate KMT5A mono-ubiquitination in DU145 
cells following KMT5A over-expression. Mono-ubiquitinated KMT5A was further shown to be 
present when expressed from a plasmid in a different cellular background, using COS7 cells 
(Figure 3.2). Interestingly, despite the high expression level of unmodified KMT5A, the level of 
mono-ubiquitinated KMT5A was much lower, in contrast to the PC cell lines. The extent of this 
post-translational modification could therefore be cell-type specific possibly caused by the 
expression level of protein(s) responsible for mono-ubiquitinating KMT5A or deubiquitinating 
enzymes (DUBs) which remove ubiquitin moieties from proteins. Furthermore, it could be due to 
the proteins that modulate the activity of the E3 responsible for KMT5A mono-ubiquitnation or 
the corresponding DUB.  Additionally, it may partly be due to the difference in the cell cycle 
distribution of the cells at the time of collection, which will be discussed further in Chapter 4.  
The Western-based ubiquitination assays performed using COS7 cells confirmed full-length 
KMT5A is mono-ubiquitinated (Figure 3.3). Furthermore, inhibiting proteasomal-mediated 
degradation by MG132 treatment led to a dramatic stabilisation of KMT5A, forming multi-
ubiquitinated KMT5A products, namely di- and tri-ubiquitinated KMT5A as seen by their distinct 
bands (Figure 3.3). Interestingly, the mono-ubiquitinated form of KMT5A was predominant over 
any of the poly-ubiquitinated KMT5A forms, indicating KMT5A is stabilised upon mono-ubiquitin 
conjugation. Therefore, this could be the underlying reason for observing mono-ubiquitinated 
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KMT5A as a prominent form in PC cell lines. Similarly, mammalian apurinic/apyrimidinic 
endonuclease (APE1), an essential DNA repair regulatory protein has been inferred to be stabilised 
in a similar manner (Busso et al., 2009). 
The C-terminal domain of KMT5A represents two thirds of the protein and comprises many of the 
evolutionary conserved lysines. Moreover, it contains the catalytic SET domain of KMT5A which 
must be tightly regulated. In addition to altering protein stability, mono-ubiquitination regulates 
the function of the protein substrate, leading to either increased or decreased activity. Interestingly, 
SETDB1 tri-methylase activity has been shown to be positively regulated by mono-ubiquitination 
of its evolutionary conserved lysine, K867, located in its SET insertion (i-set) domain (Sun and 
Fang, 2016). As already discussed in Chapter 1.5.2, the SET domain of human methyltransferases 
is flanked by distinctive sub-domains at its N and C termini, n-SET and c-Set, respectively. These 
sub-domains are separated by a considerably variable i-set region which acts as a substrate docking 
platform, whilst the majority of its invariant residues are associated most directly with the active 
site (Xiao et al., 2003). As mono-ubiquitination played such a crucial role in the activity of 
SETDB1, sequence alignment of human SETDB1 and KMT5A was performed to determine 
whether the i-set sequence or the sequence flanking the mono-ubiquitinated lysine (K867) in 
SETDB1 is common with that of KMT5A or is it similar to the region between KMT5A C2 and 
C3 required for KMT5A mono-ubiquitination. However, there were no similarities found. 
Although, no evidence has been provided by this body of work, KMT5A enzymatic activity could 
also be subject to a similar regulation, all of which suggests that the C-terminus is targeted for 
mono-ubiquitination.  
In an effort to identify the site(s) of KMT5A mono-ubiquitination, site-directed mutagenesis was 
used to substitute the lysine of interest with an arginine. Six different lysine residues, located in 
KMT5AC-terminus, previously identified as putative ubiquitination sites in a mass spectrometry 
study (Kim et al., 2011), were selected and individually mutagenised. The fact that these lysines 
were evolutionary conserved among different species, implied that some of them might have an 
important role in KMT5A regulation other than mediating its poly-ubiquitination and degradation. 
However, these lysines were found not to be responsible for KMT5A mono-ubiquitination as the 
mono-ubiquitinated levels of KMT5A were not affected upon their mutagenesis. Subsequently, all 
the remaining lysine residues in KMT5A C-terminus were individually mutagenised (25 lysines in 
total), but none of the single point mutations caused an apparent change in mono-ubiquitination of 
KMT5A (Figure 3.7). This suggested that either these lysines are not the primary site for accepting 
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a single ubiquitin moiety or that there is a compensatory mechanism whereby mono-ubiquitination 
can take place on alternative lysines following mutation of the primary site, with the “alternative 
hypothesis” being reported by many other studies (Ju and Xie, 2006; Demuc et al., 2009; Li et al., 
2014c; Ray et al., 2014). However, an alternative speculation is that KMT5A is mono-ubiquitinated 
at multiple lysine residues, where the di- and tri-ubiquitinated KMT5A products visualised on 
Western blotting could actually be mono-ubiquitin conjugations at two or three different lysine 
residues, respectively. This suggests, there are more than one primary lysine site in KMT5A 
undergoing mono-ubiquitin conjugation. As a result, it was not possible to find a major mono-
ubiquitin acceptor site as mutating individual lysine did not prevent mono-ubiquitin conjugation at 
the other lysines available.  
To study this further in the future and to confirm our speculation it would be useful to use a mutant 
ubiquitin containing no lysines (K0-Ub), which would only allow for mono-ubiquitination, in our 
ubiquitination assays. As K0-Ub is unable to form ubiquitin chains, the level of mono-, di- and tri-
ubiquitin KMT5A should not be affected relative to wild-type ubiquitin, should those forms of 
KMT5A be mono-ubiquitination at multiple lysines.  
Interestingly, mono-ubiquitinated KMT5A persisted after KMT5A knockdown in PC cell lines 
which further suggests it is a more stable form of KMT5A and hence its prevalence in PC cell lines; 
whereas the di-ubiquitinated KMT5A was found to be depleted, (Figure 3.4). Mono-ubiquitination 
of KMT5A represents the transition between unmodified and di-ubiquitinated (assuming chain 
formation) KMT5A forms where its latter form could be more susceptible to becoming further 
poly-ubiquitinated and degraded. However, proteasomal degradation of ubiquitinated proteins has 
been reported to require four or more ubiquitin molecules in the poly-ubiquitin chain conjugated 
to the substrate protein (Pickart, 2000; Pickart and Fushman, 2004). In addition to the canonical 
lys48-linked poly-ubiquitination and proteolysis by the proteasome, multiple mono-ubiquitination 
at different sites has also been shown to signal for protein degradation by the proteasome (Boutet 
et al., 2007; Dimova et al., 2012). This may account for depletion of di-ubiquitinated KMT5A, and 
the absence or undetectable endogenous levels of these higher molecular weight forms (Figure 3.4), 
further supporting speculation of KMT5A being mono-ubiquitinated at multiple lysine residues. 
Additionally, it helps to explain the stabilisation of mono-, di- and tri-ubiquitinated KMT5A 
products upon MG132 treatment, indicating multiple mono-ubiquitinated forms of KMT5A could 
potentially be targeted for degradation (Figure 3.3). However, it does not explain why di-
ubiquitinated KMT5A forms are only depleted with KMT5A knockdown. It would be of great 
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value to perform cycloheximide experiments to follow the stability of the unmodified, mono- and 
di-ubiquitinated KMT5A forms in some of the PC cell lines.  
In the current work, mass spectrometry analysis was also used to identify the lysine residue(s) that 
can be mono-ubiquitinated in KMT5A. Unfortunately, our first attempt was not successful and 
indicated that a much larger amount of material was required. This would have involved scaling 
up the work at a level that was no longer practical.  
Whilst the specific lysine(s) undergoing mono-ubiquitin conjugation remains unknown, it was 
possible to apply an alternative strategy to localise a region of KMT5A being mono-ubiquitinated. 
Firstly, a series of truncations were made from the larger KMT5A C-terminus fragment and 
subsequently assessed for their ability to become mono-ubiquitinated. This system enabled a region 
in KMT5A which is required for its mono-ubiquitination to be defined. The inability of the 
shortened fragment C2 of KMT5A C-terminus to be mono-ubiquitinated (or di-, tri-ubiquitinated) 
whilst the slightly lengthened fragment C3 of KMT5A was efficiently mono-ubiquitinated (and 
also di- and poly-ubiquitinated) highlights a short region within the C-terminal KMT5A that is 
important for KMT5A mono-ubiquitination, Figure 3.9. Interestingly, KMT5A C-terminus 
fragment C3 was modified to the greatest extent compared to the longer fragments including the 
KMT5A C-terminus (Figure 3.9). De-stabilisation of mono-ubiquitinated KMT5A as the C-domain 
gets longer could be due to degradation as more lysines are available for ubiquitination, or de-
ubiquitination. For example, the longer fragments may include peptide binding sequence for 
protein partners involved in KMT5A turnover, or possibly introduce a phosphorylation site 
required for de-ubiquitination as there are reports of phosphorylation-dependent de-ubiquitination 
(Ramachandran et al., 2016). 
The fact that K321 is the sole additional lysine present in fragment C3 compared to fragment C2, 
and appears to be responsible for the formation of higher molecular weight KMT5A products, may 
conflict with initial speculation that KMT5A is mono-ubiquitinated at multiple lysines. 
Furthermore, this may suggest the detected di- and tri-ubiquitinated forms of KMT5A are chains 
of ubiquitin rather than multiple mono-ubiquitin additions in the protein. However, mono-
ubiquitination of C3 may lead to a conformational change in KMT5A C-terminus that exposes 
other lysine residues for further mono-ubiquitination at multiple sites.  
As K321 was the only lysine in the amino acid stretch between fragments C2 and C3, it was thought 
that K321 is the primary ubiquitin acceptor site in KMT5A. Therefore, K321 was mutated in 
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KMT5A C-terminus background, but it failed to abolish KMT5A mono-ubiquitination (Figure 
3.11). This could have been due to the fact that KMT5A fragment C3 is mono-ubiquitinated at 
multiple sites, whereby mutating K321 does not affect mono-ubiquitin conjugation occurring at 
other available lysines, in line with our initial speculation. Additionally, it may mean that the 
peptide sequence (aa 310-330) contains an important recognition sequence for an associated protein 
partner that is involved with KMT5A mono-ubiquitin conjugation, whilst the site of mono-
ubiquitination may lie somewhere else in the KMT5A C-terminus. Alternatively, a phosphorylation 
event may be required for KMT5A to become mono-ubiquitinated, as many ubiquitination events 
are preceded by phosphorylation (Fuchs et al., 1996; Tsvetkov et al., 1999; Chernov et al., 2001). 
However, analysis of KMT5A phosphorylation sites using available online software in this stretch 
of amino acids did not reveal any strong consensus phosphorylation sites. In contrast to these 
speculations, K321 could potentially be the primary mono-ubiquitin acceptor site in KMT5A, but 
due to promiscuity of the ubiquitination sites in KMT5A, other lysines may act as backup ubiquitin 
acceptor sites and compensate for the loss of K321. Similarly, the same problem has been reported 
by other studies investigating the site of mono-ubiquitination in various proteins. As an example, 
Han et al., (2016), Li et al., (2014) and Ray et al., (2014) identified the site of mono-ubiquitination 
in survival motor neuron (SMN), ovarian tumour domain-containing ubiquitin aldehyde binding 
protein 1 (Outb1) and signal transducers and activator of transcription-3 (STAT3), respectively, by 
mass spectrometry; whilst, they failed to identify the same site using site-directed mutagenesis 
where the authors speculated the alternative lysine hypothesis to be the underlying reason.  
Assessment of the role of KMT5A N-terminus in the mono-ubiquitination pattern of KMT5A C-
terminus fragments was consistent with our notion that the C-domain of KMT5A is solely targeted 
for mono-ubiquitination.  The newly created truncated fragments that included the N-terminal 
domain of KMT5A retained the same mono-ubiquitination pattern as the C-terminal constructs. 
The N-terminus-containing fragments, N-C1 and N-C2 failed to be ubiquitinated whereas fragment 
N-C3 underwent mono-ubiquitination (Figure 3.12 and 3.13). It is important to note that both 
fragments C3 and N-C3 were more abundantly expressed, regardless of the presence or absence of 
the KMT5A N-terminus than the other generated longer fragments. Although, the site(s) of mono-
ubiquitination is almost certainly not located in KMT5A N-terminus, this region may still 
contribute to the level of KMT5A mono-ubiquitination through providing stability, binding site 
and other post-translational modifications which positively or negatively regulate mono-ubiquitin 
conjugation of KMT5A. Other post-translational modifications, in particular phosphorylation, 
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could underlie the presence of an additional ubiquitinated KMT5A form in the ubiquitination assay 
for the N-terminal domain containing fragment N-C3, (Figure 3.13). The important contribution of 
alternative post-translational modifications within the KMT5A N-terminus has previously been 
demonstrated by Wu et al., (Wu et al., 2010) showing that de-phosphorylation of KMT5A at serine 
100 promotes KMT5A ubiquitination by the APCCdh1 complex.  To investigate this further it would 
be possible to mutate consensus phosphorylation sites in the N-terminal domain of C-terminal 
deleted constructs and monitor the degree of mono-ubiquitination. 
To continue the work in identifying the site of mono-ubiquitination, it would be of significant value 
to generate a set of KMT5A deletion constructs where the extreme C-terminus adjacent to the stop 
codon is retained, whilst regions back towards the N-terminus are progressively added. Similarly, 
the short peptide between fragments C2 and C3 could be expanded out in both C and N terminal 
directions. Moreover, the lysine residues on the surface of KMT5A can be identified using 
structural information, and a mutant KMT5A with all these lysines knocked out generated. The 
mutated lysines could then be reintroduced one at a time to monitor the re-appearance of mono-
ubiquitinated KMT5A.  
In summary, this body of work suggests the presence of mono-ubiquitinated KMT5A as a novel 
post-translational modification has been demonstrated and validated which has not been previously 
reported. The region of KMT5A important to enable mono-ubiquitination was shown to be 
localised within its C-terminus, specifically, amino acids 310-330. This could either be required 
for KMT5A mono-ubiquitination, or may contain important lysine residues responsible for mono-
ubiquitin conjugation in KMT5A. However, the specific lysine site(s) undergoing mono-
ubiquitination, and the underlying mechanism for KMT5A to be modified by mono-ubiquitin 
linkage remains unknown and warrants further investigations.  
 
  
99 
 
4 Investigating the role of mono-ubiquitinated KMT5A and its regulation by 
Skp2 
4.1 Introduction 
KMT5A plays an important role in an array of biological processes, by regulating the mono-
methylation of histone H4K20 and non-histone proteins. More importantly, KMT5A has been 
shown to be a co-activator of the AR in CRPC, enhancing AR transcriptional activity. As KMT5A 
level, and in turn its activity, are under tight cell cycle regulation through post-translational 
modifications, and having demonstrated the dominant existence of mono-ubiquitinated KMT5A in 
PC cell lines in Chapter 3, it was hypothesized that regulatory mechanisms of KMT5A could be 
exploited to indirectly target the AR. Whilst, much effort has been made to understand the role 
unmodified KMT5A plays in many cellular processes and the functional consequences of its 
fluctuating levels during the cell cycle, nothing is known about the role of mono-ubiquitinated 
KMT5A. Therefore, the first aim of this chapter is to characterize the role of mono-ubiquitinated 
KMT5A.  
In addition to previously characterized ubiquitination-mediated degradation of KMT5A by the 
SCFβ-TRCP, CRL4Cdt2 and APCCdh1 complexes during G1, S phase and mitosis, respectively, Skp2 
has also been suggested to play a role in ubiquitinating KMT5A for proteasomal degradation 
(Abbas et al., 2010; Centore et al., 2010; Oda et al., 2010; Wu et al., 2010; Wang et al., 2015). 
Skp2 is the F-box component of the SCF complex (Skp1-Rbx1-Cul1- F-Box) and functions as an 
E3 ligase (Schulman et al., 2000). Skp2 regulates an array of downstream substrates and as such is 
essential in modulating several cellular functions such as cell cycle proliferation, cellular 
senescence, DNA repair and signal transductions (Carrano et al., 1999; Sutterlüty et al., 1999; 
Frescas and Pagano, 2008; Lin et al., 2010). Moreover, Skp2 is also involved in regulating 
epigenetic events by targeting chromatin modifying enzymes in PC (Lu et al., 2015).  
Substantial evidence demonstrated that Skp2 plays a critical role in the tumourigenesis of various 
cancers including PC. Skp2 levels have been shown to be increased in PIN, suggesting induction 
of Skp2 is an early event in cellular transformation (Yang et al., 2002). Moreover, Skp2 is 
dramatically elevated in PC, where increased copy number of Skp2 gene has been reported in 
metastatic prostate tumours (Robbins et al., 2011). Importantly, Skp2 protein levels are inversely 
correlated with recurrence-free survival (Yang et al., 2002).  
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Despite the identification of many of the Skp2 substrates, there is emerging evidence of additional 
substrates. For example KMT5A has been suggested to be a target of Skp2 for ubiquitination and 
destruction by the proteasome (Yin et al., 2008). However, no direct evidence has been published 
to confirm this to date. Therefore, the role of Skp2 in regulating KMT5A is understudied and 
remains elusive. As such, the second aim of this chapter is to investigate the role of Skp2 in 
regulating KMT5A. 
4.2 Hypothesis 
Firstly, based on the fact that post-translational modifications of KMT5A are under cell cycle 
regulation, it is hypothesised that the underlying mechanism regulating KMT5A mono-
ubiquitination is cell cycle dependent.  
Secondly, due to the dominant existence of mono-ubiquitinated species of KMT5A in PC cell lines 
as shown in the previous chapter, it is hypothesised that mono-ubiquitinated KMT5A has an 
important role in the cell.  
Thirdly, Skp2 is a well-known cell cycle regulator, responsible for G1-S transition of the cell cycle 
through ubiquitination and degradation of the cell cycle inhibitor, p27 (Carrano et al., 1999; 
Sutterlüty et al., 1999). KMT5A has also been extensively shown to regulate cell cycle progression; 
whereby, it is degraded when cells are transitioning from G1 to S phase of the cell cycle. In this 
regard, it is predicted that Skp2 modulates KMT5A through ubiquitination.  
4.2.1 Aims 
 Investigate the cell cycle control of KMT5A mono-ubiquitination  
 Determine mono-ubiquitinated KMT5A cellular localisation 
 Determine the effect of mono-ubiquitinated KMT5A on the cell cycle  
 Establish the role of Skp2 in KMT5A ubiquitination 
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4.3 Results 
4.3.1 Investigating the cell cycle control of mono-ubiquitinated KMT5A 
Given that post-translational modifications of KMT5A are strongly modulated depending on 
the cell cycle stage, we sought to investigate whether the regulation of mono-ubiquitination 
itself is subjected to the same regulatory mechanism. For this purpose, exponentially growing 
LNCaP and LNCaP-AI cell lines were sorted according to their cell cycle phase using Hoechst 
staining as described in Chapter 2.11.1. LNCaP and LNCaP-AI cell lines were chosen as it was 
initially thought mono-ubiquitinated KMT5A could be differentially regulated between these 
two cell lines as a possible underlying mechanism for KMT5A’s opposing manner in regulating 
the AR.  
Asynchronous cells were sorted into the different cell cycle phases after placing tight gates for 
each phase to prevent as much contamination as possible by excluding the collection of cells in 
other phases of the cell cycle, shown in Figure 4.1A. The separation system of cells was 
validated using the mitotic marker, phosphorylated serine 10 on histone 3 (pS10-H3), which 
was shown to be significantly enriched in the G2/M sorted pool of the cells compared to the 
mixed population, as of expected (Figure 4.1B).  
Consistent with the reported KMT5A expression levels, unmodified KMT5A was expressed at 
very low levels in the G0/G1 population of cells, which was further reduced in the S phase; 
whereas, it was expressed at very high levels in the G2/M phase of the cell cycle (Figure 4.1B). 
Thus, unmodified KMT5A level was used as an internal control for the system as its levels 
reflected that of the published literature. Interestingly, mono-ubiquitinated KMT5A was found 
to be enriched in the S phase sorted population of cells for both LNCaP and LNCaP-AI (Figure 
4.1B).Although at first sight, mono-ubiquitinated KMT5A levels appeared to be similar across 
the different phases of the cell cycle, it became evident that despite the very low levels of 
unmodified KMT5A in S phase, mono-ubiquitinated KMT5A is expressed to a similar extent 
as in other phases of the cell cycle, in particular G2/M, where the unmodified KMT5A is at its 
highest level. It is therefore apparent that the ratio of modified : unmodified KMT5A varies 
dramatically between the different cell cycle phases with the highest ratio of mono-
ubiquitinated KMT5A : unmodified KMT5A being evident in S phase. This observation is in 
keeping with our hypothesis that mono-ubiquitination of KMT5A occurs in a cell cycle 
dependent manner. 
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Figure 4-1: Mono-ubiquitinated KMT5A is enriched in proliferating cells. Exponentially growing LNCaP and 
LNCaP-AI cell lines were stained with Hoechst at 20 µg/mL for 40 minutes at 37 oC in the dark. For each cell line, 
the asynchronous (Asynch) population was sorted into the different cell cycle phases using flow cytometry. (A)  
LNCaP (i) and LNCaP-AI (ii) were separated into G0/G1, S and G2/M. The histograms demonstrate the cell cycle 
distribution of cells and the vertical lines define the gates to isolate cells in the indicated phases of the cell cycle. 
Data was analysed using FlowJo software. (B) Western blot analysis was performed for each of the sub-populations 
after being re-suspended in SDS sample buffer for KMT5A, the mitotic marker, pS10-H3, and loading control α-
tubulin. This blot is a representative of three independent repeats.  
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4.3.2 The expression of mono-ubiquitinated KMT5A is cell cycle dependent 
Having demonstrated and validated a robust cell sorting system, we aimed to extend our data 
to assess the level of KMT5A mono-ubiquitination in cells transitioning from G1 to S, and then 
from S to G2 phases of the cell cycle. The experiment was performed as before but only in the 
LNCaP cell line, as no difference in KMT5A mono-ubiquitination was observed between the 
LNCaP and LNCaP-AI tested in Chapter 4.3.1, and might be the same in LNCaP-AI cells. 
Figure 4.2A demonstrates that the levels of unmodified KMT5A throughout the cell cycle 
confirms the data in the previous section and is in line with the literature, where KMT5A is 
expressed at low levels in G0/G1. Upon transition of cells from G1 to S phase (G1>S), 
unmodified KMT5A levels declined rapidly and is at its lowest level during S phase. However, 
as cells transitioned from S to G2 (S>G2), unmodified KMT5A expression significantly 
increased and reached its peak in mitosis. In a striking contrast, mono-ubiquitin conjugated 
KMT5A is at its highest level in S phase, despite the very small pool of unmodified KMT5A 
present, suggesting that mono-ubiquitinated KMT5A is the abundant form of total KMT5A in 
this phase of the cell cycle. On the other hand, mono-ubiquitinated KMT5A levels declined 
rapidly as cells exited the S phase and progressed into the G2/M phase of the cell cycle; 
whereby, mono-ubiquitinated KMT5A is at its lowest expression level despite the large pool of 
unmodified KMT5A.  
The unmodified and mono-ubiquitinated KMT5A bands on this Western blot were quantified 
using densitometry and data presented as a line graph, demonstrates the ratio of mono-
ubiquitinated KMT5A to its unmodified form for the corresponding cell cycle phases (Figure 
4.2B). Interestingly, it became evident that unmodified and mono-ubiquitinated KMT5A levels 
are inversely correlated in all the phases of cell cycle, with the highest ratio of mono-
ubiquitinated KMT5A to unmodified KMT5A in S phase (Figure 4.2C).  
Moreover, Skp2 expression was also investigated as a potential regulator of KMT5A. As 
already alluded to, KMT5A has been suggested to be regulated by Skp2, although there is a 
lack of detailed studies to confirm this. Skp2 expression was shown to be consistent with other 
studies, where, it is almost undetectable in G0/G1, suddenly increased as cells transitioned from 
G1 to S phase and rose even further during S phase. Its levels then appears to be maintained 
throughout the remaining phases (Figure 4.2B).  
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Figure 4-2: Mono-ubiquitinated KMT5A oscillation is cell cycle dependent. Exponentially growing LNCaP 
cells were stained with Hoechst at 20 µg/mL in the dark. Following 40 minutes incubation at 37 oC, the cells were 
sorted into the respective cell cycle phases using flow cytometry. (A) The retrieved cells were lysed with SDS 
sample buffer and subject to Western analysis for KMT5A, Skp2 and the loading control, α-tubulin. (B) 
Densitometry was used to quantify the unmodified and mono-ubiquitinated KMT5A bands, and the absolute values 
represented graphically. (C) The ratio of mono-ubiquitinated KMT5A to unmodified KMT5A using the raw 
densitometry data.  
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4.3.3 Mono-ubiquitinated KMT5A expression is associated with cellular confluency 
During the course of these experiments it was observed that the level of mono-ubiquitinated 
KMT5A was influenced with the confluency of cells for different experiments that were 
performed. As the relative proportion of mono-ubiquitinated KMT5A was found to be enriched 
in S phase where LNCaP cells are in a proliferative state, it suggested that KMT5A mono-
ubiquitination is affected by cellular confluency. Sub-confluent cells are actively dividing and 
colonising the available space and are thus in a more proliferative state. Conversely, growth 
slows and ceases when cells are over confluent, entering quiescence. Therefore, it was 
hypothesised that sub-confluent cells express higher levels of mono-ubiquitinated KMT5A.  
To test this hypothesis, LNCaP cells were seeded at different densities and grown for 48 hours 
in FM, after which three different confluences were chosen (30%, 50% and 80-90%) as seen in 
Figure 4-3A. Western blot analysis revealed that sub-confluent cells at 30% and 50%, which 
are rapidly dividing as confirmed by the expression level of mitotic marker pS10-H3, exhibited 
higher levels of KMT5A mono-ubiquitination. However, upon becoming highly confluent at 
80-90%, the level of mono-ubiquitined KMT5A modestly declined, Figure 4-3B.  
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Figure 4-3: Mono-ubiquitination of KMT5A is elevated in dividing cells. LNCaP cells were seeded at different 
cellular densities and left to grow for 48 hours in FM. (A) The cells were assessed for their confluency using 
microscopy and images were taken for the following confluencies, 30, 50 and 80-90%. (B) The indicated cell 
confluencies were collected for Western blotting for KMT5A, mitotic marker pS10-H3 and the loading control, α-
tubulin. This is a representative blot of two independent repeats. 
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4.3.4 Mono-ubiquitinated KMT5A is cytoplasmic  
Mono-ubiquitination regulates the cellular localisation of proteins (Grompe and D'Andrea, 
2001; Li et al., 2003; van der Horst et al., 2006). Many groups have demonstrated KMT5A to 
be mainly in the nucleus due to its role in maintaining genome integrity and chromatin structure. 
KMT5A mobilisation between cellular compartments has only been reported by Yin et al 
(2008) who showed KMT5A distribution varies greatly between cells, and is cell cycle 
dependent. In order to addressed the localization of mono-ubiquitinated KMT5A, cellular 
fractionation was carried out on LNCaP cells which were grown in FM, followed by Western 
blot analysis.  
The efficiency of the cellular fractionation was visualised using the nuclear protein PARP and 
the cytoplasmic protein α-tubulin and confirmed there was relatively little contamination 
between the nuclear and cytoplasmic samples (Figure 4.4A). Unmodified KMT5A was present 
in equal quantities in the chromatin fraction, nucleus and the cytoplasm, whereas mono-
ubiquitinated KMT5A was found exclusively in the cytoplasm (Figure 4.4A). This observation 
suggested that mono-ubiquitination of KMT5A could either result in its nuclear export or 
restrict its entry into the nucleus. 
To further elucidate that mono-ubiquitin conjugation is responsible for the cytoplasmic 
localisation of mono-ubiquitinated form of KMT5A, cellular fractionation was performed using 
the mono-ubiquitin competent KMT5A truncated fragments N-C2 and N-C3 that were 
overexpressed in COS7 cells. As expected, KMT5A fragment N-C3 which undergoes mono-
ubiquitin conjugation, showed mono-ubiquitinated KMT5A is located almost exclusively in the 
cytoplasm, although small amounts could be observed in the nucleus following longer 
exposures (Figure 4.4B). Furthermore, unmodified KMT5A was present in both the nucleus 
and cytoplasm in an approximate 50/50 ratio, as seen with endogenous unmodified KMT5A’s 
distribution in the LNCaP cells (Figure 4.4A) In contrast, KMT5A fragment N-C2 which is not 
modified by mono-ubiquitination, only expressed the unmodified form of KMT5A, which 
exhibited the same distribution pattern as unmodified KMT5A fragment N-C3 and endogenous 
KMT5A (Figure 4.4A and B). It is important to note, that the higher molecular weight bands 
present on the Western blot for KMT5A N-C2, do not correspond to any mono-ubiquitinated 
form as they have  too high a molecular weight to be a mono-ubiquitin conjugated N-C2 
product, and are therefore non-specific binding. Collectively, the data suggests mono-ubiquitin 
conjugation is responsible for mono-ubiquitinated KMT5A cytoplasmic accumulation.
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Figure 4-4: Mono-ubiquitinated KMT5A is exclusively localised in the cytoplasm. (A) LNCaP cells were 
subjected to cellular fractionation, followed by Western blot analysis for endogenous KMT5A, cytoplasmic marker 
α-tubulin and nuclear marker PARP. (B) COS7 cells overexpressing the mono-ubiquitin deficient (fragment N-
C2) and mono-ubiquitin competent (fragment N-C3) KMT5A constructs were subject to cellular fractionation, 
followed by Western blot analysis for KMT5A, cytoplasmic marker α-tubulin and nuclear marker PARP. Asterisk 
indicates non-specific binding. 
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4.3.5 Investigating the role of KMT5A mono-ubiquitination on the cell cycle 
KMT5A plays a crucial role in cell cycle progression, where KMT5A knockdown and over-
expression studies demonstrate mild to dramatic cell cycle disturbances depending on the 
experimental conditions (Abbas et al., 2010; Centore et al., 2010). The enzymatic activity of 
KMT5A has been reported to be a negative regulator of DNA replication and cellular proliferation, 
hence the degradation of KMT5A in S phase (Centore et al., 2010). However, an opposite role for 
mono-ubiquitinated KMT5A is suggested by its accumulation in proliferative cells. Importantly 
though, despite the accumulation of mono-ubiquitinated KMT5A in S phase, it was then found to 
be exclusively residing in the cytoplasm, suggesting indeed that KMT5A is incompatible with 
DNA replication. Therefore, the biological relevance of oscillating mono-ubiquitinated KMT5A 
expression during the cell cycle was investigated.  
To this end, COS7 cells were transfected with mono-ubiquitin deficient (fragments N-C1 and N-
C2) and mono-ubiquitin-competent (fragment N-C3) KMT5A fragments. Following 48 hours post-
transfection, PI based flow cytometry was performed to determine any cell cycle profile changes. 
However, analysis of the data did not show any alterations in the cell cycle profile of cells 
overexpressing the mutant forms of KMT5A compared to non-transfected COS7 cells (Figure 4.5). 
As in some studies, KMT5A overexpression-mediated changes have been observed with longer 
expression time points as compared to 48 hours used in our experiment, it was considered such 
changes on the cycle and proliferation require longer KMT5A overexpression. Due to time 
constraints, this experiment was performed only once, but if it was to be repeated, constructs should 
be overexpressed for longer time points and also include the full-length, wild-type KMT5A as a 
positive control. Furthermore, as the transient transfection efficiency in COS7 cells is expected to 
be around 50-70% it would be important to separate only those cells expressing the constructs for 
further analysis. This could be achieved by co-transfecting an identifiable marker-containing 
plasmid, such as GFP and sorting cells by flow cytometry prior to Western blotting.  
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Figure 4-5: Transient overexpression of KMT5A truncated mono-ubiquitin deficient and competent truncated 
derivatives of KMT5A does not affect the cell cycle. COS7 cells were transfected with KMT5A mono-ubiquitin 
deficient (fragments N-C1 and N-C2) and mono-ubiquitin competent (fragment N-C3) constructs. Non-transfected 
COS7 cells were only treated with the LT-1 cocktail without any plasmid. Following 48 hours incubation in FM, the 
cells were subjected to cell cycle analysis subsequent to flow cytometry using propidium iodide. Data was analysed 
using Cyflogic software for 10,000 cells. This experiment was conducted once.  
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4.3.6 Alteration in KMT5A mono-ubiquitination affects cell proliferation 
In order to elucidate the role of KMT5A mono-ubiquitination on cell cycle progression, cell 
proliferation rates were examined.  COS7 cells were transfected with full-length wild-type KMT5A 
and its truncation mutants, fragments N-C2 and N-C3, in a 6-well plate for 48 hours. Then the cells 
were trypsinised and seeded out in a 96-well plate and left to grow for six days in the IncuCyte 
system (Essen Bioscience), measuring dynamic alterations in cellular confluence over this time 
period. This approach was conducted to firstly, enable efficient transfection of the constructs and 
secondly, allow sufficient time for KMT5A overexpression-mediated effects to take place. As 
mono-ubiquitinated KMT5A was found to be at its highest level in proliferating cells despite the 
very low levels of unmodified KMT5A, as well as the data strongly supporting mono-
ubiquitination being responsible for the cytoplasmic localisation of mono-ubiquitinated KMT5A, 
it was predicted that mono-ubiquitin deficient KMT5A fragment N-C2 would reduce proliferation 
rate compared to wild-type KMT5A. This was suggested because N-C2 cannot undergo mono-
ubiquitination or at least efficient mono-ubiquitination for it to be excluded from the nucleus. 
However, mono-ubiquitin competent KMT5A fragment N-C3, which is modified by mono-
ubiquitination is able to localise to the cytoplasm and should therefore not have a significant effect 
on proliferation compared to wild-type KMT5A. 
Interestingly, the overexpression of KMT5A N-C2 caused a reduction in cell proliferation 
compared to wild-type KMT5A. Conversely, KMT5A N-C3 overexpression increased 
proliferation in comparison to wild-type KMT5A (Figure 4.6). Although it is promising that this 
observation supports the hypothesis and is consistent with previously published data with regards 
to the negative role of KMT5A on cell proliferation, further experimental optimisation is required. 
For example, cell density should be optimized to ensure sufficient cells are seeded to enable them 
to reach the logarithmic phase of cell growth earlier than the 3 days achieved in this initial 
experiment. Such a delay may affect transfected KMT5A expression levels and any effects that 
KMT5A may have had on the rate of proliferation. 
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Figure 4-6: The ubiquitination status of KMT5A affects cellular proliferation. COS7 cells were transfected with 
wild-type KMT5A and its truncated mutants in a 6-well plate. 48 hours post-transfection, the cells were trypsinised, 
seeded in a 96-well plate and left to grow for 6 days in the IncuCyte system (Essen Bioscience), analysing the cellular 
confluency of wells every 4 hours. This experiment was performed once.  
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4.3.7 Skp2 is associated with KMT5A mono-ubiquitination 
Skp2 plays an important role in cell cycle progression where it is responsible for driving G1 to S 
phase transition via ubiquitination of the cell cycle inhibitor, p27, to result in its subsequent 
proteasomal destruction. Skp2 has been suggested to play a secondary role to the CRLCdt2 complex 
in KMT5A ubiquitination and proteasomal mediated degradation (Centore et al., 2010); however, 
there is insufficient evidence to confirm this to date. Moreover, KMT5A is mainly ubiquitinated at 
the G1-S transition (Yin et al., 2008; Centore et al., 2010), and unmodified KMT5A levels declined 
rapidly at this stage of the cell cycle whilst Skp2 expression was found to be significantly 
upregulated (Figure 4.2A). Therefore, the role of Skp2 in regulating KMT5A was investigated.   
In order to determine the role of Skp2 in regulating KMT5A, a constant amount of KMT5A was 
co-expressed with increasing amounts of Skp2 in COS7 cells, as increasing the levels of Skp2 is 
expected to result in increased levels of KMT5A destruction via higher level of ubiquitination. The 
whole cell lysates were collected for Western blot analysis. Interestingly, mono-ubiquitinated 
KMT5A was found to be significantly upregulated with higher concentrations of Skp2 at 1 µg and 
2 µg (Figure 4-7, lanes 5 and 6), with lower concentrations of 0.1, 0.2 and 0.5 µg causing a clear 
but modest increase (Figure 4-7, lanes 2-4). In contrast, poly-ubiquitination of KMT5A was not 
affected at these lower Skp2 concentrations, and was only markedly upregulated at higher 
concentrations of Skp2. However, it would have been prudent to include an MG132 treatment arm 
to determine the poly-ubiquitination pattern of KMT5A.  
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Figure 4-7: Mono-ubiquitination of KMT5A is promoted with increasing amounts of Skp2. COS7 cells were co-
transfected with a constant amount of KMT5A plasmid and an increasing amount of Skp2 plasmid (0.1, 0.2, 0.5, 1 and 
2 µg). All the reactions were balanced with appropriate empty vector. Western blot analysis of the cell lysates was 
carried out 48 hours post-transfection for KMT5A, Skp2 and the loading control, α-tubulin. 
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4.3.8 KMT5A and Skp2 proteins interact 
Skp2 is a crucial component of the SCFSkp2 E3 ubiquitin ligase complex. As well as providing 
specificity, Skp2 is responsible for recruiting the substrates to the complex to allow ubiquitin 
transfer from the ubiquitin activated E2 enzyme. As Skp2 was found to cause an increase in 
KMT5A mono-ubiquitination (Figure 4-7) it indicated that these two proteins may come into direct 
contact with each other. To address this theory, HEK293T cells were transfected with equal 
amounts of Myc-KMT5A and Skp2, and anti-Skp2 antibody mediated immunoprecipitation was 
performed according to Chapter 2.9.1 to determine whether KMT5A protein could be co-
precipitated. 
KMT5A was detected by Western blotting following Skp2 pull down compared to control lanes, 
IgG and the antibody control only (Figure 4.8A). To further confirm this interaction, a reciprocal 
immunoprecipitation was performed with anti-Myc antibody mediated immunoprecipitation of 
KMT5A. Similarly, Skp2 was determined to interact with KMT5A (Figure 4.8B). Therefore, Skp2 
and KMT5A interact supporting the theory that Skp2 has the potential to post-translationally 
modify KMT5A. 
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Figure 4-8: KMT5A and Skp2 are found in a complex. HEK293T cells were transfected with equal amounts of 
Myc-KMT5A and Skp2 for 48 hours. Cells were lysed in non-denaturing conditions and pre-cleared with excess 
protein G sepharose (PGS) for 4 hours to remove proteins that bind PGS non-specifically. (A) Skp2 or (B) KMT5A 
(Myc) was immunoprecipitated overnight with 2 µg of the appropriate antibody and negative control IgG. The 
following day, antibody bound complexes were isolated after incubation with PGS for 1 hour. Western blot analysis 
was then conducted.  
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4.3.9 Skp2 enhances KMT5A mono-ubiquitination 
As an interaction between Skp2 and KMT5A has been confirmed (Figure 4.8), the ability of Skp2 
to promote mono-ubiquitin conjugation of KMT5A was tested by performing in vivo ubiquitination 
assays using Ni-NTA beads in COS7 cells, under denaturing conditions. As maximal KMT5A 
mono-ubiquitination and poly-ubiquitination was observed with 1 µg of Skp2 (Chapter 4.3.7), this 
amount was used in these ubiquitination assays. COS7 cells overexpressing His-Ub, Flag-KMT5A 
and Flag-Skp2 were subjected to denaturing polyhistidine pull down (Chapter 2.9.2) followed by 
Western blot analysis.  
Figure 4.9 demonstrates that the addition of Skp2 alone significantly increased KMT5A mono-
ubiquitination and leads to KMT5A stabilisation, as seen by the stronger smearing pattern (lane 6 
versus 4). As MG132 inhibits the proteasome, thereby preventing degradation of proteins, Skp2-
mediated ubiquitinated KMT5A was expected to be stabilised following MG132 treatment. 
Unexpectedly, combining Skp2 overexpression with MG132 treatment did not cause any further 
stabilisation of KMT5A (lanes 6 and 7). This observation suggests that ubiquitinated products of 
KMT5A generated by Skp2 are not targeted for proteasomal degradation. 
Interestingly, treatment with MG132 in the absence of Skp2 was sufficient to inhibit KMT5A 
degradation. However, MG132-mediated stabilisation of KMT5A occurred to a greater extent and 
also affected heavier multi-ubiquitinated KMT5A products than Skp2 overexpression alone (lane 
6 versus 5), indicating Skp2 is mainly involved in promoting KMT5A mono-ubiquitination. 
Interestingly, the presence of Skp2 prevented the stabilisation effect of MG132 on KMT5A, as 
heavier poly-ubiquitinated forms of KMT5A are present at a lower level with combined Skp2 
overexpression and MG132 treatment than MG132 treatment alone (lane 7 versus 5). Overall, the 
data suggests that Skp2 mainly mediates mono-ubiquitination of KMT5A rather than poly-
ubiquitination.  
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Figure 4-9: Skp2-mediated ubiquitination of KMT5A does not result in protein turnover. COS7 cells were 
transfected with the indicated constructs for 48 hours. All reactions were balanced with the appropriate empty vector. 
MG132 at 20 µM was added were indicated in the final 16 hours. In vivo ubiquitination assays were then performed 
under denaturing conditions using Ni-NTA beads to immunoprecipitate ubiquitinated proteins. Western blotting was 
carried out on input and immunoprecipitated samples for KMT5A, Skp2 and α-tubulin as the loading control.  
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4.3.10 Skp2 does not mediate the mono-ubiquitination of KMT5A C-terminus  
Having provided evidence that Skp2 significantly elevates mono-ubiquitination of full length 
KMT5A (Figure 4.9), and that the site(s) of mono-ubiquitination is located in KMT5A C-domain 
(Figure 3.7), the ability of Skp2 to mono-ubiquitinate KMT5A C-terminus was tested. For this 
purpose, a constant amount of KMT5A C-terminus and His-Ub constructs were co-expressed with 
an increasing amount of either WT-Skp2 or a catalytically-dead truncated form of Skp2 obtained 
from Dr Lin (The University of Texas) (Xu et al., 2015). After 48 hours of transfection, cell lysates 
were collected for Western blot analysis.  
The addition of Ub leads to increased mono-ubiquitination of KMT5A C-terminus (Figure 4-10A, 
lane 3 versus 2), similar to full length KMT5A observations (Figure 4-9). However, co-expression 
of WT-Skp2 at lower concentrations did not further affect C-terminus mono-ubiquitination, 
whereas at higher concentrations Skp2 caused a clear reduction of this modification (Figure 4-10A, 
lanes 4 – 6), in contrast to full length KMT5A findings. The decrease in mono-ubiquitination of C-
terminus however could be due to the reduced total KMT5A C-terminus levels, suggesting Skp2 
is causing its degradation at higher concentrations. A truncated form of Skp2 that is missing its C-
terminal leucine-rich domain (LRR-Skp2) was also utilised in this experiment as a negative control. 
Skp2 binds to its protein substrates through its LRR domain and recruits them to the SCF complex 
(Zhang et al., 1995; Sutterlüty et al., 1999). As KMT5A was found to be in complex with Skp2, 
the LRR-Skp2 protein should not be able to interact with KMT5A and therefore, compromise Skp2 
function in ubiquitinating KMT5A; hence, it is called the E3 ligase-dead Skp2 form by Dr Lin and 
also in this work. However, catalytically-dead mutant Skp2 (LRR-Skp2) showed a strong ability 
in enhancing mono-ubiquitination of KMT5A C-terminus (Figure 4-10A, lanes 7-9) which was not 
expected as it should not be able to bind KMT5A to mediate its ubiquitination. Although similarly 
to the WT-Skp2, increased expression of catalytically-dead Skp2 construct also reduced the level 
of KMT5A C-terminal mono-ubiquitination. 
Given the reduction in total KMT5A C-terminus level upon co-expression of WT-Skp2, we wanted 
to determine if WT-Skp2 caused C-terminal domain proteolysis. To this end, COS7 cells were 
transfected with a constant amount of KMT5A C-terminus and His-Ub, and increasing amounts of 
WT-Skp2 either in the absence or presence of MG132. As in part A, addition of Ub led to an 
upregulation of mono-ubiquitinated KMT5A C-terminus (Figure 4-10B, lane 3 versus 2), with 
Skp2 not influencing the level of mono-ubiquitination (Figure 4-10B, lanes 4-6 versus 3). Co-
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treatment with MG132 in the presence of Skp2 expression did not cause any stabilisation of 
KMT5A C-terminus, suggesting it is not degraded by Skp2. 
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Figure 4-10: Skp2 does not promote KMT5A C-terminus mono-ubiquitination. (A) COS7 cells were transfected 
with a constant amount of KMT5A C-terminus and His-Ub with increasing amount of either wild-type Skp2 (WT-
Skp2) or ligase-dead Skp2 (LRR-Skp2). After 48 hours incubation, cell lysates were generated using SDS sample 
buffer and subjected to Western blot analysis for KMT5A and Skp2. (B) KMT5A C-terminus was co-expressed with 
an increasing amount of WT-Skp2 in COS7 cells. MG132 was added in the final 16 hours of the 48 hour incubation 
period, where indicated. The cells were lysed using SDS sample buffer and analysed by Western blotting. All reactions 
were balanced using appropriate empty vector.  
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4.3.11 Investigating the role of the SCF complex in Skp2-mediated mono-ubiquitination of full 
length KMT5A 
Skp2 is the F-box component of the SCF ubiquitin E3 ligase complex, which works in complex 
with the other SCF components, S-Phase Kinase-Associated Protein 1 (Skp1), Cullin 1 (Cul1), and 
a Ring-Box 1 (Rbx1/Roc1). As already mentioned, the F-box protein, Skp2, determines the 
specificity of the complex as it recognises and targets specific substrates to the SCF complex for 
ubiquitination and proteasomal-mediated degradation. Skp2 was found to mainly mediate KMT5A 
mono-ubiquitination in preference to poly-ubiquitination, which did not cause protein turnover 
(Figure 4-9). Hence, to ensure that the inability of Skp2 to cause turnover was because the other 
components of the SCF complex were not over-expressed alongside Skp2, it is important to address 
the SCF components relating to Skp2 function. 
As such, an in vivo ubiquitination assay using Ni-NTA beads under denaturing conditions (Chapter 
2.9.2) was performed, in COS7 cells to determine KMT5A ubiquitination in the absence and 
presence of exogenous SCF complex by over-expressing all the components of the complex at the 
same ratio. Western blot analysis of the input samples indicated that addition of WT-Skp2 alone 
and in combination with its SCF complex elevates KMT5A mono-ubiquitination (Figure 4.11, 
lanes 3 and 5 versus 2). However, analysis of the immunoprecipitated ubiquitinated proteins 
revealed that firstly, Skp2 overexpression alone leads to an increase in the mono-ubiquitination and 
poly-ubiquitination of KMT5A compared to its basal levels (Figure 4.11, lanes 2 versus 3), as also 
observed previously. Secondly however, the level of KMT5A mono-ubiquitination was not 
noticeably altered when the SCF components were expressed in combination with WT-Skp2, as 
compared to Ub overexpression alone (Figure 4.11, lane 5 versus 2). Furthermore, reconstituting 
the SCF complex actually attenuated Skp2-mediated KMT5A mono-ubiquitination in comparison 
to WT-Skp2 overexpression alone (Figure 4.11, lane 5 versus 3), bringing the mono-ubiquitination 
and also poly-ubiquitination down to basal levels, which might suggest the intact exogenous SCF 
complex is promoting KMT5A poly-ubiquitination for degradation.  
As also seen previously, the catalytically-dead truncated Skp2 (LRR-Skp2) caused a greater mono-
ubiquitination of KMT5A than WT-Skp2 in the absence of the SCF components (Figure 4.11, lane 
4 versus 3), which was not expected.  Moreover, both the WT-Skp2 and LRR-Skp2 were heavily 
ubiquitinated when over-expressed without the SCF components (Figure 4.11, lanes 3 and 4). On 
the other hand, LRR-Skp2 no longer caused an upregulation in KMT5A mono-ubiquitination upon 
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co-expression with all the SCF components (Figure 4.11, lane 6 versus 4), and did not change the 
level of mono-ubiquitination of KMT5A relative to the basal level in the absence of SCF 
components (Figure 4.11, lane 6 versus 2). It is important to note, that co-expression of the SCF 
components significantly suppressed the ubiquitination of both WT-Skp2 and LRR-Skp2. 
There are obvious limitations with this particular experiment in that unmodified KMT5A has been 
immunoprecipitated when only the ubiquitinated proteins modified by exogenous His-Ub were the 
target of Ni-NTA beads pull down.  This could be due to a technical error in this experiment or the 
unmodified KMT5A sticking directly to Ni-NTA beads. Moreover, as the stoichiometry of the SCF 
complex and any possible interaction is unknown, comprehensive optimisation experiments with 
varying amounts of the complex components should be carried out to obtain conditions where the 
SCF complex performs at its maximal activity.  
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Figure 4-11: The role of the SCF complex in Skp2-mediated mono-ubiquitination of full length KMT5A. COS7 
cells were transfected with the indicated plasmids for 48 hours. All reactions were balanced with the appropriate empty 
vector. Denaturing in vivo ubiquitination assay with Ni-NTA beads was then performed, followed by Western blot 
analysis for KMT5A and Skp2.  
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4.3.12 Investigating the role of the SCF complex in Skp2-mediated KMT5A C-terminus mono-
ubiquitination 
As Skp2 alone promotes the mono-ubiquitin conjugation of full length KMT5A, but not the C-
terminal fragment, it was questioned whether the presence of the SCF components could facilitate 
Skp2-mediated mono-ubiquitination of KMT5A C-terminus. Again, in vivo ubiquitination assay 
using Ni-NTA beads under denaturing conditions was employed in COS7 cells overexpressing the 
indicated constructs, and KMT5A C-terminus mono-ubiquitination was assessed with Skp2 alone 
or in combination with its SCF complex. 
Firstly, KMT5A C-terminus ubiquitination pattern observed in Figure 4.12A, lane 2 is similar to 
the full length KMT5A (Figure 4.9), with distinct bands forming which correspond to mono-, di-, 
tri and poly-ubiquitinated forms of KMT5A C-terminus (Figure 4.12A). Secondly, similar to the 
whole cell lysate observations in Chapter 4.2.10, co-expression of WT-Skp2 did not cause an 
obvious change in mono-ubiquitinated KMT5A C-terminus (Figure 4.12A, lane 3 versus 2). 
Thirdly, upon co-expression of the SCF components with WT-Skp2 a clear suppression of C-
terminus mono-ubiquitination and poly-ubiquitination was observed (Figure 4.12A, lane 4 versus 
3), with its levels becoming even lower than basal mono-ubiquitinated levels (Figure 4.12A, lane 
4 versus 2) and of mutant Skp2-mediated mono-ubiquitination (Figure 4.12A, lane 5 versus 4) 
which was unexpected. This may suggest the ubiquitinated KMT5A C-terminus products are being 
targeted for degradation by the proteasome. Finally, the catalytically dead mutant Skp2 (LRR-
Skp2) did not alter basal mono-ubiquitination levels of the KMT5A C-terminus (Figure 4.12A, 
lane 5 versus 2).  
As the expression of WT-Skp2 when combined with the SCF components led to a significant 
reduction in C-terminus mono-ubiquitination and poly-ubiquitination, it was considered it may be 
due to disturbing the stoichiometry of the complex. As optimising the concentration of each of the 
SCF components is a comprehensive task and not the aim of this project, different SCF components 
were overexpressed at the same concentration whilst increasing the concentration of WT-Skp2 in 
the ubiquitination assay. Similar to data shown in Chapter 4.2.10, Ub expression caused the 
formation of mono-ubiquitinated C-terminus (Figure 4.12B). Interestingly, the basal mono-
ubiquitination level of the C-domain was modestly decreased in the presence of the SCF complex 
when no Skp2 was overexpressed (Figure 4.12B, lane 3 versus 2). Upon reintroducing Skp2 at 
lower concentrations, mono-ubiquitination was increased back to basal levels (Figure 4.12B, lanes 
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4 and 5 versus 2).  However, higher concentrations of Skp2 caused a clear reduction in C-terminus 
KMT5A mono-ubiquitination (Figure 4.12B, lanes 7-8 versus 4-5). 
There are again similar problems with this particular repeat, as also observed in Chapter 4.2.11, in 
that unmodified KMT5A C-terminus is immunoprecipitated, despite the Ni-NTA beads only 
targeting ubiquitinated proteins which have undergone modification by the His-Ub.  
Overall, elucidating the role of the SCF complex in Skp2-mediated mono-ubiquitination of full 
length KMT5A and its C-terminus proved difficult as there were discrepancies in the level of 
KMT5A mono-ubiquitination and poly-ubiquitination between experiments. Unfortunately, no 
firm conclusions could be drawn from some of the in vivo polyhistidine pull down ubiquitination 
assays for various reasons, including for example the immunoprecipitation of the unmodified form 
of KMT5A. Moreover, there was a large amount of cell death observed following the transfection 
of cells with a large amount of plasmid DNA required to accommodate the overexpression of all 
the SCF components. 
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Figure 4-12: The role of the SCF complex in Skp2-mediated mono-ubiquitination of KMT5A C-terminus. (A 
and B) Denaturing in vivo ubiquitination assays using Ni-NTA beads performed in COS7 cells transfected with the 
indicated plasmids. (L.E.) and (S.E.) denotes long and short exposure, respectively. 
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4.4 Discussion  
Cell cycle regulation of KMT5A mono-ubiquitination  
KMT5A plays a critical role in maintaining genome integrity and ensuring cell cycle progression. 
As such, its activity is under tight cellular control, mainly through regulation of its expression level 
during the cell cycle by post-translational modifications. This has mainly been shown to be via the 
poly-ubiquitination of KMT5A by the SCFβ-TRCP, CRL4Cdt2 and APCCdh1 complexes in G1, S and 
late mitosis phases of the cell cycle, respectively (Centore et al., 2010; Oda et al., 2010; Wu et al., 
2010; Wang et al., 2015). Published work to date has concentrated on determining KMT5A activity 
in its unmodified form which is shown to be incompatible with DNA replication. This study has 
demonstrated that mono-ubiquitinated KMT5A is a dominant form of post-translationally modified 
KMT5A in the cell lines that were tested, yet nothing is known about its function and underlying 
mechanism(s) of action. The initial aims of this chapter were therefore to determine whether 
KMT5A mono-ubiquitination, similar to its poly-ubiquitination, is under the control of cell cycle 
regulation, and to establish the role mono-ubiquitinated KMT5A may have on cell cycle 
progression.  
Work by several groups has shown KMT5A protein level varies greatly throughout the cell cycle. 
Specifically, it is transiently expressed at its highest levels during early mitosis, reduces as cells 
exit mitosis and enter G1, declines rapidly as cells transition from G1 to S phase and is further 
suppressed to undetectable levels during the S phase (Figure 1.6). Reassuringly, similar 
observations were seen in prostate cancer cell lines that were used in this study (Figure 4.2A). 
Furthermore, upon investigation of mono-ubiquitinated KMT5A a striking contrast to its 
unmodified levels was observed. Mono-ubiquitinated KMT5A levels were found to peak during S 
phase of the cell cycle. Conversely, as cells exit the S phase to transition into G2 phase and further 
progress into the G2/M phase, mono-ubiquitinated KMT5A declined sharply, despite high levels 
of unmodified KMT5A (Figure 4.2A). Therefore mono-ubiquitinated KMT5A protein levels 
exhibit a cell cycle-dependent oscillation which is inversely correlated with the unmodified 
KMT5A fluctuations during the cell cycle.   
Importantly, the significant rise in KMT5A mono-ubiquitination in S phase is concomitant with 
DNA synthesis and corresponds to a highly proliferative state. This was further confirmed by 
demonstrating mono-ubiquitinated KMT5A is most abundant in actively dividing, low confluency 
cells as compared to the less proliferative, high confluency cells (Figure 4.3). This suggested that 
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mono-ubiquitination of KMT5A is promoted during cell proliferation. Interestingly, this 
observation is in contrast to the suppressive role of unmodified KMT5A on DNA replication and 
cell growth, hence KMT5A poly-ubiquitination and degradation in S phase and mitosis. 
To assess the biological significance of mono-ubiquitinated KMT5A, mono-ubiquitin deficient and 
competent KMT5A truncated fragments N-C1 and N-C2 which were generated in Chapter 3.4.12, 
were utilised to determine any cell cycle changes due to the presence of mono-ubiquitinated 
KMT5A. However, overexpression of these constructs did not influence the cell cycle profile of 
COS7 cells compared to non-transfected cells (Figure 4.5). There are different reports on the effect 
of KMT5A overexpression on the cell cycle, all of which show cell cycle defects, though to varying 
degrees depending on the level of KMT5A expression. For instance, similar to the data here, Abbas 
et al (Abbas et al., 2010) showed that whilst wild-type KMT5A transduction did not influence cell 
proliferation, KMT5A PIP mutant that is a stable form of KMT5A which is resistant to the 
CRL4Cdt2-mediated proteolysis, inhibited cell proliferation after cells underwent two rounds of cell 
division. Furthermore, the KMT5A PIP mutant caused re-replication, induced apoptosis and 
arrested cells at the G2/M phase of the cell cycle, all of which was dependent on KMT5A enzymatic 
activity (Abbas et al., 2010). Moreover, Centore et al (Centore et al., 2010) showed DNA synthesis 
was reduced, cell proliferation decreased gradually, and the ATR checkpoint response was 
activated upon constitutive expression of wild-type KMT5A. However, the overexpressed wild-
type KMT5A was rapidly degraded in this study. Again this was addressed by using the stable 
KMT5A PIP mutant which caused dramatic effects including a significant loss in replicating cells, 
proliferation and induction of a prominent G2 arrest, which were dependent on the catalytic activity 
of KMT5A (Centore et al., 2010). Therefore, the rapid degradation of exogenous wild-type 
KMT5A has hindered research into this area. This could also be one of the underlying reasons for 
the lack of any apparent alteration in the cell cycle following overexpression of our KMT5A 
mutants in COS7 cells, however the percentage transfection efficiency under these conditions also 
needs to be considered. Although we expected the mono-ubiquitin deficient form of KMT5A 
(fragment N-C2) to be stable compared to its mono-ubiquitin competent form (fragment N-C3), as 
it does not undergo mono-ubiquitination and therefore should not be subject to poly-ubiquitination. 
Nonetheless, as already mentioned, complete lack of ubiquitination of KMT5A fragment N-C2 is 
not likely, as there are other lysines available which can potentially be modified by ubiquitin 
conjugation; hence, leading to poly-ubiquitination and degradation. Moreover, all the KMT5A C-
truncated fragments contain the PIP degron that is required for ubiquitination and degradation by 
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the CRL4Cdt2 complex, and can therefore be subject to this mode of destruction. Therefore, 
investigating the stability of the KMT5A fragments is required. 
As already alluded to, all studies to date have shown KMT5A’s effect on the cell cycle is dependent 
on its enzymatic activity (Jørgensen et al., 2007; Abbas et al., 2010; Centore et al., 2010; Jørgensen 
et al., 2011). As we have truncated KMT5A from the C-terminal end the region comprising the 
SET domain responsible for KMT5A catalytic activity has been partially deleted. Moreover, the 
two critical residues for enzymatic activity, Arg 336 and Asp 379, are missing in these KMT5A 
fragments. Mutation of these two residues and inactivation of KMT5A’s enzymatic activity has 
been demonstrated to alleviate the inhibitory effects of the stable KMT5A PIP mutant on cell 
proliferation (Abbas et al., 2010). The KMT5A truncated fragments generated therefore lack the 
essential enzymatic activity required for normal proliferation which could account for their lack of 
impact on the cell cycle observed in this Chapter (Figure 4.5). However, despite all these 
possibilities, mono-ubiquitinated KMT5A was shown to be exclusively located in the cytoplasm 
(Figure 4.4). As a result, any potential direct effect mono-ubiquitinated KMT5A may have is not 
expected to be due to its enzymatic activity on nuclear H4K20, which is the substrate through 
which KMT5A is shown to affect the cell cycle. 
Moreover, cells were shown to require two rounds of the cell cycle to be completed for KMT5A 
overexpression-mediated effects to take place. Therefore cell proliferation with COS7 cells 
overexpressing the KMT5A mutants was assessed using the IncuCyte system. Interestingly, mono-
ubiquitinated KMT5A fragment N-C3 overexpression led to enhanced cell proliferation compared 
to wild-type KMT5A; whilst, mono-ubiquitin-deficient KMT5A fragment N-C2 led to a reduction 
in proliferation (Figure 4.6), suggesting mono-ubiquitination of KMT5A positively regulates cell 
proliferation. Although this approach allowed prolonged KMT5A overexpression to take effect on 
cell proliferation, the KMT5A constructs overexpressed could have been substantially degraded 
before cells reached their exponential growth due to the small numbers seeded in this experiment, 
and may have undermined the data.  
Additionally, the truncated KMT5A fragments may lack other critical residues or motifs that 
contribute to KMT5A function. In order to more accurately elucidate the effect of mono-
ubiquitinated KMT5A on cellular proliferation and its consequences in a more physiological 
setting, it would be desirable to perform these experiments in PC cell lines using full-length 
KMT5A mutant constructs. A commonly used technique in generating a mono-ubiquitinated 
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protein mimetic could be utilised, where a direct, in-frame fusion of an ubiquitin sequence with the 
N-terminus (Haglund et al., 2003; van der Horst et al., 2006) or C-terminus (Terrell et al., 1998; 
Li et al., 2003) of wild-type protein results in a constitutive mono-ubiquitinated form of the protein 
being expressed. In order to further stabilise mono-ubiquitinated KMT5A, further mutation to 
remove or inactivate the PIP degron responsible for KMT5A destruction by the CRL4Cdt2 complex 
could be conducted to prevent the rapid degradation, as reported. Stably expressing PC cell lines 
with the resultant construct could then be utilised as a more appropriate physiological model. 
The association of the inhibitory effect of KMT5A’s enzymatic activity on DNA replication and 
proliferation is consistent with KMT5A nuclear-cytoplasmic shuttling during the cell cycle. Post-
translational modifications have been shown to regulate KMT5A localisation in addition to its 
stability and activity. Wu et al (Wu et al., 2010) demonstrated phosphorylation of KMT5A at serine 
100 causes chromatin disassociation, preventing it from mono-methylating H4K20. Moreover, Yin 
et al (Yin et al., 2008) showed dramatic changes in KMT5A distribution during the cell cycle, 
whereby the newly synthesized KMT5A in S phase was excluded from the nucleus and exported 
into the cytoplasm throughout S phase. Upon reaching G2 phase, KMT5A was removed from the 
cytoplasm as it re-entered the nucleus. This was shown using a single living cell imaging technique 
but the underlying mechanism leading to KMT5A localisation remained unknown. However, as 
this technique did not distinguish between unmodified and modified KMT5A, it is not known 
which form(s) of KMT5A was being translocated in their observations. Interestingly, although in 
contrast to its unmodified form, mono-ubiquitinated KMT5A was enriched in proliferating cells 
(Figure 4.3), it was later found to reside in the cytoplasm (Figure 4.4). This finding is therefore 
consistent with DNA replication being incompatible in the presence of KMT5A and suggests 
mono-ubiquitination is a potential mechanism to promote the absence of KMT5A in the nucleus 
when the cell is proliferating. Mono-ubiquitination is reported to signal for protein localisation for 
many different proteins. For example, low levels of Mdm2 have been shown to induce mono-
ubiquitination of p53 without dramatically affecting its stability and led to the nuclear export of 
p53 (Li et al., 2003). Interestingly, mono-ubiquitinated KMT5A was found exclusively in the 
cytoplasm, unlike unmodified KMT5A which was present in the chromatin, nucleus and cytoplasm 
(Figure 4.4). From this, several speculations can be made: firstly, KMT5A may undergo mono-
ubiquitination in the cytoplasm and lead to its interaction with a cytoplasmic protein which retains 
mono-ubiquitinated KMT5A in this compartment. Secondly, KMT5A is mono-ubiquitinated in its 
nuclear localisation sequence (NLS) in the cytoplasm which prevents it from entering the nucleus, 
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as shown for the tumour suppressor, BAP1 protein (Mashtalir et al., 2014). However, there are no 
reports of a NLS in KMT5A and no classical NLS was found upon manual inspection of the 
KMT5A amino acid sequence. Although, cNSL mapper online software predicted a putative non-
classical NLS within KMT5A C-terminus consisting of three lysine sites (data not shown). A third 
more likely alternative is that KMT5A is mono-ubiquitinated in the nucleus, which then signals for 
its nuclear export. This may be mediated by a KMT5A conformational change exposing its nuclear 
export sequence (NES), causing its exportat into the cytoplasm. Again, there are no reports of a 
NES in KMT5A and we did not find a classical NES in KMT5A amino acid sequence. However, 
two different online software programmes, LocNES and NetNES predicted different regions in 
KMT5A to comprise a NES. Alternatively, exportat of mono-ubiquitinated KMT5A may be 
facilitated through interaction with other ubiquitin-binding proteins. It is important to note that the 
lack of mono-ubiquitinated KMT5A detection in the nuclear compartment does not mean it is not 
present at all. Mono-ubiquitination of KMT5A in the nucleus may result in its extremely rapid 
exclusion and hence extremely low nuclear levels that are not detected in our Western blots. 
Collectively, the data strongly suggests mono-ubiquitination of KMT5A during S phase leads to 
its nuclear export, to maintain low levels of KMT5A in the nucleus. To test this further, ubiquitin-
mediated fluorescence complementation could be utilised to monitor ubiquitination in living cells 
(Fang and Kerppola, 2004). In this technique, the amino terminal part of a fluorescent protein, e.g. 
YFP is tagged to ubiquitin, and the carboxyl terminal portion of YPF is attached to the protein of 
interest, in this case KMT5A. Following co-transfection of the constructs and the covalent 
attachment of ubiquitin-N-terminal-YFP to KMT5A, YFP complementation is achieved resulting 
in a fluorescent signal. Distribution of mono-ubiquitinated KMT5A and its levels could be 
monitored during the cell cycle in real time. It is further speculated that, de-ubiquitination of mono-
ubiquitinated KMT5A in G2 phase can enable it to re-enter the nucleus. This speculation is 
supported by the requirement of unmodified KMT5A in G2/M phase of the cell cycle and 
localisation of KMT5A into the nucleus during this phase by Yin et al as discussed earlier (Yin et 
al., 2008). In summary, the data has demonstrated mono-ubiquitination of KMT5A is under the 
cell cycle control and mono-ubiquitination regulates the cellular distribution of KMT5A. 
Skp2-mediated mono-ubiquitination of KMT5A  
In the next part of the work, the role of Skp2 E3 ligase was investigated in ubiquitinating KMT5A. 
Multiple E3 ligases have thus far been shown to precisely regulate KMT5A protein levels 
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throughout the cell cycle, each functioning through a different mechanism to ensure efficient poly-
ubiquitination and degradation of KMT5A. The CRL4Cdt2 complex specifically recognises 
KMT5A that is bound to PCNA on chromatin during S phase and therefore poly-ubiquitinates and 
degrades KMT5A, as well as its other substrates, in a replication-coupled manner. CRL4Cdt2-
mediated destruction of KMT5A in S phase is required to prevent H4K20Me1 deposition and 
premature chromatin compaction in replicating cells, ensuring proper DNA replication and entry 
into mitosis. The KMT5A level then increases and peaks in early mitosis to modulate chromatin 
compaction. Furthermore, the APCCdh1 complex targets KMT5A that has undergone 
dephosphorylation on serine 100 by the Cdc14 phosphatase and has dissociated from chromatin. 
Moreover, the SCFβ-TRCP complex has been shown to poly-ubiquitinate KMT5A in a 
phosphorylation-dependent manner at serine 253 by CK1 during G1 (Figure 1.6). 
In addition, Skp2 has been suggested to play a role in regulating KMT5A through proteolytic 
degradation during S phase. Skp2 is a positive regulator of the cell cycle and is frequently 
overexpressed in PC. Skp2 accumulates during G1-S transition and poly-ubiquitinates the cell 
cycle inhibitor p27 for proteasomal degradation. Whilst Skp2 knockdown has been reported to lead 
to increased KMT5A levels during S phase by Yin et al (Yin et al., 2008),it was recently reported 
to not affect KMT5A stability by Wang et al (Wang et al., 2015). However, despite these 
observations, no detailed study have investigated the role of Skp2 in ubiquitinating KMT5A.  
We identified Skp2 as a novel KMT5A-associated protein. The association of KMT5A and Skp2 
was confirmed by co-immunoprecipitation analysis using HEK293T cells expressing exogenous 
KMT5A together with Skp2 (Figure 4.8). However, the interaction may not be direct and other 
factor(s) may mediate KMT5A-Skp2 interaction. Over-expression of Skp2 increased KMT5A 
mono-ubiquitination. This was demonstrated using in vivo ubiquitination assay in COS7 cells, 
where Skp2 significantly up-regulated KMT5A mono-ubiquitination. In addition, Skp2 also caused 
a modest increase in KMT5A poly-ubiquitination, though to a much lesser extent than of mono-
ubiquitination without using MG132 to inhibit the proteasome (Figure 4.9). This indicated that 
Skp2-mediated mono-ubiquitination of KMT5A is not involved in protein turn over. This was 
supported when treatment with MG132 did not affect Skp2-mediated KMT5A mono-
ubiquitination, as well as poly-ubiquitination, suggesting these products are not targeted for 
proteasomal degradation (Figure 4.9). This is in contrast to the established role of Skp2 as an E3 
ligase which has been shown to ubiquitinate its substrates for proteolysis by the proteasome. 
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Furthermore, it conflicts with Yin et al (Yin et al., 2008) who suggested Skp2 plays a role in 
KMT5A poly-ubiquitination and degradation during S phase of the cell cycle as Skp2 knockdown 
in HeLa cells during G1-S transition caused an up-regulation in KMT5A expression. However, Yin 
et al., (2008) does not undermine our observations as the role of Skp2 is not investigated in any 
detail, and lacks the use of appropriate ubiquitination assays. Similar to Yin et al, work by Oda et 
al (Oda et al., 2010) suggests a similar role for Skp2 in KMT5A regulation as KMT5A was shown 
to be upregulated in Skp2-/- compared to wild type MEFs following exposure to UV treatment. 
KMT5A stabilisation however was markedly enhanced in the whole cell extracts compared to the 
chromatin-bound fraction. This suggested that in addition to the CRL4Cdt2-mediated poly-
ubiquitination and degradation, KMT5A is subject to destruction through CRL4Cdt2-independent 
mechanisms.  Additionally, the stable KMT5A PIP mutant that is resistant to CRL4Cdt2-mediated 
proteolysis during S phase was observed to be degraded, although at a slower rate than wild-type 
KMT5A which further indicates KMT5A is targeted by two independent pathways when cells are 
replicating their DNA. 
Interestingly, despite MG132’s ability to dramatically stabilise KMT5A which led to the formation 
of higher molecular weight KMT5A poly-ubiquitinated products, further inclusion of Skp2 caused 
a clear reduction in MG132-mediated poly-ubiquitination of KMT5A. Moreover, the degree of 
Skp2-mediated poly-ubiquitination was significantly lower than of MG132-mediated poly-
ubiquitination of KMT5A (Figure 4.9). This further suggests that Skp2-mediated mono-
ubiquitination of KMT5A causes KMT5A stabilisation on its own. Poly-ubiquitination of proteins 
requires the conjugation of four or more ubiquitin molecules in order to signal for their proteasomal 
degradation (Deveraux et al., 1994), which could explain why Skp2 does not induce KMT5A 
degradation. This implies that Skp2 may primarily affect KMT5A localisation and/or activity rather 
than stability, indicating a unique role for Skp2 in KMT5A regulation. Although evidence 
supporting Skp2-mediated mono-ubiquitination is currently lacking, new substrates for Skp2 are 
emerging where Skp2 is shown to be involved in regulating their function. For example, Skp2 has 
recently been shown to poly-ubiquitinate LKB1 through non-proteolytic K63-linked 
ubiquitination, thereby modulating LKB1 activity to impact cancer cell survival under energy stress 
(Lee et al., 2015).  The fact that Skp2 attenuated the ability of MG132 to cause KMT5A poly-
ubiquitination could also be attributed to Skp2-mediated mono-ubiquitination of KMT5A which 
may subsequently impact the accessibility of KMT5A for other ligases that promote KMT5A poly-
ubiquitination and degradation. There are 25 lysine residues in the KMT5A C-terminus that are 
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potential sites to ubiquitination. Treatment with MG132 may favour ubiquitination of KMT5A at 
lysine sites that favour protein turnover but once Skp2 is added at maximal level to saturate the 
system, the equilibrium may be pushed towards Skp2-mediated KMT5A mono-ubiquitination 
which is a more stable form. Alternatively, Skp2 may regulate E3 ligases that target KMT5A for 
poly-ubiquitination and degradation. Consistent with this idea, Lu et al (2014) demonstrated Skp2 
indirectly inhibits K63-linked ubiquitination of JARID1B via E3 ubiquitin ligase TRAF6 (Lu et 
al., 2015). E2-ubiquitin-conjugating enzymes determine the linkage specificity of poly-
ubiquitination chains. As Skp2 was shown to up-regulate KMT5A mono-ubiquitination, it would 
be interesting to identify the E2-ubiquitin-conjugating enzymes responsible for mediating Skp2 
function. 
Skp2 primarily enhanced KMT5A mono-ubiquitination at lower concentrations whilst promoted 
poly-ubiquitination at higher concentrations, suggesting Skp2 level may control the ratio of 
KMT5A mono-ubiquitination to poly-ubiquitination. Skp2 expression was elevated during G1-S 
transition, which further increased in S phase. This may in turn result in mainly KMT5A mono-
ubiquitination early in the transition phase when Skp2 levels are low and then poly-ubiquitination 
of KMT5A as Skp2 levels further rise. Such a dual ubiquitination mechanism has been reported 
for BAP1 and MDM2-mediated ubiquitination of p53, where the in situ concentration of MDM2 
is a critical factor in determining the ratio of p53 mono-ubiquitination to its poly-ubiquitination (Li 
et al., 2003). However, requirement of an additional co-factor in facilitating Skp2-mediated poly-
ubiquitination of KMT5A cannot be excluded, as complete poly-ubiquitination of mono-
ubiquitinated p53 has been demonstrated to require p300 as an E4 ligase (Shi et al., 2009).  
Despite significantly elevating full-length KMT5A mono-ubiquitination, Skp2 was unable to 
increase C-terminal KMT5A fragment mono-ubiquitination above basal mono-ubiquitination 
levels (Figure 4.10). This could be a consequence of disrupting KMT5A-Skp2 interaction if Skp2 
requires interaction with the KMT5A N-terminus. Alternatively, a post-translational modification 
on the N-terminus may facilitate Skp2-mediated mono-ubiquitination of full-length KMT5A. 
Although, there is no known consensus sequence for Skp2 substrates, Skp2 is known to recognise 
its substrates in a phosphorylation-dependent manner. The cross-talk between phosphorylation and 
ubiquitination has been demonstrated by Wu et al (2010) who showed KMT5A phosphorylation at 
serine 100 caused KMT5A stabilisation by preventing its degradation by the APCCdh1 complex. 
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Subsequently, de-phosphorylation of the same site leads to APCCdh1-mediated poly-ubiquitination 
and degradation of KMT5A during late mitosis (Wu et al., 2010). 
Having determined that Skp2 alone was capable of promoting KMT5A mono-ubiquitination, we 
sought to elucidate whether the SCF complex plays a role in this regulation. Unlike Skp2 alone, 
further addition of the SCF complex caused a reduction in KMT5A mono-ubiquitination (Figure 
4.11). This may be a consequence of disrupting the proportion of individual components of the 
SCF complex which will subsequently undermine the overall balance of the system, affecting the 
outcome of the whole complex. In this study we examined different concentrations of Skp2 in 
combination with constant amounts of the core SCF components. However, we did not consider 
the contribution of endogenous level of each SCF core component in the experiments, which may 
have impacted the results. Of note, in the majority of published studies, the role of Skp2 in 
ubiquitinating its substrates has been investigated without including the SCF components.  
The ligase-dead mutant Skp2 we had available as a negative control for Skp2 function, did not 
function as expected. This truncated form promoted increased mono-ubiquitination of full-length 
and C-terminus KMT5A. However, being truncated, it may fail to act within the SCF complex as 
its binding to the SCF components may be attenuated. Alternatively, it could still bind other 
proteins, recruiting them to SCF complex promoting aberrant activity. Additionally, both WT-Skp2 
and mutant Skp2 were heavily ubiquitinated when expressed without the SCF components. 
However, when expressed in combination with the SCF components, their ubiquitination was 
significantly reduced, indicating the SCF complex, probably when bound to Skp2, protects Skp2 
from excessive ubiquitination. 
Role of Skp2-mediated KMT5A mono-ubiquitination as a coordinator of cell cycle progression 
Based on the data collected in this thesis and reported elsewhere, a model is proposed for the role 
of mono-ubiquitinated KMT5A in the G1-S transition, summarised in Figure 4.13. 
During G1-S transition and throughout S phase of the cell cycle, KMT5A that is bound to the 
chromatin becomes poly-ubiquitinated and subsequently degraded by the CRL4Cdt2 complex in a 
PIP degron- and PCNA-dependent manner, to prevent H4K20Me1 deposition and thereby enable 
DNA replication and timely cell cycle progression. During S phase, as new KMT5A is re-
synthesised, it undergoes mono-ubiquitination in the nucleus, signaling for its cytoplasmic 
translocation. As poly-ubiquitination is a time-consuming and energy-consuming event, it is 
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speculated that mono-ubiquitination-mediated exclusion of nuclear KMT5A could be an additional 
mechanism to facilitate its rapid removal from the nucleus during S phase to ensure KMT5A levels 
are kept at a minimum level. Skp2 upregulation in S phase would promote this process by primarily 
mediating KMT5A mono-ubiquitination. Therefore, KMT5A mono-ubiquitination plays a role in 
regulating the levels of KMT5A and consequently is important in maintaining the genome integrity 
and proper cell cycle progression. Mono-ubiquitinated KMT5A may then undergo de-
ubiquitination to facilitate KMT5A re-entering the nucleus during G2/M, and its histone methylase 
activity being required for mitotic chromatin compaction and progression of the cell cycle. Some 
of the mono-ubiquitinated KMT5A may also undergo further ubiquitination for degradation by the 
proteasome. The APCCdh1 complex then degrades KMT5A as cells exit mitosis and the SCFβ-TRCP 
continues the destruction in G1, to ensure the cell has minimal levels of KMT5A as it enter the S 
phase. 
As mono-ubiquitination is not only a pre-requisite for degradation, once mono-ubiquitinated 
KMT5A is in the cytoplasm, it may have additional roles by interacting with other proteins and in 
turn modulating their activity. In support of this speculation, novel substrates of KMT5A are 
currently under investigation and it has been shown that almost half of the substrates identified are 
cytoplasmic proteins (personal communication with Dr Fabio Pittella Silva, Memorial Sloan 
Kettering Cancer Centre). Therefore, it is concluded that mono-ubiquitination of KMT5A and its 
export into the cytoplasm may have biological relevance as an additional mechanism to the 
CRL4Cdt2-mediated nuclear destruction of KMT5A during S phase. Moreover, due to the 
prevalence of mono-ubiquitinated KMT5A in the PC cell lines tested, and the fact that mono-
ubiquitination exerts non-proteolytic effects on the protein of interest, mono-ubiquitinated KMT5A 
must have important additional, as-yet-unidentified roles through regulating proteins residing in 
the cytoplasm.
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Figure 4-13: Proposed model for the role of mono-ubiquitinated KMT5A. During G1-S transition, KMT5A that is bound to the chromatin is targeted by the 
CRL4Cdt2 complex for poly-ubiquitination and proteasomal mediated degradation. As cells progress into the S phase, newly synthesised and/or remaining KMT5A 
are primarily subjected to mono-ubiquitination by Skp2 and targeted for cytoplasmic localisation. The diagram is independently drawn based on information from 
(Yin et al., 2008; Oda et al., 2009). 
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5 Investigating the role of Skp2 in androgen receptor signalling in prostate 
cancer 
5.1 Introduction  
As previously described in Chapter 4, Skp2 is an E3 ubiquitin ligase which positively regulates 
cell cycle progression by promoting G1-S transition. This is primarily mediated through 
ubiquitination and degradation of its substrate, the cyclin-dependent kinase inhibitor, p27 
(Carrano et al., 1999; Sutterlüty et al., 1999). Skp2 is overexpressed in various types of cancers, 
including colorectal carcinoma, oral epithelial carcinoma, lymphomas, breast cancer and PC 
where its upregulation is inversely correlated with p27 protein levels (Catzavelos et al., 1997; 
Porter et al., 1997; Gstaiger et al., 2001; Hershko et al., 2001; Latres et al., 2001). Specifically, 
Skp2 has been shown to play a role in the development of prostate cancer with elevated Skp2 
expression being observed in premalignant prostate lesions, indicating deregulation of Skp2 is 
an early event in transformation, and even higher levels are evident in metastasis. In addition, 
Skp2 level is correlated with tumour stage, histological grade and recurrence in prostate cancer. 
Therefore, the oncogenic roles of Skp2 make it a promising target for therapeutic intervention 
and potentially a useful prognostic biomarker (Yang et al., 2002; Ben-Izhak et al., 2003). 
Although the role of Skp2 in prostate tumourigenesis is well established, the molecular 
mechanism(s) by which Skp2 regulates tumour growth has not been fully elucidated. In addition 
to p27, Skp2 regulates a variety of downstream effectors in cellular processes, both dependent 
and independent of its E3 ligase complex. Skp2 has been reported to cross-talk with a broad 
spectrum of signalling cascades such as phosphatidylinositol 3-kinase (PI3K)/Akt, AR, PTEN 
and p27 in prostate cancer, which is believed to result in its critical role in prostate 
tumourigenesis (Mamillapalli et al., 2001; Yang et al., 2002; Van Duijn and Trapman, 2006). 
More recently, Skp2 has been shown to play a role in epigenetic events by regulating histone 
modification enzymes, such as JARID1B/KDM5B, a histone demethylase responsible for 
H3K4 tri- and di-methylation. Aberrant elevation of H3K4Me3 is reported to contribute to 
prostate cancer development and its progression to CRPC, which is positively regulated by 
Skp2 through inhibition of JARID1B activity (Lu et al., 2015). 
The role of Skp2 in regulating the AR directly, and the modulation of Skp2 by the AR signalling 
however has been controversial and remains unclear. Skp2 expression has been shown to be 
upregulated upon activation of the AR signalling cascade; whilst Skp2 functioned downstream 
of the AR and promoted cell proliferation without altering AR level and activity (Wang et al., 
2008a). In contrast, Skp2 has also been demonstrated to be negatively regulated by the AR 
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signalling cascade (Jiang et al., 2012; Kokontis et al., 2014). Furthermore, more contradictory 
data has revealed that Skp2 negatively regulates AR activity by targeting the AR for poly-
ubiquitination and destruction by the proteasome (Li et al., 2014a). The lack of consistency is 
partly due to the complexity of AR signalling and also the many pathways in which Skp2 is 
involved, which can consequently influence the AR signalling cascade. Importantly, there are 
some shortcomings with each of these reports, in that they are not sufficiently detailed, failing 
to investigate alternative PC cell lines which differ in their sensitivity to androgens, are limited 
to investigating one AR-regulated gene and either lack Skp2 protein or mRNA expression data.  
 In Chapter 4, Skp2 was shown to promote KMT5A mono-ubiquitination which was not 
associated with protein turnover. Although, a potential Skp2-mono-ubiquitinated KMT5A axis 
may exist in the modulation of AR signalling, Skp2 may affect KMT5A and AR regulation 
independently of each other. Hence, the overall aim of this chapter is to independently 
investigate the role of Skp2 in AR regulation, by performing experiments in androgen-
dependent and independent cell lines. 
5.2 Hypothesis 
Skp2 regulates PC cell growth and survival either directly or indirectly of the AR signalling 
cascade.   
5.2.1 Aims 
 Determine the androgenic regulation of Skp2 
 Determine whether Skp2 modulates AR activity  
 Investigate the underlying mechanism of Skp2-mediated AR regulation by assessing 
AR localisation and phosphorylation status 
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5.3 Results  
5.3.1 Differential androgenic response of Skp2 protein in LNCaP and LNCaP-AI cell lines 
A number of reports have described the involvement of androgen and the AR in regulating Skp2 
either at the protein or mRNA level. However, these studies mostly contradict each other (Wang 
et al., 2008a; Pernicová et al., 2011; Jiang et al., 2012; Kokontis et al., 2014; Li et al., 2014a). 
This may be partly due to the difference in cell lines used to investigate Skp2 levels, for example 
androgen dependent and independent cells have been investigated. Consequently, androgenic 
regulation of Skp2 remains unclear. In order to address this in both the androgen-dependent and 
androgen-independent states of PC, the parental LNCaP androgen-sensitive cell line and its 
castrate-resistant derivative, LNCaP-AI cell line were used to investigate Skp2 response to 
androgenic stimulation. To this end, LNCaP and LNCaP-AI cells were grown in steroid-
deprived conditions by using dextran-coated charcoal stripped serum media, before being 
subjected to androgenic stimulation with 10 nM DHT for various time points.  
In the androgen-dependent LNCaP cell line, DHT stimulation markedly induced the protein 
expression of the AR-regulated gene, PSA, used as a positive control. The AR protein 
expression also increased upon activating the AR signalling with 10 nM DHT, as expected 
(Figure 5.1). Furthermore, DHT treatment led to the upregulation of Skp2 protein levels which 
was only apparent at 48 hours post androgenic stimulation. This was in contrast to PSA which 
was acutely elevated after 8 hours and continued to rise with longer DHT treatments up to 48 
hours. This suggested that androgenic regulation of Skp2 occurs at the post-translational level 
or could be a secondary effect of androgen-AR signalling. 
However, in the androgen-independent cell line, LNCaP-AI, PSA protein could not be detected. 
These cells express significantly lower levels of PSA, where Western blotting is frequently not 
sensitive enough to detect such minute PSA levels. Similar to the LNCaP cells however, the 
AR expression was enhanced with 10 nM DHT stimulation. In contrast, DHT stimulation did 
not upregulate Skp2 in the LNCaP-AI, and even seemed to cause a subtle down-regulation at 
48 hours post DHT treatment. Therefore Skp2 protein expression was found to respond 
differentially in response to DHT treatment in LNCaP and LNCaP-AI cell lines. 
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Figure 5-1: Skp2 protein expression responds differently to androgenic stimulation in LNCaP and LNCaP-
AI cells. LNCaP and LNCaP-AI cells were cultured in steroid-depleted media (SDM) for 72 hours before being 
treated with 10 nM DHT for the indicated time points. Cell lysates were collected with SDS sample buffer and 
analysed by Western blotting for AR, Skp2, PSA and the loading control, α-tubulin. This is a representative blot 
of three independent repeats. 
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5.3.2 Differential effect on Skp2 protein levels in response to increasing androgen 
concentration in LNCaP and LNCaP-AI cell lines 
Skp2 has been previously reported to be under dual modulation by androgens at sub-
physiological compared to physiological and supra-physiological concentrations (Jiang et al., 
2012). As shown in Figure 5.1, Skp2 responds in an opposing manner to androgenic stimulation 
between LNCaP and LNCaP-AI cell lines. To further confirm this observation, a range of DHT 
concentrations was used to stimulate both cell lines over 48 hours. Western blot analysis for the 
LNCaP cell line treated with androgens revealed Skp2 proteins levels clearly increased at both 
10 and 100 nM DHT and more subtly at 1 nM DHT. However, it remained unchanged at sub-
physiological DHT levels of 0 - 0.1 nM in LNCaP cells. In addition, PSA levels showed similar 
expression kinetics at these DHT concentrations, although no PSA could be detected at sub-
physiological concentrations of DHT. Conversely, in the LNCaP-AI cell line it was observed 
that Skp2 protein expression was suppressed by 10 and 100 nM DHT treatment, but sub-
physiological DHT concentrations did not affect Skp2 levels (Figure 5.2A). Interestingly, the 
changes in Skp2 level in response to DHT concentration mirrors that of AR expression. 
The difference in Skp2 regulation is interesting between these two cell lines, as LNCaP-AI cell 
line is derived from parental LNCaP cells following continuous growth in steroid-depleted 
conditions to model androgen-independent disease. As LNCaP and LNCaP-AI cells are 
normally cultured in FM and SDM, respectively, it was decided to examine Skp2 expression in 
both cell lines in FM and SDM (Figure 5.2B). Consistently, Skp2 protein expression was 
markedly down-regulated in LNCaP cells upon culturing them in SDM. However, Skp2 protein 
levels did not obviously alter in the LNCaP-AI cells following their growth in the different 
culture media (Figure 5.2). This could be due to FM not containing sufficiently high levels of 
androgens that would lead to Skp2 suppression, or other factors such as some growth hormones 
that are removed in charcoal-treated media may prevent Skp2 down-regulation following 
LNCaP-AI growth in full media. Overall, the data clearly demonstrates that Skp2 is regulated 
by androgen in LNCaP cells but in LNCaP-AI cells this mechanism is different and Skp2 
protein expression is diminished by high androgen concentrations. This suggests that during the 
changes which occurs in LNCaP to transition from an androgen dependent to an androgen 
independent state, the regulation of Skp2 by the androgenic pathway is altered. 
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Figure 5-2: Differential effect on Skp2 protein levels in response to androgen concentration range in the 
LNCaP and LNCaP-AI cell lines. Western blot analysis of AR, Skp2, positive control PSA and the loading 
control, α-tubulin for (A) LNCaP and LNCaP-AI cells cultured in steroid-depleted media (SDM) and treated with 
increasing concentration of DHT for 48 hours before being subject to Western blot analysis and (B) LNCaP and 
LNCaP-AI cells grown in either in FM or SDM prior to collection for Western blot.  
 
  
146 
 
5.3.3 Skp2 response to DHT stimulation is similar in LNCaP and LNCaP-AI cell lines at 
the transcription level 
It was then sought to determine whether the changes observed in the Skp2 protein level were 
also evident at the transcriptional level in both LNCaP and LNCaP-AI cell lines. In order to 
investigate this, the effect of 10 nM DHT treatment on Skp2 transcription in LNCaP and 
LNCaP-AI cell lines was examined. QRT-PCR was undertaken to determine mRNA levels of 
Skp2, with PSA included as a positive control of an androgen regulated gene, following 
androgen deprivation of the cell lines for 72 hours and subsequent stimulation with 10 nM DHT 
for various time points. AR mRNA expression was also examined over this time period in both 
cell lines. 
In the LNCaP cells, PSA up-regulation was induced by 4.2 fold at 8 hours after DHT stimulation 
and was sustained for at least a further16 hours (Figure 5.3). However, in contrast to its protein 
levels, the AR expression was not altered at the transcriptional level, except after 48 hours 
where there was a small down-regulation, possibly due to the over-activation of AR signalling 
which has been reported to supress AR expression. Nonetheless, consistent with the AR protein 
and mRNA expression data, androgenic stimulation causes stabilisation of the AR protein by 
binding to the AR (Bennett et al., 2010). In contrast to the protein level, Skp2 mRNA levels 
were found to be unaffected with DHT treatment. Similarly, in the LNCaP-AI cells, PSA 
mRNA expression was induced following 8 hours DHT treatment, as expected. Although the 
reason for its observed small decrease at 24 hours is unclear. Of note, the PSA mRNA level in 
LNCaP-AI cells is approximately two orders of magnitude lower than that found in the LNCaP 
cells, consistent with difficulties observed in detecting PSA protein in LNCaP-AI cells by 
western analysis (Figure 5.1). Conversely, the AR mRNA in LNCaP-AI cells increased 
following 16 and 24 hours DHT stimulation and was further elevated at 48 hours by 1.9 fold. 
Interestingly, similar to LNCaP cells, the Skp2 mRNA remained unaltered even at 48 hours 
DHT treatment (Figure 5-3). Therefore, the data implies androgenic regulation of Skp2 is not a 
primary event and Skp2 is not directly regulated by androgen-AR signalling.      
  
147 
 
 
Figure 5-3: Androgenic stimulation does not alter Skp2 transcription in LNCaP and LNCaP-AI cell lines. 
Quantitative RT-PCR demonstrating the effect of 10 nM DHT treatment on Skp2, PSA and AR relative to the 
control gene, HPRT1. LNCaP and LNCaP-AI cells were grown in steroid-depleted media (SDM) prior to 
stimulation with 10 nM DHT for the indicated time points and subject to gene expression analysis for one repeat, 
n=1. 
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5.3.4 Validation of Skp2 protein depletion using siRNA oligonucleotides  
Having determined Skp2 is not a direct downstream effector of the androgen-AR signalling 
cascade, it was questioned whether there was any role for Skp2 in regulating AR signalling, as 
Skp2 is frequently upregulated in CRPC, concomitant with re-activation of AR signalling 
(Yang et al., 2002; Nguyen et al., 2011; Robbins et al., 2011). For this purpose, three Skp2 
siRNA oligonucleotides were tested for their efficiency in LNCaP and LNCaP-AI cell lines 
grown in their native media to deplete Skp2 protein. Following 72 hours siRNA treatment, Skp2 
and its substrate, p27, protein levels were tested.  
Figure 5.4 demonstrates that all three Skp2 siRNA oligonuclotides, and additionally the pool 
(P) of combined Skp2 siRNAs, resulted in a significant suppression of Skp2 protein to almost 
undetectable levels compared to the non-silencing control. Consistent with Skp2 depletion, p27 
used as the positive control was markedly up-regulated, as expected. 
 
 
 
 
Figure 5-4: Validation of Skp2 siRNA oligonucleotides. LNCaP and LNCaP-AI cells grown in their native 
culture media were reverse-transfected with one of three Skp2 siRNA oligonucleotides, a combined pool of the 
three Skp2 siRNAs (P), or non-silencing (N/S) control siRNA at 25 nM. After 72 hours incubation, cell lysates 
were generated using SDS sample buffer and Western blot performed for Skp2, the positive control p27 and 
loading control α-tubulin. This is a representative blot of multiple independent repeats. 
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5.3.5 Skp2 protein depletion reduces growth of PC cell lines 
Given the role of Skp2 in promoting cell cycle transition and the impact of its depletion on p27 
levels, cell growth was then examined following Skp2 silencing using Skp2 siRNA 3, in LNCaP 
and LNCaP-AI cell lines. To this end, siRNA-mediated Skp2 knockdown was performed in a 
6-well plate for 72 hours with the PC cells being cultured in their native growth media for the 
course of the experiment. Following this, the cells were trypsinised, seeded in wells of a 96-
well plate and left to grow. Growth of cells was monitored in the incucyte system over a period 
of 5.5 – 6.0 days, measuring confluency every 6 hours.   
In keeping with its role in promoting cell growth, Skp2 suppression led to reduced cell growth 
in both the LNCaP and LNCaP-AI cell lines, inhibiting cell proliferation by approximately fifty 
per cent (Figure 5.5).  
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Figure 5-5: Skp2 suppression downregulates cell growth. LNCaP and LNCaP-AI cells were either transfected 
with non-silencing (N/S) or Skp2 siRNA in their native media. Cell growth (relative confluency) was then 
monitored using the IncuCyte system. Data are a mean of two independent experiments, and error bars represent 
SEM.  
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5.3.6 Skp2 knockdown causes G1 cell cycle arrest in PC cell lines  
As the role of Skp2 in promoting cell proliferation is mainly mediated by facilitating G1 to S 
phase transition, its effect on cell cycle was analysed in more detail. LNCaP and LNCaP-AI 
cells were transfected with Skp2 siRNA in their native growth culture. Following 72 hours 
incubation, the cells were stained with propidium iodide and subjected to flow cytometry.  
In response to Skp2 knockdown, there was a clear increase in the percentage of cells in G1 for 
both cell lines, with a reciprocal decrease in the percentage of cells undergoing DNA replication 
in S phase, and in the G2/M phase of the cell cycle (Figure 5.6). Additionally, Skp2 depletion 
subtly increased the subG1 population, indicative of apoptotic/necrotic cells. This finding is in 
line with the role of Skp2 in regulating cell cycle progression, as well as, modulating apoptosis 
(Harada et al., 2005; Lee and McCormick, 2005). These siRNA results are also consistent with 
previous published data that Skp2 depletion blocks cell cycle progression in G1-S transition 
(Carrano et al., 1999).  
 
 
Figure 5-6: Skp2 depletion induces G1 cell cycle arrest in PC cell lines. LNCaP and LNCaP-AI cells grown in 
their native media were reverse transfected with either 25 nM non-silencing (N/S) or Skp2 siRNA. Following 72 
hours post transfection, cells were subject to cell cycle analysis using propidium iodide based flow cytometry, for 
one repeat, n=1.  
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5.3.7 Determining the role of Skp2 in AR-mediated protein expression 
Having validated the Skp2 siRNA, the role of Skp2 in regulating AR activity was investigated. 
As such AR transcriptional activity was determined by Western blotting for representative AR 
target genes, PSA and ATAD2. Although less well defined, the expression of ATAD2 is known 
to be activated by androgens through induction of AR binding to ARE within the ATAD2 distal 
enhancer region (Zou et al., 2009; Altintas et al., 2012). For this purpose, LNCaP and LNCaP-
AI cells were either transfected with Skp2 or non-silencing control siRNA in steroid-depleted 
conditions for 72 hours. The cells were then stimulated with 10 nM DHT for various time 
points, followed by Western blot analysis.  
Figure 5.7 demonstrates that in the control androgen-sensitive LNCaP cells, DHT treatment 
resulted in an up-regulation of PSA expression, which was not affected following Skp2 
depletion. Similarly, the protein expression of ATAD2 was induced upon DHT stimulation 
when transfected with non-silencing control siRNA. Interestingly however, Skp2 knockdown 
led to the down-regulation of ATAD2 protein. Furthermore, the reduction was evident in the 
absence of supplemented androgens (0 hour DHT); prior to induced AR signalling, suggesting 
basal transcription of ATAD2 is affected. In line with the data for the LNCaP cells, ATAD2 
protein expression was also increased following DHT stimulation in the LNCaP-AI non-
silencing siRNA control cells. Skp2 depletion, similarly to the results in LNCaP cells, caused a 
reduction in ATAD2 protein in LNCaP-AI cells. As expected, the low level expression of PSA 
protein in LNCaP-AI cells explained the lack of PSA detected by western blotting in this cell 
line.  
Moreover, consistent with the previous data (Figure 5.2), Skp2 protein expression was up-
regulated in the control LNCaP cells with DHT stimulation, but remained unchanged in the 
LNCaP-AI cells when taking α-tubulin levels into account. Furthermore, the AR protein 
expression increased after androgenic stimulation in both cell lines as observed previously 
(Figure 5.1) and was not affected when Skp2 was inhibited. 
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Figure 5-7: Skp2 depletion differentially affects AR-mediated gene expression. LNCaP and LNCaP-AI cells 
were reverse transfected with 25 nM siRNA either against Skp2 or the non-silencing (N/S) control for 72 hours 
whilst being cultured in steroid-depleted media (SDM). Cells were then treated with 10 nM DHT for the indicated 
time points before being collected for Western blot analysis for AR, PSA, ATAD2, Skp2 and the loading control 
α-tubulin. This is a representative blot of three independent repeats. 
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5.3.8 Assessing the effect of Skp2 depletion on AR-regulated gene expression 
Skp2 knockdown led to a differential regulation of PSA and ATAD2 protein expression. 
Moreover, in the LNCaP cells, the reduction in ATAD2 protein in the absence of androgenic 
stimulation indicated that this could be due to Skp2 depletion altering ATAD2 basal 
transcription (Figure 5-7).  Therefore, in order to further validate that Skp2 differentially affects 
AR-regulated gene expression, and also to determine whether it occurs at the basal transcription 
level, the AR transcriptional activity was assessed using qRT-PCR. As such, expression of 
additional AR-regulated genes including KLK2 and TMPRSS2 was examined. As the effect on 
ATAD2 was similar in both LNCaP and LNCaP-AI cell lines, this experiment was only 
performed in the LNCaP cells.  
In keeping with being AR target genes, PSA, KLK2, TMPRSS2 and ATAD2 mRNA levels 
were all up-regulated by 2.4, 6.7, 5.7 and 2 fold respectively following 8 hours DHT 
stimulation. They further increased their expression at 16 hours post DHT treatment to 7.2, 19, 
10.8 and 2.5 fold respectively, which were then maintained up to 24 hours of DHT treatment in 
the control non-silencing siRNA transfected cells (Figure 5.8). On the other hand, whilst 
TMPRSS2 was not influenced, the transactivation of PSA was induced to a greater extent (4.6 
fold) and less so for KLK2 (7 fold) following Skp2 depletion post 8 hours DHT treatment. 
However, the mRNA expression of KLK2 and TMPRSS2 genes was reduced compared to non-
silencing cells at 16 and 24 hours DHT treatment in the absence of Skp2 (Figure 5.8). This may 
imply that the AR requires Skp2 at later stages of its transcriptional activity at KLK2 and 
TMPRSS2 gene promoters. In a stark contrast, ATAD2 levels were reduced by almost 50% in 
the absence of DHT stimulation when Skp2 was depleted, implying that basal transcription of 
ATAD2 is inhibited. However, following DHT treatment, ATAD2 was still up-regulated with 
a similar magnitude as control cells. In line with the previous data (Figure 5.3), DHT did not 
affect Skp2 mRNA, and Skp2 siRNA knockdown efficiently inhibited Skp2 transcription 
(Figure 5.8).  Overall, Skp2-mediated regulation of AR transcriptional activity appears complex 
as it causes a different outcome for different AR-target genes. 
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Figure 5-8: Skp2 depletion does not affect classical AR-mediated gene expression. LNCaP cells were reverse 
transfected with 25 nM Skp2 or the control non-silencing (N/S) siRNA while being cultured in steroid-depleted 
media (SDM). Following 72 hours post transfection, cells were stimulated with 10 nM DHT for the indicated time 
points before being subject to gene expression analysis by QRT-PCR. Data are normalised to the control gene 
HPRT1. Graph represents the mean from three independent repeats and error bars depict SEM. * represent a p-
value <0.05, ** p < 0.01 and *** p < 0.001. 
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5.3.9 Skp2 depletion does not affect protein AR levels 
Skp2 has previously been reported as an E3 ligase for the AR where it has been shown to 
ubiquitinate and target the AR for proteasomal degradation, leading to reduced AR protein level 
and transcriptional activity (Li et al., 2014a). However, this cannot explain the data shown in 
(Figure 5.8) as Skp2 depletion would generally be expected to cause an up-regulation of AR-
target genes. In contrast, Skp2 mRNA suppression caused a down-regulation of ATAD2 at the 
basal transcriptional level and reduced DHT-induced KLK2 and TMPRSS2 transcription. In 
order to elucidate the mechanism by which Skp2 knockdown causes decreased AR activity, the 
effect of Skp2 on AR protein level was investigated. As there is controversy in the literature 
regarding the regulation of AR stability by Skp2, three different siRNA oligonucleotides were 
utilised in LNCaP and LNCaP-AI cell lines grown in their native media, to silence Skp2 for 72 
hours after which AR protein levels were determined. Figure 5.9A demonstrates that Skp2 
inhibition did not alter AR expression. This finding is in agreement with earlier results where 
Skp2 knockdown in steroid-depleted conditions followed by androgenic stimulation did not 
change AR levels (Figure 5.7). 
At the time this work was being performed, another study by Li et al  (Li et al., 2014a) was 
published which showed Skp2 negatively regulates AR activity where Skp2 inhibition led to 
restoration of the AR protein expression in PC3 and DU145 AR-negative cell lines. As this is 
an observation at the other end of the spectrum to the data reported here, this experiment was 
repeated with the same experimental conditions stated in the paper, alongside our experimental 
conditions in PC3 cells, as well as, CWR22RV1 cells, the latter cell line expresses both a full-
length mutant AR and a shorter constitutively active isoform of AR lacking the ligand binding 
domain (AR-V). However, in keeping with previous observations in this thesis, Skp2 depletion 
did not alter AR levels and was not able to restore AR expression in PC3 cells in either of the 
experimental conditions despite a clear up-regulation of p27 protein levels (Figure 5.9B). 
Interestingly, in the CWR22RV1 cell line, despite unaffected full-length AR levels, Skp2 
knockdown did cause a small reduction in the shorter AR-V isoform, suggesting Skp2 may 
differentially regulate AR isoforms. 
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Figure 5-9: AR level is not altered by Skp2 depletion. Western blots of AR (FL, full-length and V, variant), 
Skp2, p27 and the loading control α-tubulin for (A) LNCaP and LNCaP-AI cells grown in their native media while 
reverse transfected with 25 nM of either three of the Skp2 siRNAs, combined pool of the three Skp2 siRNAs or 
the non-silencing control siRNA for 72 hours before being subject to Western blotting. (B) Direct comparison of 
the effect of Skp2 knockdown on AR level between Li et al., (2014) and our experimental conditions. PC cell lines 
were reverse transfected using 10 nM siRNA for 48 hours and 25 nM for 72 hours under Li’s and our experimental 
conditions, respectively. 
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5.3.10 Skp2 protein forms a complex with the AR 
Although Skp2 was found to not regulate AR levels, it was speculated that Skp2 may modulate 
AR transcriptional activity independently of AR ubiquitination through an alternative 
mechanism which may require interacting with the AR. In order to establish if Skp2 and AR 
are found in a complex, immunoprecipitation was performed in LNCaP cells grown in their 
native media to pull down endogenous Skp2, followed by AR detection in the 
immunoprecipitated samples.  
Interestingly, Skp2 was found to be in a complex with AR as AR was detected following Skp2 
immunoprecipitation but not in the negative IgG or the antibody only control lanes (Figure 
5.10). However, this experiment was conducted only once and unfortunately the Western blot 
for Skp2 was not particularly clear to demonstrate successful Skp2 immunoprecipitation. The 
co-immunoprecipitation of AR did however suggest the possibility that Skp2 binding to the AR 
may perturb AR signalling. 
 
 
 
Figure 5-10: Skp2 and AR are found in a complex. Immunoprecipitation was performed under non-denaturing 
conditions with either 2µg anti-Skp2 or the negative control IgG antibody. Antibody control (Ab only) is a lysate-
free sample control. Samples were subject to Western blot for Skp2 and AR. The experiment was conducted once. 
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5.3.11 Skp2 does not affect AR localisation 
In addition to its ubiquitin ligase activity, Skp2 has also been reported to act independently of 
its SCF complex where it has been shown to regulate its substrates by sequestering them 
(Kitagawa et al., 2008). AR translocates to the nucleus upon binding androgen to activate gene 
transcription. Therefore, it was hypothesised that cytoplasmic Skp2 may retard AR localisation 
to the nucleus following androgenic stimulation with DHT. To investigate this further, LNCaP 
cells were simultaneously starved in SDM and transfected with siRNA for 72 hours, followed 
by DHT stimulation for 2 hours prior to undergoing nuclear-cytoplasmic fractionation to 
compare AR subcellular localisation in response to DHT in the presence and absence of Skp2.  
As expected, the AR was translocated to the nucleus following DHT stimulation in the control 
non-silencing siRNA transfected cells. However, despite initial indications, Skp2 silencing did 
not alter AR localisation (Figure 5.11A). Surprisingly, Skp2 was found to be almost exclusively 
cytoplasmic which was unexpected as Skp2 has previously been reported to be predominantly 
nuclear, though present in both compartments (Signoretti et al., 2002; Radke et al., 2005; Gao 
et al., 2009).   
This observation could possibly be explained by the fact that Skp2 localisation has previously 
not been characterised under steroid deprivation as was the case in our experimental conditions. 
Moreover, the fractionation method utilised may underlie the lack of Skp2 detection in the 
nuclear compartment, as an insoluble pellet comprising protein that are tightly bound to the 
chromatin is left behind following removal of the cytoplasmic and nuclear extracts. Recently, 
Skp2 has be shown to ubiquitinate macroH2A1 (mH2A1), a member of H2A family, for 
degradation (Xu et al., 2015), indicating that Skp2 may have not been completely solubilised 
while being associated with mH2A and was consequently discarded as part of the insoluble 
pellet.  
Therefore, the insoluble pellet which consists of cellular debris but mostly chromatin was re-
suspended in SDS sample buffer and subjected to Western blotting. Interestingly, Skp2 was 
indeed found to be present in the chromatin-containing fraction (Figure 5.11B). However, it 
would have been more prudent to use a histone marker as a control to confirm the presence of 
histones in this fraction rather than PARP. Moreover, ideally, Skp2 localisation should be 
characterised in LNCaP cells when grown in their native media rather than in steroid depleted 
conditions as LNCaP cells are dependent on androgens for growth and survival and slowed 
growth due to starvation may in turn affect Skp2 levels as well as localisation. Consistently, 
Skp2 levels were found to decrease upon culturing LNCaP in SDM.  
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Figure 5-11: Skp2 depletion does not alter AR nuclear translocation upon androgenic stimulation. (A) 
LNCaP cells were reverse transfected in steroid-depleted media (SDM) for 72 hours. Cells were then stimulated 
with 10 nM DHT for 2 hours prior to being subject to cellular fractionation using the NE-PERTM nuclear and 
cytoplasmic extraction kit (Thermo Scientific) into the nuclear (Nuc) and cytoplasmic (Cyto) samples. (B) The 
remaining insoluble pellet (chromatin fraction) was re-suspended in SDS sample buffer and Western blot was 
performed on the samples for AR, Skp2, the nuclear and cytoplasmic controls PARP1/2 and α-tubulin, 
respectively. 
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5.3.12 Skp2 does not influence AR phosphorylation at serine 81 
As previously mentioned, p27 is a cell cycle inhibitor which functions through regulating 
cyclin-cyclin dependent kinase (cyclin/CDK) complexes. Skp2 suppression led to up-regulation 
of p27 and reduced transcriptional activity of AR at some AR target genes without affecting 
AR levels and localisation. As AR is phosphorylated by cyclin/CDKs at serine 81 (pS81-AR) 
upon binding androgen to regulate AR ability to bind chromatin and gene transcription, it was 
hypothesised that Skp2 suppression may perturb phosphorylation of AR at serine 81. To this 
end, LNCaP and LNCaP-AI cells were transfected in SDM for 72 hours and then stimulated 
with DHT, followed by Western blot analysis.  
It was observed that Skp2 depletion did not alter the overall phosphorylation level of AR at 
serine 81 (Figure 5.12). Although, this is difficult to accurately visualise in the LNCaP cell line 
because AR levels are dependent on androgens in these cells as seen by total AR being down-
regulated to very low levels following growth in SDM which was then increased following 
DHT treatment. The considerable change in total AR levels between androgen stimulated and 
vehicle treated cells in both non-silencing and Skp2 siRNA arms is therefore the principle 
underlying reason for the changes observed in pS81-AR level which reflect total AR levels. 
However, the failure to alter pS81-AR levels in combined response to DHT treatment and Skp2 
depletion is apparent in the LNCaP-AI cells as these cells are androgen-independent with their 
AR protein expression being sustained when androgen is depleted, undergoing only subtle 
changes in overall levels in response to androgen treatment. Under androgen deprived 
conditions, AR phosphorylation was almost undetectable despite high levels of the AR in 
LNCaP-AI cells, as expected. However, following DHT treatment, there was a strong induction 
of AR phosphorylation on serine 81 which occurred to a similar extent when Skp2 was depleted. 
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Figure 5-12: AR phosphorylation at serine 81 is not influenced upon Skp2 suppression. LNCaP and LNCaP-
AI cells underwent reverse transfection using 25 nM siRNA whilst simultaneously starved in steroid-depleted 
media (SDM) for 72 hours. They were then treated with 10 nM DHT for 8 hours prior to collection for Western 
blotting to analyse AR phosphorylation at serine 81 (pS81-AR), AR, PSA, Skp2 and α-tubulin. 
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5.3.13 Skp2 over-expression does not affect AR transcriptional activity 
It was determined that Skp2 did not influence AR level, localisation and phosphorylation on 
serine 81, all of which are important in regulating AR transcriptional activity. However, as Skp2 
depletion led to reduced ATAD2 basal transcription, it was questioned whether Skp2 may act 
as a transcriptional cofactor for AR. For this purpose, transient transfection of a luciferase gene 
reporter was applied in an assay to determine AR activity. HEK293T cells were initially 
transfected with AR and an AR-responsive luciferase reporter, which consists of three androgen 
responsive elements (ARE) upstream of a luciferase reporter. Upon binding of the ectopically 
expressed AR to the AREs, it can promotes active transcription of the luciferase gene which is 
therefore reflective of the activity of the AR. This transcriptional activity can in turn be altered 
depending on the presence of activating ligand and AR co-regulatory proteins. Briefly, cells 
were seeded in steroid-depleted media before being transfected for 48 hours, with 10 nM DHT 
added in the final 24 hours of incubation period.  
As expected, luciferase activity was up-regulated by 2.1 fold upon addition of 10 nM DHT, 
indicating increased AR activity (Figure 5.13). Although this fold increase was substantially 
lower than expected. However, co-expression of Skp2 had no additional effect on the activity 
of AR and so the experiment was terminated with one repeat.  
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Figure 5-13: Over-expression of Skp2 does not enhance AR transcriptional activity. HEK293T cells were 
transfected with AR, ARE3-luc, pCMV-β-gal for normalisation either in the absence or presence of Skp2 construct. 
Following 24 hours incubation in steroid-depleted media (SDM), cells were treated with 10 nM DHT and were 
incubated for a further 24 hour period prior to performing the luciferase assay. Each reading is the mean of triplicate 
wells. Data was normalised using β-galactosidase activity.  
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5.4 Discussion  
The aberrant elevation of Skp2 is recognised to contribute to the initiation and progression of 
different cancers, including PC. This is due to the diverse range of substrates that are regulated 
by Skp2; hence, placing Skp2 as a critical player in various important cellular processes (Guo 
et al., 1997; Von Der Lehr et al., 2003; Moro et al., 2006; Chan et al., 2010). The altered 
regulation of AR signalling by Skp2 has been suggested to be a possible underlying mechanism 
in prostate tumourigenesis; however, this has remained unclear due to the controversial 
literature to date. In Chapter 4, it was demonstrated that Skp2 regulates the mono-ubiquitination 
of KMT5A, where KMT5A has recently been identified as a novel co-activator of AR in CRPC 
cell line models. Although this suggested that Skp2 could potentially influence the AR through 
mono-ubiquitination of KMT5A, Skp2 could also exert its effect independently of KMT5A. 
Therefore, the aim of this chapter was to conduct an independent set of research experiments to 
determine the importance of Skp2 in AR signalling, addressing both the lack of previous 
detailed investigations and exploring different avenues of AR regulation by Skp2. Moreover, it 
aimed to determine whether Skp2 is under the androgenic-AR regulation in androgen dependent 
and independent cell lines.  
The androgenic modulation of Skp2 could be an important underlying mechanism in Skp2 
regulation considering the fact that it is frequently concomitantly overexpressed with the AR in 
CRPC. Moreover, it has been found that the ADT-mediated downregulation of AR leads to 
senescence as a result of Skp2 suppression (Pernicová et al., 2011). Therefore, in this chapter, 
the effect of androgenic stimulation on protein and transcript level of Skp2 was determined, 
which has been an area of controversy to date. As already alluded to, the discrepancy in the 
literature with regards to androgen-AR regulation of Skp2 and vice versa, could be due to the 
use of different PC cell lines exhibiting different sensitivity to androgens, the limited number 
of AR-target genes studied, insufficient range of time points and either missing protein or 
mRNA data, all of which have been addressed to some extent in this part of the work.  
It was found that Skp2 is not subject to direct regulation by the AR as androgenic stimulation 
only led to changes in Skp2 protein expression after a prolonged 48 hours exposure to DHT, 
compared to PSA which responded within 8 hours post DHT treatment (Figure 5.1). This was 
later confirmed at the transcriptional level which further validated Skp2 as not being a direct 
target of the AR as DHT had no effect on Skp2 mRNA level in either LNCaP or LNCaP-AI 
cell lines, whilst PSA was clearly induced (Figure 5.3). This finding is in line with the fact that 
the Skp2 promoter does not contain any identifiable AREs. The Skp2 protein however 
responded differently between the androgen-dependent and independent cell lines, LNCaP and 
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LNCaP-AI. Whereas Skp2 was up-regulated with DHT treatment in LNCaP cells, it was down-
regulated following DHT treatment in LNCaP-AI cells (Figure 5.1 and Figure 5.2). This may 
be of relevance in the treatment of CRPC where Skp2 is suggested to be a promising therapeutic 
target, should ADT be utilised to also suppress Skp2 expression. Consistent with the data 
presented herein, Chuu et al  (Kokontis et al., 2014) reported Skp2 protein suppression by 
synthetic androgen, R1881, at physiological concentration of 10 nM in the LNCaP 104-R2 cell 
line representative of late stage CRPC. Conversely, in the androgen-dependent LNCaP 104 
cells, sub-physiological concentration of R1881 induced Skp2 protein expression. However, 
this was observed following 96 hours of R1881 treatment which was the only time point used 
in this study. Nonetheless, it does demonstrate the slow kinetics of Skp2 response to androgen 
in line with the data presented here, further supporting the argument that Skp2 is not directly 
regulated by the AR. Furthermore, Wang et al  (Wang et al., 2008a) reported Skp2 is up-
regulated with androgen at both mRNA and protein levels in LNCaP cells. Although, Skp2 
protein response to androgen was observed at 24 hours, occurring with faster kinetics compared 
to its mRNA expression where changes were observed after 72 hours, indicating a secondary 
effect on Skp2 transcription rather than being a direct effect of the androgen-AR signalling. 
Consistently, the androgen-AR was shown to be responsible for the increased Skp2 protein 
stability mediated through the D-box degron in Skp2 N-terminus. These observations however 
contrast that of Jiang et al (Jiang et al., 2012) who showed Skp2 expression is down-regulated 
by R1881 treatment at physiological and higher concentrations in LNCaP cells.  Although the 
same group reported the changes in Skp2 expression is at the level of transcription, this was 
only evident following 12 hours of androgenic stimulation.  
Deregulated Skp2 function promotes cell transformation and Skp2 has been reported to mediate 
androgen-dependent proliferation of PC cells. Supporting this statement, experiments in 
LNCaP and LNCaP-AI cells showed that Skp2 depletion caused a dramatic inhibition of cell 
growth, reducing cell proliferation by almost 50% (Figure 5.5) which was associated with an 
accumulation of cells in G1 phase of the cell cycle (Figure 5.6). Given the impact of Skp2 
knockdown on cell growth, its effect on AR transcriptional activity was then investigated. As 
Skp2 was found to be expressed in an opposing manner following androgen treatment between 
LNCaP and LNCaP-AI cells, it suggested Skp2 expression changes may differentially alter AR 
activity in these cells. Whilst, PSA protein expression which could only be detected in the 
LNCaP cells was not affected, Skp2 depletion led to reduced protein levels of ATAD2 in both 
cell lines tested (Figure 5.7). Although there was no differences in the cell lines, data indicated 
that Skp2 differentially regulates AR-target genes and to further confirm it, mRNA level of 
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PSA and ATAD2, as well as additional AR target genes, KLK2 and TMPRSS2 were examined. 
In contrast with the protein expression data, Skp2 suppression induced PSA transcription. 
Interestingly, Skp2 knockdown led to reduced transcription of KLK2 and TMPRSS2 at later 
time points of 16 and 24 hours with DHT treatment, it caused a significant reduction in ATAD2 
transcription under steroid-depleted conditions. Although, there was no overall change in the 
level of ATAD2 mRNA induction following DHT stimulation (Figure 5.8). This implied that 
Skp2 regulation may only be applicable to a subset of AR-regulated genes, where Skp2 
functions in a promoter dependent manner. Unfortunately most of the reports on the role of 
Skp2 in regulating AR signalling have drawn conclusions based on one AR-target gene, PSA, 
without including different time points, with the data obtained being inconsistent between 
studies. For example, whilst Wang et al (Wang et al., 2008a) showed Skp2 knockdown is 
unable to affect PSA expression, Li et al (Li et al., 2014a) showed Skp2 depletion enhances 
AR-mediated expression of PSA. Lacking time course experiments to monitor AR 
transcriptional activity of course is a major flaw as AR transcription is known to occur in a 
cyclical manner (Felten et al., 2013) and the published data therefore does not undermine the 
data presented here.  
ATAD2, also known as ANCCA, is a member of the AAA+ ATPase family of bromodain-
containing proteins and is up-regulated in many solid human tumours, including androgen 
dependent and independent prostate tumours. It has been identified as a co-activator of several 
transcription factors such as the AR, ER and Myc. Down-regulation of ATAD2 by Skp2 
depletion is reported herein for the first time. ATAD2 itself is regulated directly by AR and is 
an androgen-responsive gene (Zou et al., 2009; Altintas et al., 2012). It therefore became of 
great interest to try to elucidate the underlying mechanism that modulated AR transcriptional 
activity. It was hypothesised that Skp2 may influence AR protein levels as it has been reported 
to act as an E3 ligase for AR (Li et al., 2014a). Although this would be unlikely as such a 
mechanism leads to attenuated transcription of all AR-target genes. Yet again, this a 
controversial area where Skp2 has been demonstrated to ubiquitinate the AR and mark it for 
proteasomal destruction (Li et al., 2014a). Furthermore, Skp2 inhibition using both siRNA and 
shRNA led to restoration of AR protein expression in PC3 and DU145 cell lines which are 
widely demonstrated to lack any AR protein (Li et al., 2014a). In contrast, Skp2 has also been 
shown to not have an effect on the AR (Wang et al., 2008a). As such, three different siRNA 
oligonucleotides against Skp2 and additionally a pool of combined siRNAs was utilised in 
different PC lines to determine AR levels following Skp2 depletion. Overall, no appreciable 
change in AR protein level was found (Figure 5.9). Despite, highly efficient knockdown of 
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Skp2 achieved here compared to the poorer Skp2 depletion achieved by Li et al (2014), AR 
upregulation was not observed when evaluated in the PC3 and CWR22RV1 cell lines under 
similar experimental conditions. Consistent with the general studies on PC3 cell line, no 
detectable AR was evident under any condition applied.  
Skp2 can also act independently of its SCF ligase complex, for example in regulating p53 where 
Skp2 sequesters p300 to prevent p300-mediated acetylation of p53 and consequently inhibits 
p53 transcriptional activity without interacting with p53 or affecting its expression (Kitagawa 
et al., 2008). It was therefore hypothesised that cytoplasmic Skp2 may sequester AR and 
abrogate AR shuttling into the nucleus. Interestingly, although Skp2 was found to be in a 
complex with AR (Figure 5.10), it did not affect AR localisation upon DHT treatment (Figure 
5.11). This however was not surprising as such a mechanism would lead to a global/general 
reduction in AR-regulated gene expression rather than of a specific gene. Although, it would 
have also been preferable to test that a well-established AR interacting partner could be detected 
by this immunoprecipitation experiment, as a positive control. Unexpectedly, Skp2 was found 
to be cytoplasmic in these experiments which may be a consequence of the starvation of cells 
in steroid-depleted media causing a cell cycle arrest, as Skp2 is predominantly nuclear in 
dividing cells. However, cytoplasmic Skp2 has been observed in many clinical tumour samples 
(Radke et al., 2005) and Akt-mediated phosphorylation of Skp2 has been suggested as an 
underlying mechanism to protect Skp2 from degradation by Cdh-1 (Gao et al., 2009). 
Cytoplasmic Skp2 has been found to regulate cell migration independently of its ability to 
regulate p27 ubiquitination and degradation. Consistently, Skp2 in the cytoplasm was shown 
not to interact with CUL1 and Skp1, or induce p27 ubiquitination. Importantly though, Skp2 
was shown to be present in the chromatin containing fraction (Figure 5.11B), consistent with 
its recently published role in modulating the histone modification H3K4me3 through JARID1B 
regulation (Lu et al., 2015).   
Having demonstrated Skp2 knockdown promoted up-regulation of p27 levels, in keeping with 
its inverse correlation in PC, it was then speculated that increased p27 inhibits cyclin/CDK 
complex activity responsible for phosphorylation of AR on serine 81 and consequently would 
attenuate AR binding to chromatin. However, there was no change in DHT-induced AR 
phosphorylation with Skp2 depletion after 6 hours of treatment (Figure 5.12). Skp2 has 
previously been reported to act as a co-factor to activate c-Myc target genes (Kim et al., 2003). 
Therefore, the ability of Skp2 to act as a co-regulator for AR was investigated in an effort to 
elucidate its mechanism of action in down-regulating ATAD2 basal transcription. Then again, 
it did not alter the activity of AR (Figure 5.13). It would have been prudent to perform this 
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experiment using AR binding sequence obtained from the ATAD2 distal enhancer region as 
Skp2 caused a significant reduction for ATAD2 only. 
The fact that none of the AR related mechanisms tested were affected by Skp2 depletion 
suggests ATAD2 may be subject to direct regulation by Skp2, independently of the AR. 
Alternatively, Skp2 could be modulating AR recruitment specifically at the ATAD2 promoter. 
DHT-induced AR recruitment at the TMPRSS2 and PSA was examined but it did not show any 
change following Skp2 depletion (data not shown), which was expected as the transcription of 
these genes were not significantly affected upon Skp2 suppression. Again, these experiments 
should also have been performed by examining recruitment at the ATAD2 promoter region. 
ATAD2 is currently an area of high interest for therapeutic targeting. We have reported here 
for the first time that ATAD2 could be under the regulation of Skp2 which could in turn provide 
a new pathway for therapeutic intervention. Importantly, considering that fact that Skp2 is 
suggested as a promising novel target in CRPC, with small molecule inhibitors being developed 
to inhibit the activity of Skp2, it is critical to have an appropriate biomarker to measure the 
outcome of Skp2-targetted therapy. PSA screening is often used to monitor the development 
and progression of PC. One important finding from this work is that PSA is not a suitable 
biomarker for therapies against Skp2. Interestingly, however, our data implies ATAD2 may be 
a potential biomarker for such a therapy. Taken together, our data suggests Skp2 is not a direct 
target of the AR. Furthermore, the effect of Skp2 silencing on proliferation is not due to its role 
as a regulator of AR signalling.  
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6 Discussion  
Currently the AR is regarded as a key therapeutic target in the treatment of advanced PC, where 
therapies aim to reduce the AR activity. Although initially successful, AR-targeted therapies 
fail through a plethora of mechanisms including: AR amplification, AR mutations, expression 
of AR splice variants, increased intratumoural steroidogenesis and altered expression of AR co-
regulators. Ultimately, these mechanisms lead to restoration of AR activity, rendering the AR-
targeted therapies ineffective. This results in the emergence of the more aggressive CRPC 
(Chan and Dehm, 2014). Therefore, exploiting the regulatory mechanisms that modulate the 
AR by targeting AR regulatory proteins to indirectly inhibit AR function may provide a possible 
solution to existing treatment limitations.  
The AR is regulated by numerous co-regulatory proteins and it is becoming evident that one 
large class are the lysine methyltransferase enzymes, whereby deregulation of these proteins 
has been shown to cause aberrant AR activity in PC. In addition to mediating histone 
modifications to regulate chromatin-related functions, these enzymes, for example SET9, have 
also been shown to directly methylate non-histone proteins including the AR, causing enhanced 
AR transcriptional activity (Gaughan et al., 2011; Ko et al., 2011). 
To identify methyltransferases and opposing demethylases that are important in AR regulation, 
an siRNA screen was previously undertaken. Results from the screen identified SET8/KMT5A 
as a novel regulatory AR protein that functions to repress AR activity in the LNCaP cells. 
Interestingly, in the castrate and drug-resistant PC cell line, LNCaP-AI, KMT5A was found to 
act in an opposite manner where it functioned as an AR co-activator (Coffey et al, unpublished 
data). The activity of KMT5A is tightly regulated primarily through PTMs, including 
ubiquitination, which ensures precise KMT5A protein levels in a cell cycle-dependent manner. 
The aim of this project was to investigate and validate a novel PTM of KMT5A which could 
potentially be exploited to indirectly target the AR.  
Results from Chapter 3 identified mono-ubiquitination as a novel PTM of KMT5A. Mono-
ubiquitinated KMT5A was found as the predominant form of modified KMT5A in several PC 
cell lines. Subsequently, KMT5A C-terminus which comprises the SET-domain responsible for 
KMT5A enzymatic activity was shown to undergo mono-ubiquitination. Despite strenuous 
efforts to identify the site of mono-ubiquitination, a specific lysine residue could not be 
identified. Instead the site responsible for mono-ubiquitination was narrowed down to a specific 
region (amino acid 310-330) within the C-terminus. Moreover, similarly, mono-ubiquitinated 
KMT5A has also been consistently observed in breast cancer cell lines, although the nature of 
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this form of KMT5A was not known at all and only became evident following the work 
conducted here (personal communication, Dr Fabio Pittella Silva, Memorial Sloane Kettering 
Cancer Centre, USA).  
The impact of mono-ubiquitination on KMT5A could be important as KMT5A is being 
considered as a therapeutic target. Mono-ubiquitination is associated with non-proteolytic 
functions and has been extensively shown to regulate the function of many proteins. For 
example, mono-ubiquitination of SETDB1 in its SET-insertion domain is essential for its 
enzymatic activity where the conjugated mono-ubiquitin is actively protected from de-
ubiquitination (Sun and Fang, 2016). Moreover, mono-ubiquitin conjugation may result in a 
conformational change in the protein structure. Similarly, should mono-ubiquitination alter the 
enzymatic activity or structure of KMT5A, this may subsequently influence the efficacy of the 
small molecule inhibitors being developed against the enzymatic activity of unmodified 
KMT5A.  
KMT5A is over-expressed in many types of cancer including bladder cancer, non–small cell 
lung carcinoma (NSCLC), small cell lung carcinoma (SCLC), chronic myelogenous leukaemia, 
hepatocellular carcinoma, and pancreatic cancer (Takawa et al., 2012). However, the 
underlying mechanisms leading to KMT5A over-expression has not been fully investigated and 
has remained largely unknown. So far, only the presence of multiple single-nucleotide 
polymorphisms in the 3’UTR of KMT5A mRNA has been shown to cause KMT5A up-
regulation. Furthermore, KMT5A over-expression was also shown in PC compared to benign 
samples (Coffey et al, unpublished data). Interestingly data from this work implied mono-
ubiquitinated KMT5A is a stable form of this protein that may be causing its prominent 
expression. Increased KMT5A stability could potentially be an underlying mechanism for its 
up-regulated levels. It is therefore essential to further interrogate the stability of unmodified and 
mono-ubiquitinated KMT5A in a number of PC cell lines. Moreover, the mono-ubiquitin 
deficient and competent KMT5A constructs generated could also provide an additional tool to 
determine the role of mono-ubiquitination in KMT5A protein stability.  
The high expression of KMT5A is positively associated with metastasis, poor overall and 
disease free survival in breast cancer patients (Yang et al., 2012; Liu et al., 2016). Consistently, 
hepatocellular carcinoma and SCLC patients with lower KMT5A expression had longer 
survival time (Ding et al., 2012; Guo et al., 2012). In addition, high KMT5A expression is 
associated with an early age of breast cancer onset, whilst its low expression contributes to a 
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lower risk of epithelial ovarian cancer (Song et al., 2009; Wang et al., 2012). However, the 
clinical significance of mono-ubiquitinated KMT5A is not known. 
Moreover, despite the up-regulated KMT5A expression in PC tissue, the molecular form of the 
KMT5A protein is not known. It is therefore of great value to distinguish between the 
unmodified and mono-ubiquitinated forms of KMT5A using antibodies specific to mono-
ubiquitinated KMT5A and perform staining on tissue microarrays (TMA) containing samples 
from patients with BPH and PC. Currently there is an acute lack of prognostic and therapeutic 
biomarkers in PC. Although, the currently used PSA monitoring is useful as part of the 
diagnostic repertoire and as an indicator of PC recurrence, it is not a cancer specific marker but 
pertinent to monitoring tumour burden. This method has led to diagnosis and overtreatment of 
PC (Shtivelman et al., 2014). It would therefore be useful to ascertain whether mono-
ubiquitinated KMT5A could be used as a potential biomarker by assessing its expression in 
association with Gleason grade, response to therapy, time to relapse or overall survival. 
Unfortunately, the current lack of an antibody to detect the mono-ubiquitinated form of KMT5A 
hinders such investigations.  
Work in Chapter 4 focussed on characterising the cell cycle control of KMT5A mono-
ubiquitination and conversely, the role of mono-ubiquitinated KMT5A on the cell cycle and 
cell growth. It was revealed that similar to its other PTMs, mono-ubiquitination of KMT5A is 
subject to dynamic changes during the cell cycle, being at its highest level in S phase despite 
minimal levels of unmodified KMT5A. Conversely, mono-ubiquitinated KMT5A was at its 
lowest level in G2/M phase, whilst, unmodified KMT5A was at its peak. Furthermore, the data 
suggested a positive association between cell proliferation and levels of KMT5A mono-
ubiquitination. Interestingly, the mono-ubiquitin conjugated form of KMT5A was found to be 
exclusively cytoplasmic. The subcellular localisation of proteins has been linked with tumour 
aggressiveness, for example the DNA repair APE1 enzyme has been observed to be present at 
higher concentrations in the cytoplasm of colorectal carcinoma cells compared to normal cells 
(Kakolyriset et al., 1997). It would therefore be useful to also determine mono-ubiquitinated 
KMT5A tissue localisation.  
The physiological role of mono-ubiquitinated KMT5A is still an open question and is 
something that will require substantial research in the future. Firstly, it is critical to identify the 
effect of mono-ubiquitination on KMT5A enzymatic activity. As such, mono-ubiquitination 
has been shown to cause activation of the substrate protein in many instances (van der Horst et 
al., 2006; Sun and Fang, 2016). Interestingly, the cytoplasmic localisation of mono-ubiquitin 
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conjugated KMT5A suggests this form of KMT5A is involved in the regulation of non-histone 
proteins. It became questionable if pathways leading to KMT5A mono-ubiquitination could 
potentially be targeted therapeutically in PC, should mono-ubiquitinated KMT5A have a 
clinical significance, as mono-ubiquitinated KMT5A was exclusively cytoplasmic. 
Consistently, KMT5A plays a role in various cellular processes and in addition to H4K20 
methylation, it methylates non-histone proteins such as p53 and Numb, resulting in a decrease 
in apoptosis (Shi et al., 2007; Dhami et al., 2013). Furthermore, it positively regulates the 
activity of Twist in promoting EMT in breast cancer (Yang et al., 2012). In support of the 
speculation here, recently presented work at the American Association for Cancer Research 
(AACR) 2016 had identified novel substrates for KMT5A (Silva et al., 2016). Intriguingly, 
almost half of the substrates were found to be cytoplasmic proteins. Although puzzled by their 
finding, based on the assumption that KMT5A is a nuclear protein, it is now evident that this 
could be due to the presence of the mono-ubiquitinated form of KMT5A. Secondly, it is of 
upmost importance to identify the substrates of mono-ubiquitinated KMT5A. These could be 
determined by mono-ubiquitinated KMT5A immunoprecipitation and mass spectrometry 
studies. Subsequently, identified proteins which have a role in PC development could be 
investigated. In contrast to its unmodified form, mono-ubiquitinated KMT5A was no longer 
considered to directly regulate the AR in the nucleus, however it may alternatively regulate PC 
independently of AR signalling. Identification of mono-ubiquitinated KMT5A substrates could 
therefore enable the discovery of additional as yet unidentified pathways in which it 
participates. Nonetheless, mono-ubiquitinated KMT5A could affect the cytoplasmic AR. The 
role of KMT5A mono-ubiquitination however suggested that it signals for KMT5A 
translocation out of the nucleus as an additional mechanism to lower the levels of nuclear 
KMT5A during S phase to enable proper cell cycle progression.  
Despite the prominent existence of mono-ubiquitinated KMT5A, nothing is known about the 
key regulatory enzymes that regulate this modification and is another area requiring research. 
Additionally, it has not yet been examined if the mono-ubiquitination of KMT5A is dependent 
on a specific phosphorylation state of KMT5A. In line with this notion, cell cycle-specific 
phosphorylation of KMT5A has been reported which regulates KMT5A binding to chromatin 
and its stability by the APCCh1 complex (Wu et al., 2010). Work in Chapter 4 also demonstrated 
that Skp2 promotes the mono-ubiquitination of KMT5A which was not associated with protein 
turnover. Skp2 up-regulation during G1 phase and even further elevation in S phase was 
concomitant with the increased KMT5A mono-ubiquitination. Given the frequent over-
expression of Skp2 in PC, coupled with up-regulated KMT5A levels, it is possible that a Skp2-
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KMT5A mono-ubiquitination axis could be of clinical significance in PC. However, the 
enzyme responsible for the basal KMT5A mono-ubiquitination remains unknown.  
Skp2 is known to play a dynamic role in the regulation of multiple cellular pathways. As Skp2 
was shown to promote KMT5A mono-ubiquitination, its role in AR signalling was 
independently investigated. In Chapter 5, Skp2 was shown to not be a direct target of the 
androgen-AR signalling cascade. Furthermore, the regulation of the AR signalling itself by 
Skp2 seemed more complex than what has been reported. Overall, despite the substantial 
reduction in PC cell growth following Skp2 depletion, Skp2 did not regulate the AR and the 
expression of its target genes, except ATAD2. However, data implicated Skp2 to be a direct 
regulator of ATAD2. Interestingly, the data revealed that PSA is an unsuitable marker for Skp2-
targetted therapies, whereas ATAD2 could potentially be a novel marker for Skp2 therapeutics. 
However, a great deal more research needs to be conducted to interrogate the underlying 
mechanism.  
In conclusion, this study identified mono-ubiquitination as a novel PTM of KMT5A which 
functions as an additional mechanism to regulate precise KMT5A levels during S phase. The 
identification of this PTM aids our understanding of KMT5A regulation by mono-ubiquitin 
conjugation. Although, this form of KMT5A is unlikely to directly regulate AR transcriptional 
activity in the nucleus, it could influence other signalling cascades to indirectly affect PC. 
Moreover, the up-regulation of KMT5A mono-ubiquitination by Skp2 could promote a rapid 
localisation of KMT5A into the cytoplasm to ensure timely progression of the cell cycle. 
Additionally, although Skp2 depletion reduces cell growth, it is not through the direct regulation 
of AR signalling.  
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